Compounds > platinum
Page last updated: 2024-08-22

platinum and Cancer of Ovary

platinum has been researched along with Cancer of Ovary in 633 studies

Research

Studies (633)

TimeframeStudies, this research(%)All Research%
pre-199023 (3.63)18.7374
1990's81 (12.80)18.2507
2000's54 (8.53)29.6817
2010's257 (40.60)24.3611
2020's218 (34.44)2.80

Authors

AuthorsStudies
Harris, HH; Huang, Z; King, AP; Lai, B; Lovett, J; Wilson, JJ; Woods, JJ1
Cadoo, KA; Chambers, SK; Chen, LM; Chmielecki, J; Cragun, JM; Geenen, JJJ; Ghamande, SA; Hamilton, EP; Jones, SF; Konecny, GE; Kumar, S; Lai, Z; Moore, KN; Mugundu, GM; Oza, AM; Plaxe, SC; Rodrigo Imedio, E; Spigel, DR; Spitz, DL; Troso-Sandoval, TA1
Abdeddaim, C; Anota, A; Brocard, F; Cancel, M; Floquet, A; Frenel, JS; Hardy-Bessard, AC; Houlier, A; Kalbacher, E; Lardy-Cleaud, A; Largillier, R; Levaché, CB; Lortholary, A; Louvet, C; Meunier, J; Mouret-Reynier, MA; Pissaloux, D; Pop, O; Provansal, M; Ray-Coquard, I; Savoye, AM; Trédan, O; Treilleux, I; Venat-Bouvet, L; You, B; Zannetti, A1
Basharina, AA; Bogush, EA; Bogush, TA; Davydov, MM; Kosorukov, VS; Scherbakov, AM1
Coleman, RL; Lainé, A; Le Saux, O; Ray-Coquard, I; Sims, TT1
Cancanelli, L; Chiumente, M; Di Spazio, L; Mengato, D; Messori, A; Rivano, M2
Kajiyama, H; Kikkawa, F; Suzuki, S; Ukai, M; Yokoi, A; Yoshihara, M; Yoshikawa, N1
Eroglu, EC; Geckil, OF; Gulec, UK; Paydas, S; Tunug, S; Vardar, MA1
Chong, GO; Hong, DG; Kim, JM; Lee, J; Lee, YH1
Liu, M; Liu, T; Sun, L; Tan, S; Tang, J; Xiao, W; Zhou, X1
Bondar, O; Patskov, A; Rybin, A; Varabina, A1
Choi, MC; Jeong, DH; Kim, BG; Kim, SI; Lee, JK; Lee, JY; Lim, MC; Park, J1
Boccia, SM; Caruso, G; Di Donato, V; Musella, A; Muzii, L; Palaia, I; Perniola, G; Sassu, CM; Tomao, F1
Gou, W; Li, J; Li, Y; Li, Z; Meng, Y; Wei, H; Zhang, Y; Zheng, W; Zhou, Y; Zhu, W1
Katsuda, T; Matsukuma, K; Nasu, H; Nishio, S; Park, J; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T1
Catalano, F; De Cegli, R; Di Schiavi, E; Guida, F; Mariniello, M; Petruzzelli, R; Polishchuk, RS1
Barnicle, A; Bennett, J; Bjurberg, M; Blakeley, C; Cibula, D; Colombo, N; Davidson, R; González-Martín, A; Ledermann, J; Lheureux, S; Lindemann, K; Madry, R; Oaknin, A; Pérez, MJR; Poveda, A; Sikorska, M; Škof, E; Weberpals, J1
Gou, S; Wang, X; Wang, Y; Zang, J; Zhang, B1
Bulleri, A; Cosio, S; Frey, J; Gadducci, A; Mezzapesa, F; Miccoli, M; Neri, E; Simonetti, E; Tintori, R1
Abadie-Lacourtoisie, S; Blanc-Fournier, C; Brachet, PE; Briand, M; Clarisse, B; Fabbro, M; Floquet, A; Follana, P; Frenel, JS; Gavoille, C; Giffard, F; Gladieff, L; Joly, F; Just, PA; Kalbacher, E; Leary, A; Leconte, A; Lequesne, J; Lesoin, A; Medioni, J; Poulain, L; Weiswald, LB; You, B1
Jimi, T; Kitai, M; Nagao, S; Nakazawa, H; Narita, M; Shibutani, T; Shiozaki, T; Yamaguchi, S; Yano, H1
Altwerger, G; Andikyan, V; Azodi, M; Bellone, S; Buza, N; Clark, M; Harold, J; Huang, GS; Hui, P; Mauricio, D; Menderes, G; Rao, GG; Ratner, E; Reader, JC; Roque, DM; Santin, AD; Schwartz, PE; Siegel, ER; Silasi, DA; Tymon-Rosario, JR; Zeybek, B1
Agnarelli, L; Dalla Via, L; Di Paolo, ML; Hyeraci, M; Labella, L; Marchetti, F; Samaritani, S1
Khamaisi, H; Mahajna, J; Mahmoud, H1
Akilli, H; Aliyeva, K; Altundag, O; Ayhan, A; Kuscu, UE; Rahatli, S1
Crabb, SJ; Hack, J1
Ikeda, Y; Iyoshi, S; Kajiyama, H; Kato, M; Kikkawa, F; Kitami, K; Koya, Y; Mogi, K; Ohnuma, S; Sugiyama, M; Tamauchi, S; Tazaki, A; Uno, K; Yokoi, A; Yoshihara, M; Yoshikawa, N1
Álvarez-Abril, B; Galluzzi, L; García-Martínez, E1
Barth, MC; Görls, H; Häfner, N; Lange, S; Runnebaum, IB; Ueberschaar, N; Weigand, W1
Arenare, L; Baldassarre, G; Bartoletti, M; Califano, D; Capoluongo, E; Chiodini, P; Costi, MP; D'Incalci, M; Greggi, S; Marchini, S; Mezzanzanica, D; Musacchio, L; Normanno, N; Perrone, F; Pignata, S; Scala, S; Schettino, C1
Au-Yeung, G; Freimund, A; Friedlander, M; Krasovitsky, M; Lee, YC; Mileshkin, L; Norris, C; Sivakumaran, T; So, J; Webber, K1
Chen, S; Wang, S; Wu, J; Wu, X; Wu, Y; Zheng, Z1
Davidson, B; Elstrand, MB1
Appleman, L; Belani, CP; Beumer, JH; Chen, A; Chew, H; Chu, E; Diergaarde, B; Ding, F; Duan, W; Garcia, AA; Giranda, V; Hurley, RM; Ivy, SP; Ji, J; Katz, T; Kaufmann, SH; Kiesel, BF; Lee, JJ; Lin, Y; Manzo, J; Morgan, RJ; Oesterreich, S; Pahuja, S; Parchment, RE; Puhalla, S; Shepherd, SP; Stoller, R; Swisher, EM; Tan, AR; Tawbi, H; Visscher, DW; Wahner Hendrickson, AE; Yu, J; Zhang, Y1
Benjamin, L; Corr, BR; Culm-Merdek, K; Fu, S; Hamilton, EP; Mockbee, C; Moore, KN; Naumann, RW; Rosengarten, RD; Stagg, R; Wenham, RM; Youssoufian, H1
Frountzas, M; Haidopoulos, D; Liatsou, E; Liontos, M; Pergialiotis, V; Rodolakis, A; Sotiropoulou, IM; Thomakos, N1
Bayón, P; Capdevila, M; Figueredo, M; Hernando, J; Jaime, C; Lorenzo, J; Morales, K; Nolis, P; Palacios, Ò; Rodríguez-Calado, S; Rodríguez-Diéguez, A1
Choi, J; Duan, QL; Nesdoly, S; Nicol, CJB; Tarnouskaya, A; Topouza, DG1
Bao, H; Feng, Z; Guo, Q; Liu, R; Ma, Y; Ou, Q; Shao, Y; Shen, Y; Wen, H; Wu, X1
Jalili, A; Kinaciyan, T; Marquart, E; Mothes-Luksch, N; Wagner, SN1
Chen, X; Fang, W; Li, A; Liang, X; Luo, Y; Luo, Z; Lyu, Q; Meng, F; Wang, Y; Zhou, D1
Chi, J; Gao, QL; Huo, Y; Jiang, J; Jiao, X; Li, G; Li, M; Li, R; Liu, J; Liu, X; Ma, G; Peng, Z; Song, C; Yu, Y; Zeng, S; Zhang, W; Zhao, Y1
Barkume, M; Chhatar, S; Duari, P; Gadre, S; Ingle, A; Kasinathan, NK; Khatri, S; Kode, J; Kolthur-Seetharam, U; Kumar, M; Manikandan, M; Nagare, M; Patkar, M; Patra, M; Sharma, A1
Aoki, Y; Arakaki, Y; Kudaka, W; Nakamoto, T; Nakasone, T; Ooyama, T; Shimoji, Y; Taira, Y1
Ghobashi, AH; Huntington, TD; Metcalfe, TX; Nephew, KP; O'Hagan, HM; Sood, R; Sriramkumar, S; Vuong, TT; Wang, W1
Belotte, J; Clements, A; Fleming, EL; Gray, HJ; Gupta, D; Hamilton, E; Hardesty, MM; Keeton, EK; Konecny, GE; Krivak, TC; Moore, RG; Richardson, DL; Wang, P; Wright, GS1
Hirata, M; Ishikawa, M; Noguchi, E; Odaka, Y; Saito, A; Shimoi, T; Sudo, K; Tanioka, M; Watanabe, T; Yonemori, K1
Li, Y; Liu, C; Sun, L1
Clarke, RG; Ferguson, MJ; Hiom, KJ; Nicholson, HA; Sawers, L; Smith, G1
Chen, M; Li, Y; Ma, X; Wang, H1
Aoki, D; Chiyoda, T; Kobayashi, Y; Kuroda, Y; Nanki, Y; Sakai, K; Saotome, K; Takahashi, M; Yamagami, W; Yoshihama, T; Yoshimura, T1
Banda, K; Chandok, H; Dobrolecki, L; Kumar, P; Lewis, MT; Liu, ET; Menghi, F; Radke, MR; Rodriguez, IV; Somlo, G; Straub, R; Swisher, EM; Yost, SE; Yuan, Y1
Bi, XH; Huang, X; Huang, Y; Jin, HH; Lan, CY; Li, R; Liu, C; Meng, J; Wang, J; Wang, YF; Xiong, Y; Yang, F; Zhang, L; Zhao, J; Zhao, WH; Zheng, M1
Pasquini, L; Petrucci, E; Riccioni, R1
Graham, TA; Haughey, MJ; Hoare, JI; Hockings, H; Huang, W; Lockley, M; Maniati, E; McNeish, IA; Mirza, H; Nicolini, F; Saxena, J; Silva, VL; Wood, GE1
Fang, F; Lai, T; Metcalfe, TX; Nephew, KP; O'Hagan, HM; Sriramkumar, S; Zong, X1
Cardenas, H; Cheng, JX; Huang, KC; Li, J; Matei, D; Tan, Y; Wang, Y; Zhao, G1
Agami, R; Amant, F; Annibali, D; Baiden-Amissah, REM; Berardi, E; Berkers, CR; Carmeliet, P; Davidson, B; De Wispelaere, W; Duarte, JAG; Eelen, G; Fendt, SM; Horlings, HM; Körner, PR; Lambrechts, D; Moens, S; Planque, M; Rizzotto, L; Rossi, M; Sonke, GS; Swinnen, JV; Talebi, A; Van Nyen, T; van Wagensveld, L; Zaal, EA1
Chen, X; Cheng, X; Dong, J; Guo, W; Ni, J; Xiao, L; Xu, X; Xue, Q; Zhao, Q1
Barber, J; Birtle, AJ; Brock, S; Crabb, SJ; Dempsey, L; Enting, D; Faust, G; Frew, J; Gale, J; Hinsley, S; Hussain, S; Jones, RJ; Lees, K; McGovern, U; Parikh, O; Powles, T; Ratnayake, G; Song, Y; Soulis, E; Sundar, S; Trevethan, A1
Kristeleit, RS; Moore, KN1
Berger, J; Boisen, M; Buckanovich, R; Coffman, LG; Courtney-Brooks, M; Edwards, RP; Frisbie, LG; Griffith, K; Lesnock, J; Liu, T; Mahdi, H; McLean, K; Normolle, D; Olawaiye, A; Orellana, TJ; Sukumvanich, P; Taylor, SE; Uppal, S1
Abe, M; Aida, T; Baba, T; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takatori, E; Tatsuki, S; Tomabechi, H1
Bowering, V; Chang, K; Dhani, NC; Karakasis, K; Kavak, N; Lheureux, S; Madariaga, A; Mitchell, SA; Oza, AM; Pittman, T; Quintos, J; Ramsahai, J; Wang, L; Welch, SA1
Barletta, JA; Bosma-Moody, A; Camp, S; Carey, E; Conway, J; Crowdis, J; Dietlein, F; Han, S; He, MX; Huang, J; Imamovic, A; Kofman, E; Liu, D; Lorch, JH; Pappa, T; Park, J; Reardon, B; Schiantarelli, J; Shannon, E; Stanizzi, D; Van Allen, EM1
Cho, H; Chung, JY; Han, GH; Kim, J; Kim, JH; Yun, H1
Bae, BK; Cho, WK; Choi, CH; Kim, TJ; Lee, JW; Lee, YY; Park, W1
Aldrich-Wright, JR; Aputen, AD; Elias, MG; Gilbert, J; Gordon, CP; Sakoff, JA; Scott, KF2
Arenare, L; Artioli, G; Baldassarre, G; Beltrame, L; Califano, D; Campanini, N; Capoluongo, ED; Cecere, SC; Chiodini, P; Cinieri, S; Colombo, N; D'Incalci, M; De Cecio, R; Llop-Guevara, A; Lorusso, D; Marchini, S; Mezzanzanica, D; Musolino, A; Nardelli, C; Normanno, N; Pellegrino, B; Perrone, F; Pignata, S; Pisano, C; Roma, C; Russo, D; Scaglione, GL; Scambia, G; Sergi, A; Serra, V; Setaro, M; Spina, A; Tasca, G1
Colombo, N; Credille, KM; Gao, B; Konstantinopoulos, PA; Lee, JM; Lee, JY; Lin, AB; McNeely, S; Miller, R; Shapira-Frommer, R; Vergote, I; Wang, XA; Young, SR1
Baba, T; Furukawa, S; Kagabu, M; Kaiho-Sakuma, M; Matsumura, Y; Nagasawa, T; Nagase, S; Ohta, T; Seino, M; Shigeta, S; Shigeto, T; Shimada, M; Shimizu, D; Shoji, T; Soeda, S; Takahashi, F; Takatori, E; Terada, Y; Tokunaga, H; Watanabe, T; Yokoyama, Y1
Bouda, J; Černaj, P; Hlaváč, V; Holý, P; Hruda, M; Mrhalová, M; Rob, L; Souček, P; Václavíková, R1
Li, X; Ling, H; Luo, Y; Ran, R; Wang, H; Wen, F; Yu, T1
Deng, X; Huang, X; Li, Z; Wang, J; Yue, H; Zhang, M1
Aghajanian, C; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; Gancedo, MA; Goble, S; Goh, JC; Holloway, RW; Kwan, T; Leary, A; Ledermann, JA; Lin, KK; Lorusso, D; Maloney, L; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI1
Chen, M; Jiang, Q; Li, J; Li, T; Luo, X; Sun, Y; Yao, L; Yuan, L1
Park, JY; Park, SG; Seo, MD; Sim, YH; Um, YJ1
Frountzas, M; Haidopoulos, D; Liatsou, E; Liontos, M; Papapanagiotou, A; Pergialiotis, V; Rodolakis, A; Thomakos, N1
Brambs, C; Grill, S; Hellmann, D; Honert, K; Kiechle, M; Konrad, SM; Krüger, A; Meindl, A; Quante, AS; Ramser, J; Schmalfeldt, B; Schmitt, M; Schwamborn, K1
Banerjee, S; Birrer, M; Drapkin, R; Richardson, DL1
Jia, Y; Liu, L; Wang, B1
Ahmed, N; Goonetilleke, L; Kadife, E; Kannourakis, G; Leung, D; Lokman, NA; Oehler, MK; Price, ZK; Ricciardelli, C; Wang, W1
Balmaña, J; Banerjee, S; Borrow, J; Burris, HA; Chen, LM; Domchek, SM; Drew, Y; Glasspool, RM; Goble, S; Kristeleit, RS; Lin, KK; Maloney, L; Oza, AM; Patel, MR; Safra, T; Shapira-Frommer, R1
Cheng, X; Fan, F; Fei, W; Gu, J; Qin, J; Shen, S; Shen, T; Wu, X; Zhang, T1
Armirotti, A; Brindani, N; De Vivo, M; Geronimo, I; Manigrasso, J; Munafò, F; Nigro, M; Ottonello, G1
Cardenas, H; Huang, H; Matei, D; Valdivia, AF; Wang, Y; Zhao, G1
An, R; Dong, J; Ma, G; Wang, K; Younis, MR; Zhang, Q; Zhu, P1
Du, X; Lv, T; Song, K; Yao, Q; You, S; Zhao, H; Zhu, X1
Aglietta, M; Arcangeli, V; Barretina-Ginesta, MP; Benedetti Panici, P; Berger, R; Biagioli, E; Bologna, A; Chekerov, R; Churruca Galaz, C; Colombo, N; D'Incalci, M; De Giorgi, U; DeCensi, A; Deryal, M; Fossati, R; Funari, G; Gadducci, A; Heinzelmann-Schwarz, V; Herbertson, R; Iglesias, M; Mäenpää, J; Mirza, MR; Montes, A; Nyvang, GB; Ottevanger, NB; Pardo, B; Poveda, A; Riniker, S; Romeo, M; Rubio-Pérez, MJ; Rulli, E; Sehouli, J; Sessa, C; Tasca, G; Tognon, G; Tsibulak, I; Vergote, I; Westermann, A; Wimberger, P; Zamagni, C; Zola, P1
Abd Aziz, NHB; Atallah, GA; Chew, KT; Kampan, NC; Md Zin, RR; Mohd Mokhtar, N; Shafiee, MNB1
Wang, H; Wang, Y; Xia, Y; Zhang, J1
Han, Z; Hong, Z; Li, S; Qin, Y; Wang, L; Wang, X; Zhu, D1
Crosbie, EJ; Edmondson, RJ; Faraahi, ZF; Gavrielides, N; Hawarden, A; Jones, DM; McCormick, A; Price, MJ; Roberts, C; Russell, B; Tyagi, S; Waddell, CA; Walker, TDJ; Whalley, B; Woodhouse, LC1
Chen, Y; He, H; Li, L; Luo, Z; Pan, Z; Yang, Z; Zhao, B1
Abe, M; Aida, T; Baba, T; Chiba, Y; Kagabu, M; Kaido, Y; Nagasawa, T; Shoji, T; Takahashi, F; Takatori, E1
Berton, D; Blanc-Durand, F; Bonichon-Lamaichhane, N; Chevalier-Place, A; de Rauglaudre, G; Desauw, C; Dohollou, N; Dubot, C; Fabbro, M; Ferron, G; Genestie, C; Herencia-Ropero, A; Kaminsky, MC; Klein, C; Kramer, C; Kurtz, JE; Leary, A; Llop-Guevara, A; Lortholary, A; Malaurie, E; Raban, N; Rouleau, E; Serra, V; Yaniz-Galende, E1
Chen, Z; Dai, W; Gong, W; Jiang, R; Li, X; Ni, M; Yin, Z; Zheng, Z; Zhou, J; Zhu, J1
Gou, S; Wang, X; Wang, Y1
Lheureux, S; Soberanis Pina, P1
Brennan, DJ; Doran, P; Glennon, K; Jeronimo, C; Lynch, L; Martin, T; Metoudi, M; Moran, B; Perry, AS; Salta, S; Shaw, J; Silva, R; Slattery, K; Treacy, A1
Dai, C; Dai, SY; Deng, DN; Gao, Y; Liu, SJ; Liu, X; Qin, QF; Wang, DH; Yan, T; Zhou, QY; Zi, D1
An, N; Bi, R; Cai, Y; Chen, D; Chen, X; Feng, Z; Ju, X; Li, J; Li, Y; Shao, D; Song, C; Wen, H; Wu, X; Xiu, Z; Zhou, Q; Zhu, S1
Jo, DY; Ko, YB; Lee, HJ; Lee, MW; Ryu, H; Song, IC; Yeon, SH; Yun, HJ1
Aschenbrenner, DS1
Aghajanian, C; Chi, DS; Chui, MH; Girshman, J; Gordhandas, S; Grisham, RN; Iasonos, A; Kahn, RM; Laibangyang, A; Long Roche, K; Manning-Geist, BL; Nemirovsky, D; Zivanovic, O1
Barth, MC; Häfner, N; Runnebaum, IB; Weigand, W1
Cainap, C; Cainap, SS; Havasi, A; Havasi, AT1
Albertella, MR; Bani, MR; Decio, A; Dellavedova, G; Formenti, L; Ghilardi, C; Giavazzi, R; Leo, E; Staniszewska, AD; Wilson, J1
Su, R; Su, X; Wang, Z; Wu, X; Yang, L1
Hu, XQ; Hua, T; Zhang, BY1
Arndt, T; Belau, AK; Braicu, EI; Canzler, U; Chekerov, R; de Gregorio, N; Mahner, S; Mustea, A; Neunhoeffer, T; Pietzner, K; Richter, R; Sehouli, J; Stocker, G; Strauß, HG; von Abel, E; Wimberger, P; Woelber, L; Yalinkaya, I1
Gao, Q; Huang, S; Jiang, Y; Jin, L; Li, B; Li, T; Lin, Y; Mao, X; Nowialis, P; Song, L; Song, Q; Xing, C; Zheng, G1
Eskander, RN; O'Malley, DM; Richardson, DL1
Compadre, AJ; Cooper, I; Fashemi, B; Graham, E; Hagemann, AR; Harrington, SP; Herencia-Ropero, A; Khabele, D; Kotnik, EN; Kuroki, LM; Llop-Guevara, A; Lomonosova, E; McCourt, CK; Mosammaparast, N; Mullen, MM; Mutch, DG; Powell, MA; Serra, V; Sun, L; Thaker, PH; Valentine, MC; van Biljon, LN; Zhao, P1
Buttitta, F; D'Angelo, E; Di Marino, P; Felicioni, L; Ferro, B; Marchetti, A; Pasciuto, MP; Primavera, FC; Rossetti, R; Tudini, M; Zampacorta, C1
Hamontri, S; Tantitamit, T1
He, Y; Li, Q; Li, X; Liu, X; Wang, M; Yang, Z; Yi, Q; Yu, Q; Yue, S; Zhao, B1
Bramhecha, Y; Dorigo, O; Ebrahimizadeh, W; Fiset, S; Ghamande, S; Ghatage, P; Hirsch, HA; Kaliaperumal, V; MacDonald, LD; Oza, AM; Pejovic, T; Provencher, D; Torrey, H; Villella, J1
Chen, S; Cui, Y; Jiang, C; Lu, W; Mei, H; Wang, Y; Wu, X; Zhang, D; Zhang, M; Zhang, W; Zhuo, Z1
Barker, HE; Barnett, S; Bedő, J; Caldwell, R; Carmagnac, A; Collins, IM; Dall, G; Dobrovic, A; Fox, SB; Grimmond, S; Hamilton, A; Hofmann, O; Kee, D; Klein, O; Kyran, EL; Lim, R; Lobley, A; McNally, O; Meniawy, T; Milesi, B; Nesic, K; Ng, AP; Nugawela, D; O'Grady, E; Olesen, I; Papadopoulos, L; Papenfuss, AT; Penington, J; Power, JD; Ratnayake, G; Scott, CL; Shield-Artin, K; Stewart, KP; Tan, TH; Tram, J; Vandenberg, CJ; Vissers, JHA; Wakefield, MJ; Zhou, W; Zhu, W1
Di, LJ; Hao, D; Li, J; Li, P; Liu, T; Lu, J; Su, M; Tai, L; Wang, L; Wang, Y; Zhao, Z1
Adawi, R; Gopas, J; Khamaisi, H; Koren Carmi, Y; Mahajna, J; Noyman, E1
Fujiwara, K; Yoshida, H1
Gao, Y1
Betzer, JF; Bignon, J; Bombard, S; Diane, O; Fontaine, G; Ghosh, D; Hue, N; Jia, T; Marinetti, A; Moulai Siasia, YM; Poupon, J; Retailleau, P; Servajean, V; Skander, M1
Borgonovo, K; Celotti, A; Ghidini, A; Lorusso, D; Luciani, A; Petrelli, F; Rea, CG; Solinas, C; Villa, A1
Abaid, LN; Ahmad, S; Brown, JV; Holloway, RW; Kendrick, JE; LeBlanc, J; McKenzie, ND; Mendivil, AA; Mori, KM1
Elsea, D; Fan, L; Kasle, A; Meng, Y; Mihai, A; Monberg, M; Muston, D1
Fujiwara, S1
Chen, X; Gao, J; Lin, S; Liu, Y; Yang, X; Zhu, H; Zhu, J; Zou, X1
Awazu, Y; Fukuda, T; Ichimura, T; Imai, K; Noda, T; Sumi, T; Tasaka, R; Uchikura, E; Yamauchi, M; Yasui, T1
Taki, M1
Berardi, R; Boscolo Bielo, L; Cortesi, L; Curigliano, G; Del Mastro, L; Favero, D; Gandini, S; Giarratano, T; Guarneri, V; Lambertini, M; Marra, A; Moscetti, L; Pistelli, M; Sposetti, C; Trapani, D; Valenza, C; Vernieri, C; Zambelli, A1
Furukawa, T; Hashimoto, H; Kawasaki, T; Kawazoe, H; Mamishin, K; Nakamura, T; Nishimura, T; Saito, Y; Seto, K; Shimoi, T; Tashiro, R; Terakado, H; Udagawa, R; Yonemori, K; Yonemura, M1
Bhandari, S; Cheline, M; Dunietz, BD; Jayawardhana, AMDS; Kaspi-Kaneti, AW; Kshetri, M; Qiu, Z; Shen, H; Zheng, YR1
Harada, H; Izumi, H; Koi, C; Kurita, T; Murakami, M; Shibahara, M; Yoshino, K1
Abramson, VG; Boughey, JC; Cogan, ES; Connolly, RM; Dearden, S; Falkson, C; Ford, JM; Goetz, MP; Gradishar, WJ; Gutin, A; Hennessy, BT; Hodgson, DR; Jankowitz, RC; Kaklamani, VG; Lai, Z; Lanchbury, JS; Lenz, L; Marcom, PK; Mayer, EL; Mills, GB; Neff, C; Richardson, AL; Slavin, TP; Solimeno, C; Stearns, V; Storniolo, AM; Telli, ML; Timms, KM; Tung, NM; Vinayak, S1
Belin, L; Bultot-Boissier, É; Churruca, C; Cibula, D; D'Hondt, V; de Gregorio, N; Denys, H; Gaba, L; Heitz, F; Heudel, PE; Joly, F; Kocián, R; Kurtz, JE; Largillier, R; Lebreton, C; Leitner, K; Lotz, JP; Martinez García, J; Mouret Reynier, MA; Oaknin, A; Pautier, P; Petru, E; Polterauer, S; Pujade-Lauraine, E; Rodrigues, M; Rosengarten, O; Schmalfeldt, B; Sehouli, J; Selle, F; Vergote, I1
Konstantinopoulos, PA; Matulonis, UA2
Ahmad, S; Al-Niaimi, AN; Barter, J; Beck, T; Chambers, SK; Coleman, RL; Crafton, SM; Crane, E; Ghamande, S; Graybill, W; Herzog, T; Holloway, RW; Indermaur, MD; John, VS; Landrum, L; Lim, PC; Lucci, JA; McHale, M; Mendivil, AA; Monk, BJ; Moore, KN; Morris, R; O'Malley, DM; Ramez, E; Reid, TJ; Richardson, D; Rose, PG; Scalici, JM; Silasi, DA; Tewari, K; Thaker, P; Wang, EW1
Akkus, MH; Aksel, B; Ates, O; Dogan, M; Oner, I; Yuksel, C1
Chai, R; Dai, Y; Gao, Y; Kang, Y; Lu, C; Xu, C; Xu, J; Yu, B1
Bu, H; Feng, S; Huang, Y; Jin, C; Kong, B; Li, N; Liu, J; Ma, Y; Song, K; Wen, H; Wu, L; Yang, X; Zhang, H1
Boekestijn, S; de Bruin, L; de Kok, PM; Kroep, JR; Loof, NM; Meij, P; Roozen, I; Santegoets, SJ; Van der Burg, SH; van der Minne, CE; Verdegaal, EME; Visser, M; Welters, MJP; Westra, IM1
Cebulski, J; Depciuch, J; Kluz, T; Kluz-Barłowska, M; Król, P; Odrzywolski, A; Paja, W; Sarzyński, J; Łączyńska-Madera, M1
Bouberhan, S; Cannistra, SA; Pujade-Lauraine, E1
Banerjee, S; Pignata, S; Pujade-Lauraine, E1
Schorge, JO1
Anderson, K; Barrie, AM; Bean, LM; Chen, XL; Connolly, DC; Cordasco, EA; Diaz Osterman, CJ; Fisch, KM; Fu, G; Győrffy, B; Heino, J; Jean, C; Jiang, S; Kleinschmidt, EG; Kolev, VN; Li, J; Mark, AM; McHale, MT; Molinolo, A; Ojalill, M; Ozmadenci, D; Pachter, JA; Rappu, P; Schlaepfer, DD; Stupack, DG; Sulzmaier, FJ; Tancioni, I; Taylor, KN; Uryu, S; Weaver, DT; Xu, G1
Bao, S; Hao, D; Liu, J; Su, J; Sun, J; Xu, D; Zhang, Y; Zhou, M1
Frank, K; Kramer, M; Kuhlmann, JD; Link, T; Passek, S; Vassileva, YD; Wimberger, P1
Blakeley, C; Davidson, R; Milner, A; Poveda, AM1
Amant, FC; Ceelen, WP; De Jaeghere, EA; Denys, HG; Gremonprez, FB; Tummers, PG; Willaert, WC1
Alabdullah, M; Ali, R; Babaei-Jadidi, R; Madhusudan, S; Miligy, I; Nateri, AS; Normatova, M; Rakha, EA1
Choi, CH; Kim, BG; Kim, HS; Kim, JW; Kim, S; Lee, JY; Lim, J; Nam, BH; Yi, JY1
Fan, S; Zhang, L; Zhang, X; Zhang, Z1
Bizin, IV; Gorodnova, TV; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Kotiv, KB; Kuligina, ES; Preobrazhenskaya, EV; Savonevich, EL; Sokolenko, AP1
Long, X; Zhou, Q; Zou, D1
Belluti, S; Costi, MP; D'Arca, D; Gozzi, G; Imbriano, C; Lauriola, A; Marverti, G; Ponterini, G1
Färkkilä, A; Hautaniemi, S; Hietanen, S; Hynninen, J; Kozłowska, E; Vallius, T1
Baldassarre, G; Belletti, B; D'Andrea, S; Lorenzon, I; Pellarin, I; Pellizzari, I; Schiappacassi, M; Sonego, M1
Hu, R; Liu, R; Zeng, Y; Zhang, W; Zhou, HH1
Criscitiello, C; Curigliano, G1
Kågedal, M; Wang, N; Yu, J1
Argyris, PP; Bazzaro, M; Brown, WL; Erickson, BK; Goergen, KM; Harris, RS; Heinzen, EP; Hou, X; Huang, Y; Jarvis, MC; Kaufmann, SH; Lee, SH; Maurer, MJ; Oberg, AL; Serebrenik, AA; Vogel, RI; Weroha, SJ1
Cai, SQ; Li, HM; Li, YA; Lu, J; Ma, FH; Ma, XL; Qiang, JW; Zhao, SH1
Adorni, M; Ballabio, S; Beltrame, L; Benvenuto, G; Bignotti, E; Calura, E; Ceppi, L; D'Incalci, M; Delle Marchette, M; Donati, F; Fruscio, R; Grassi, T; Marchini, S; Martini, P; Odicino, F; Paracchini, L; Perego, P; Ravaggi, A; Romani, C; Romualdi, C; Sales, G; Sartori, E; Todeschini, P; Tognon, G; Zanotti, L1
Gabra, H; George, A; Krell, J; Lythgoe, M; McNeish, I; Rahman, N; Rumford, M; Tookman, L1
Bieńkowska, A; Dominikowska, J; Fabijańska, M; Małecki, M; Ochocki, J; Orzechowska, M; Rybarczyk-Pirek, AJ1
Bajpai, J; Deodhar, K; Ghosh, J; Gulia, S; Gupta, S; Maheshwari, A; Rath, S; Shylasree, TS; Thakur, M1
Adalsteinsson, VA; Buendia Buendia, J; Cohen, O; D'Andrea, AD; Dunn, CE; Freeman, SS; Geradts, J; Helvie, K; Hughes, ME; Isakoff, S; Ivy, SP; Kim, D; Kochupurakkal, B; Krop, IE; Lin, NU; Lloyd, MR; LoRusso, P; Marini, L; Matulonis, U; Shapiro, GI; Tolaney, SM; Wagle, N; Waks, AG; Wander, S; Winer, EP1
Penson, RT1
Alharbi, M; Guanzon, D; He, Y; Hooper, JD; Lai, A; Morgan, T; Pejovic, T; Perrin, L; Salas-Burgos, A; Salomon, C; Sharma, S; Shiddiky, MJA; Winters, C; Yamauchi, Y; Zuñiga, F1
Tomao, F; Tomao, S; Vici, P1
Aghajanian, C; Armstrong, DK; Banerjee, S; Cameron, T; Clamp, AR; Coleman, RL; Colombo, N; Dean, A; Fong, PC; Gancedo, MA; García-Donas, J; Goble, S; Goh, JC; Holloway, RW; Leary, A; Ledermann, JA; Lorusso, D; Maloney, L; O'Malley, DM; Oaknin, A; Oza, AM; Scambia, G; Swisher, EM; Weberpals, JI1
Burger, RA; Cory, L; Giuntoli, RL; Haggerty, AF; Ko, EM; Latif, NA; Morgan, MA; Nasioudis, D1
Ekmann-Gade, AW; Engelholm, SA; Fago-Olsen, CL; Hogdall, CK1
Bai, W; Bepler, G; Caruso, JA; Chen, W; Heyza, J; Hu, C; Hu, CL; Jang, H; Lou, Z; Malysa, A; Moses, N; Patrick, S; Polin, L; Stemmer, P; Wang, C; Xiang, S; Zhang, M; Zhang, XM1
Kergreis, A; Lord, RM; Pike, SJ1
Hinchcliff, EM; Meyer, LA; Westin, SN1
Avgeris, M; Braicu, I; Dorn, J; Dreyer, T; Loverix, L; Magdolen, V; Magkou, P; Mahner, S; Mavridis, K; Michaelidou, K; Obermayr, E; Panoutsopoulou, K; Reinthaller, A; Scorilas, A; Sehouli, J; Vergote, I; Zeillinger, R1
Chen, K; Cheng, X; Dai, H; Li, H; Shi, T; Sun, M; Wang, M; Wei, Q1
Brown, EJ; Devins, K; George, E; Greenberg, RA; Hallberg, D; Jagannathan, V; Johnson, N; Kim, H; Kinose, Y; Kumar, S; Ly, K; Medvedev, S; Mills, GB; Scharpf, RB; Schwartz, L; Simpkins, F; Velculescu, VE; Verma, P; Wang, Y; Xu, H; Zhang, R1
Lou, G; Mi, W; Qi, R; Tian, S; Xing, L; Zhang, C; Zhang, Y1
Chen, W; Shan, B; Wu, X; Yang, H; Ye, S; Zhong, S; Zhou, S1
Ghobashi, AH; Matthews, TD; Miller, SA; Nephew, KP; O'Hagan, HM; Pawelczak, KS; Sriramkumar, S; Turchi, JJ; VanderVere-Carozza, PS1
Golden, JA; Hu, V; Kohane, IS; Matulonis, UA; Mutter, GL; Wang, F; Yu, KH1
Jiang, G; Kang, J; Li, W; Liu, L; Owusu, L; Wang, J; Wang, X; Xu, X; Zhang, C; Zhang, L; Zhou, L1
Beachler, DC; Dinh, J; Dychter, S; Jamal-Allial, A; Lamy, FX; Lanes, S; Russo, L; Taylor, DH; Verpillat, P; Yin, R1
Chovanec, J; Hernychova, L; Ihnatova, I; Lattova, E; Nalezinska, M; Nenutil, R; Novotny, MV; Stuchlikova, E; Uhrik, L; Valik, D; Vojtesek, B; Zahradnikova, M; Zdrahal, Z1
Adawi, R; Gopas, J; Khamaisi, H; Koren Carmi, Y; Mahajna, J; Mahmoud, H1
Baldassarre, G; Belletti, B; Pellarin, I1
Chen, C; Chen, H; Chen, X; Li, R; Ma, B; Wu, J1
Bakhonsky, VV; Becker, J; De Groot, HJM; Fokin, AA; Hausmann, H; Overkleeft, HS; Pashenko, AA; Schreiner, PR1
Gao, S; Hou, J; Zhang, C1
Goto, M; Hori, K; Ito, K; Onoue, M; Takaki, E; Takei, T; Tashima, L; Tsuji, S; Yamashita, M; Yoshioka, E1
Kang, S; Li, Y; Wu, J; Zhao, J; Zuo, W1
Kato, K; Matsuoka, A; Nishikimi, K; Otsuka, S; Shozu, M; Takahashi, Y; Tate, S1
Fujiwara, H; Fujiwara, K; Kondo, E; Michimae, H; Motohashi, T; Nishio, S; Nonaka, M; Ohishi, T; Sugiyama, T; Tabata, T; Takano, M; Yabuno, A1
Chung, HH; Hwang, WY; Kim, HS; Kim, JW; Kim, K; Kim, SI; Kim, YB; Lee, M; No, JH; Park, NH; Song, YS; Suh, DH1
Addi, L; Alfano, L; Baldassarre, G; Bruzzese, F; Budillon, A; Capone, F; Costa, A; Di Gennaro, E; Iannelli, F; Lombardi, R; Milone, MR; Moccia, T; Pucci, B; Roca, MS; Sonego, M1
Bondi, R; Dalla Via, L; Hyeraci, M; Labella, L; Marchetti, F; Pagot, G; Samaritani, S1
Blagden, SP; Nicum, S1
Cui, Q; Hu, Y; Liu, H; Ma, D1
Killock, D1
An, R; Bu, H; Duan, W; Gu, K; Guo, H; Hu, W; Li, G; Li, N; Liu, J; Lou, G; Meng, Y; Pan, H; Wan, X; Wang, J; Wang, L; Wang, Q; Wang, Y; Wu, L; Wu, Q; Wu, X; Xiong, J; Yang, X; Yao, S; Yin, R; Zhang, B; Zhang, H; Zhang, X; Zhou, Q; Zhu, J; Zhu, Y1
Chan, JJ; Ghosh, W; Hettle, R; Tan, DS; Viswambaram, A; Yu, CC1
Brown, R; Chiu, DS; Choi, H; Hoppe, MM; Huntsman, DG; Jaynes, P; Jeyasekharan, AD; Karnezis, A; Kaye, SB; Leung, S; Lie, S; Lim, DGZ; Lim, S; P S Yeong, J; Pang, BNK; Patel, NR; Pitt, JJ; Sato, K; Scott, CL; Sedukhina, AS; Tan, DSP; Tan, TZ; Topp, MD; Upadhyayula, SS; Wardyn, JD1
Aghajanian, C; Beltman, J; Brenton, JD; Castro, C; Chen, LM; Coleman, RL; Goble, S; Green, M; Harding, T; Konecny, GE; Kristeleit, RS; Leary, A; Lin, KK; Ma, L; Maloney, L; McNeish, IA; O'Malley, DM; Oaknin, A; Oza, AM; Provencher, D; Ray-Coquard, I; Shapira-Frommer, R; Simmons, AD; Swisher, EM; Tinker, AV; Xiao, JJ1
Braisted, JC; Chan, DW; Cheung, ANY; Gao, Y; Li, J; Li, Y; Li, Z; Liu, SS; Nemes, P; Ngan, HYS; Pei, H; Sun, J; Wei, H; Wu, R; Yang, H; Yung, MMH; Zhang, Y; Zheng, W; Zhu, W1
Hoare, JI; Lockley, M; Martin, SA; Metcalf, S; Nicolini, F; Saxena, J; Silva, VL1
Fujiwara, H; Fujiwara, K; Kanuma, T; Nakamura, K; Nakamura, Y; Sakurai, M; Satoh, T; Suzuki, M; Takahashi, S; Takei, Y1
Apaijai, N; Charoenkwan, K; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Khunamornpong, S; Kingnate, C; Kumfu, S1
Aghajanian, C; Chambers, SK; Chen, LM; Coleman, RL; Dobrovic, A; Dominy, E; Dorigo, O; Elvin, JA; Ghatage, P; Giordano, H; Goble, S; Harding, T; Kaufmann, SH; Konecny, GE; Kristeleit, RS; Kwan, TT; Leary, A; Lin, DI; Lin, KK; Ma, L; Maloney, L; McNeish, IA; Musafer, A; O'Malley, DM; Oaknin, A; Oza, AM; Provencher, D; Ray-Coquard, I; Scott, CL; Swisher, EM; Tinker, AV; Vo, LT; Wahner Hendrickson, AE; Welch, S1
Chen, J; Gong, S; Luo, Z; Wang, X; Wang, Y; Yu, Z; Zhou, D1
Brabec, V; Clarkson, GJ; Imberti, C; Kasparkova, J; Novakova, O; Paterson, MJ; Sadler, PJ; Shi, H; Soulié, C1
Harsono, AB; Nisa, AS; Pasaribu, M; Suardi, D; Susanto, H; Trianasari, N; Winarno, GNA; Yuseran, H1
Cass, I; Kamrava, M; Karlan, B; Kim, S; Li, A; Rimel, BJ; Rogatko, A; Walsh, CS1
Cullen, GD; Goergen, K; Jin, L; Kalogera, E; Oberg, AL; Ray, U; Roy, D; Shridhar, V; Staub, J; Thirusangu, P; Wahner Hendrickson, AE; Xiao, Y1
Miao, J; Wang, M; Wu, Y; Yin, Z1
Kim, HS; Lee, M; Lee, N; Lee, S; Paik, H; Park, SJ; Yim, GW1
Chen, A; Chen, Z; Kanetsky, PA; Permuth, JB; Reid, BM; Saglam, O; Sellers, TA; Vyas, S1
Cao, S; Chen, J; Chen, X; Lin, B; Lin, S; Sun, H; Zhang, Y; Zhuang, C1
Bartom, ET; Dhir, R; Lengyel, E; Matei, D; Murmann, AE; Nephew, KP; Patel, M; Peter, ME; Wang, Y1
Diao, G; Huang, J; Liang, Z; Liu, Q; Sun, X1
Abakumova, TV; Antoneeva, II; Dolgova, DR; Gening, SO; Gening, TP1
Havrilesky, LJ; Moss, HA; Perhanidis, JA; Secord, AA1
Elzarkaa, AA; Malik, E; Soliman, AA1
Adorno-Cruz, V; Berry, E; Cowan, M; Kocherginsky, M; Lurain, JR; Matei, D; Nelson, V; Neubauer, NL; O'Shea, KL; Pineda, MJ; Shahabi, S; Swetzig, WM; Taiym, D1
Choi, MC; Hwangbo, S; Kim, K; Kim, MK; Kim, SI; Kwak, YH; Lee, JM; Lee, JW; Lee, M; Shim, SH; Shin, SJ; Yoo, J1
Alexandre, J; Berton-Rigaud, D; Bohan, P; Casado, A; Del Campo, JM; Fernández Teruel, C; Fernández, C; Galmarini, CM; Gonzalez-Martin, A; Guerra Alía, EM; Kahatt, C; Pérez de la Haza, A; Poveda, A; Provansal, M; Ray-Coquard, I; Rodriguez, I; Soto, A1
Ali, JL; Altman, AD; Lichtensztejn, Z; McManus, KJ; Nachtigal, MW; Neufeld, M; Penner-Goeke, S1
Li, LW; Li, W; Liu, HX; Liu, S; Liu, YC; Ma, R; Sun, LM1
Buderath, P; Chebouti, I; Hauch, S; Kasimir-Bauer, S; Kimmig, R; Kuhlmann, JD; Wimberger, P1
Cantrell, LA; Duska, LR; Garcia, C; Montemorano, L; Saks, E1
Carter, CA; Cottrill, HM; Oronsky, B; Ray, CM; Spira, AI; Trepel, JB1
Ebbesson, A; Hartman, L; Hedenfalk, I; Jönsson, JM; Malander, S; Martín de la Fuente, L; Måsbäck, A; Nilbert, M1
Amato, LB; Bucci, C; Dusi, S; Gasparre, G; Girolimetti, G; Guerra, F; Iommarini, L; Kurelac, I; Leone, G; Maffia, M; Perrone, AM; Porcelli, AM; Tiranti, V; Vergara, D; Vidone, M1
Chen, Y; Teng, NNH; Westhoff, GL1
Broggini, M; Damia, G; Guffanti, F; Ricci, F1
Armenia, J; Bagnoli, M; Baldassarre, G; Belletti, B; Benevol, S; Califano, D; Canzonieri, V; Chiappetta, G; D'Andrea, S; Dall'Acqua, A; Giorda, G; Mezzanzanica, D; Militello, L; Pellarin, I; Pellizzari, I; Schiappacassi, M; Sonego, M; Sorio, R1
Hutchinson, L1
Bañuelos-Ramírez, JL; Cantón-Romero, JC; Carrillo-Ibarra, S; Castellanos-González, JA; Miranda-Díaz, AG; Rodríguez-Carrizalez, AD; Sifuentes-Franco, S1
Monk, BJ1
Colombo, N2
Marth, C; Poveda, A1
Fang, L; Li, P; Wang, H1
Birrer, MJ; Konner, JA; Martin, LP; Matulonis, UA; Moore, KN; O'Malley, DM; Ponte, JF; Vergote, I1
Blyth, K; Coffelt, S; Dowson, S; Farquharson, M; Kim, J; Kruspig, B; Mason, S; Matzuk, M; McNeish, IA; Murphy, D; Port, J; Stevenson, D; Walton, JB1
Cardenas, H; Fang, F; Huang, H; Jiang, G; Keer, HN; Liu, Y; Matei, D; Nephew, KP; Perkins, SM; Zhang, C1
Ahuja, A; Aksoy, BA; Bowtell, DDL; Buros, J; Christie, EL; Hammerbacher, J; O'Donnell, T; Snyder, A1
Banerjee, S; Birrer, MJ; Colombo, N; Malek, K; Moore, KN; Oaknin, A; Oza, A; Pautier, P; Vergote, I1
Clamp, AR; Edmondson, RJ; Evans, DGR; Jayson, GC; Morgan, RD1
Bowden, NA; Tang, D; van Zyl, B1
Devgan, G; Dychter, SS; Fujiwara, K; Monk, BJ; Pujade-Lauraine, E1
Cai, E; Cai, J; Sun, S; Wang, W; Wang, Z; Wen, Y; Yang, Q; Yu, L; Zhao, S1
Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Blumenthal, GM; Charlab, R; Chen, XH; Dave, K; Dinin, J; Eradiri, O; Ghosh, S; Goldberg, KB; Horne, HN; Howie, LJ; Ibrahim, A; Ison, G; Janoria, KG; Kelly, SL; Kluetz, PG; Lee, EY; Li, F; Manheng, W; Palmby, TR; Pazdur, R; Philip, R; Pierce, WF; Pierre, V; Ramamoorthy, A; Song, P; Sridhara, R; Tang, S; Yu, J; Zhang, L1
Barak, S; Braisted, JC; Cai, X; Cai, Y; Chan, DW; Chen, CW; Chen, X; Cheung, ANY; Dai, S; Dai, Z; Han, Z; Hao, J; Hao, Q; Huang, X; Kai, Y; Lee, JB; Li, Z; Liu, SS; Meng, Y; Ngan, HYS; Pei, H; Peng, W; Shinn, P; Song, Z; Southall, NT; Sun, W; Tzatsos, A; Xu, Y; Yung, MMH; Zheng, W; Zhou, W; Zhu, W1
Liu, K; Ran, L; Song, F; Song, J; Wang, S; Zhang, W1
Komiyama, S; Kubushiro, K; Kugimiya, T; Takahashi, R; Takeya, C1
Lang, JH; Ren, T; Shen, K; Sun, J; Sun, TT; Wang, S; Xiang, Y1
Alkodsi, A; Carpén, O; Erkan, EP; Färkkilä, A; Grénman, S; Hautaniemi, SK; Hietanen, S; Huhtinen, K; Hynninen, J; Kaipio, K; Kauppi, L; Lehti, K; Lehtonen, R; Li, Y; Pietilä, E; Roering, P; Tumiati, M; Tuominen, MM; Vähärautio, A1
Hashimoto, H; Kontani, K; Mimura, M; Miyatake, T; Nagamatsu, M; Nishikawa, A; Takeda, M; Yokoi, T1
Cheng, Y; Dai, JY; Kooperberg, C; Wang, X1
Alaseem, A; Alhazzani, K; Alobid, S; Cheema, K; Dondapati, P; Kaur, P; Levy, A; Rathinavelu, A; Thallapureddy, K1
Fujiwara, H; Hamano, T; Itamochi, H; Kamiura, S; Kato, K; Kigawa, J; Komiyama, S; Shoji, T; Sugiyama, T; Tanabe, H1
Gourley, C1
Corrado, G; Ferrandina, G1
Hjortkjær, M; Jakobsen, A; Kanstrup, H; Steffensen, KD1
Besharat, RA; Besharat, ZM; Farooqi, AA; Ferretti, E; Gasparri, ML; Khalid, S; Mueller, MD; Panici, PB; Papadia, A; Sabato, C; Taghavi, K1
Degasper, C; Fiegl, H; Lax, SF; Marth, C; Shivalingaiah, G; Sprung, S; Tsibulak, I; Wenzel, S; Wieser, V; Zeimet, AG1
Bouberhan, S; Cannistra, SA; Shea, M1
Braicu, I; Darb-Esfahani, S; Ganapathi, MK; Ganapathi, RN; Lanchbury, JS; Patel, JN; Reid, J; Sehouli, J; Solimeno, C; Timms, KM; Tshiaba, P1
du Bois, A; Fielding, A; Friedlander, M; Gourley, C; Ledermann, J; Lowe, ES; Mann, H; Matei, D; Matulonis, U; McMurtry, EL; Meier, W; Parry, D; Rowe, P; Rustin, G; Safra, T; Scott, C; Selle, F; Shapira-Frommer, R; Shirinkin, V; Spencer, S; Vergote, I1
Beach, JA; Bowtell, DDL; Christie, EL; Freimund, AE1
Choi, MC; Jeong, DH; Kang, S; Kim, JW; Kim, KH; Kim, TH; Kim, YB; Kim, YM; Lee, IH; Lee, JW; Lee, JY; Lee, KB; Lee, YJ; Park, JY; Park, SY; Pujade-Lauraine, E1
Buderath, P; Chebouti, I; Kasimir-Bauer, S; Kimmig, R; Kuhlmann, JD; Puppel, SH; Reuter, M; Wimberger, P1
Binju, M; Cohen, PA; Kaur, P; Padilla, MA; Singomat, T; Suryo Rahmanto, Y; Yu, Y1
Cho, U; Chung, HH; Hwangbo, S; Kim, HS; Kim, JH; Kim, SI; Lee, M; Lee, S; Park, T; Song, M; Song, YS; Suh, DS1
Bian, J; Caron, MC; Chowdhury, D; D'Andrea, AD; De, S; Detappe, A; Doench, JG; Drané, P; He, YJ; Konstantinopoulos, PA; Legube, G; Masson, JY; Meghani, K; Moore, J; Niraj, J; Ronato, DA; Root, DE; Sharma, A; Yang, C1
Alonso, T; Cabezas, S; Callata, HR; Casado, A; Díaz-Rubio, E; Fernández, C; Gajate, P; Manzano, A; Marquina, G; Sotelo, M1
Matei, D; Mitra, AK; Mitra, S; Nephew, KP; Wang, Y; Zong, X1
Wu, L; Zhong, L1
Chen, L; Cheng, X; Dong, C; Liu, F; Liu, G; Liu, L; Liu, Z; Ren, H; Wu, A; Zheng, Y1
Bielenberg, DR; Chang, J; Fernandes, D; Gartung, A; Hammock, BD; Huang, S; Hwang, SH; Kieran, MW; Panigrahy, D; Schmidt, BA; Sukhatme, VP; Yang, J; Zurakowski, D1
Sikic, BI; Villalobos, VM; Wang, YC1
Achelle, S; Beauvineau, C; Bombard, S; Ghosh, D; Landras-Guetta, C; Mahuteau-Betzer, F; Morel, E; Naud-Martin, D; Teulade-Fichou, MP; Verga, D1
Aglietta, M; Borella, F; Di Renzo, MF; Erriquez, J; Ferrero, A; Genta, S; Ghisoni, E; Giannone, G; Katsaros, D; Maggiorotto, F; Mittica, G; Sarotto, I; Sciarrillo, A; Valabrega, G1
Heindl, A; Huang, X; Lan, C; Li, J; Wang, Y; Yan, S; Yuan, Y1
Amira, G; Fayek, IS; Mansour, O; Morsi, A; Nader, H1
Gonzalez-Martin, A; Lorusso, D; Pignata, S1
Isohashi, F; Kimura, T; Kodama, M; Komura, N; Mabuchi, S; Matsumoto, Y; Ogawa, K; Shimura, K; Tomimatsu, T; Yokoi, E1
Bender, DP; Devor, EJ; Gonzalez-Bosquet, J; Goodheart, MJ; Leslie, KK; McDonald, ME; Newtson, AM; Salinas, EA; Smith, BJ; Thiel, KW1
Nagao, S1
Arcusa, Á; Barretina-Ginesta, P; Bover, I; Casado, A; Del Campo, JM; García, Y; González-Martín, A; González-Santiago, S; Guerra, E; Herrero, A; Mallol, P; Martín, L; Martínez, A; Mori, M; Ortega, E; Romero, I; Rubio, MJ; Santaballa, A; Vicente, D; Vidal, L1
Diep, LM; Gajdzik, B; Normann, MC; Oldenburg, J; Rud, E; Solheim, O; Türzer, M1
Baldassarre, G; Belletti, B; Califano, D; Castillo-Tong, DC; Coan, M; Costa, A; Couté, Y; D'Andrea, S; Dall'Acqua, A; Kraut, A; Losito, S; Pellarin, I; Schiappacassi, M; Sonego, M; Spizzo, R; Vecchione, A; Vinciguerra, GLR1
Feng, JG; Mou, HZ; Ni, MW; Xu, Q; Zhang, SJ; Zhang, YL; Zheng, ZG; Zhou, GM; Zhou, J; Zhou, Y1
Carnero, A; Domínguez-Piñol, J; Espinosa-Sánchez, A; Estevez-Garcia, P; Felipe-Abrio, B; García-Carrasco, M; García-Heredia, JM; Jiménez-García, MP; Marin, JJ; Muñoz-Galván, S; Navas, LE; Otero-Albiol, D; Quiroga, AG; Suarez-Martinez, E; Verdugo-Sivianes, EM1
Canzonieri, V; Cecchin, E; De Mattia, E; Gagno, S; Garziera, M; Giorda, G; Montico, M; Poletto, E; Roncato, R; Scalone, S; Sorio, R; Toffoli, G1
An, X; Feng, Y; Hao, D; He, Y; Jin, X; Li, X; Li, Y; Li, Z; Ma, J; Meng, H; Tang, J; Wang, G; Wang, T; Wang, X; Weng, M; Wu, D; Yang, C; Yang, S; Yang, W; Zhang, L; Zheng, T; Zhu, Y1
Alconchel, F; Barceló, F; Cascales-Campos, PA; Gil, E; Gil, J; Gómez-Ruiz, ÁJ; González-Gil, A; Martínez, J; Navarro-Barrios, Á; Nieto, A1
Markman, M4
Deshpande, J; Dickson, EL; Geller, MA; Grad, A; Hoostal, S; Klein, M; Linden, MA; Lou, E; Monu, M; Subramanian, S; Teoh, D; Vogel, RI; Wong, P; Łukaszewski, T1
Cai, Y; Hou, Y; Li, K; Rong, Z; Song, W; Wang, W; Xie, H; Xu, H1
Al-Ali, H; Azzam, DJ; Brothers, SP; Ince, TA; Lohse, I; Volmar, CH; Wahlestedt, C1
Aust, S; Cacsire Castillo-Tong, D; Dudek, G; Grimm, C; Horvat, R; Pils, D; Pils, S; Polterauer, S; Reinthaller, A; Schmid, B; Speiser, P1
Dietl, J; Engel, JB; Gambaryan, S; Hahne, JC; Honig, A; Meyer, SR; Walter, U1
Balsari, A; Berardi, M; Canevari, S; Cataldo, A; De Cecco, L; Iorio, MV; Mezzanzanica, D; Sommariva, M; Tagliabue, E1
Chen, W; Guo, WJ; Guo, ZJ; Huang, B; Sun, Y; Tao, FF; Xu, Q; Zhang, L; Zhang, YM1
Bodnar, L; Grala, B; Kozlowski, W; Smoter, M; Stec, R; Szczylik, C; Zieniuk, K1
Benbrook, DM; Hines, L; McCumber, M; Moore, KN; Moxley, KM; Premkumar, P; Queimado, L; Thavathiru, E; Thompson, D; Zuna, RE1
Barnett, JC; Havrilesky, LJ; Ledermann, JA; Myers, ER; Peterson, BL; Secord, AA1
Lv, X; Pan, ZH; Su, A; Zhang, J; Zhou, QM1
Dimitrova, N; Kamalakaran, S; Levine, DA; Lucito, R; Varadan, V; Wrzeszczynski, KO1
Brown, R; He, Y; Hertz, DL; McLeod, HL; McWhinney-Glass, S; Motsinger-Reif, AA; Paul, J; Winham, SJ; Yen Revollo, J1
Brown, R; Dai, W; Masrour, N; Paul, J; Siddiqui, N; Zeller, C1
Ferrari, F; Gadducci, A; Landoni, F; Peiretti, M; Perrone, F; Sartori, E; Tana, R1
Bernhardy, AJ; Capelletti, M; Choi, YE; Chowdhury, D; D'Andrea, AD; Harrell, MI; Johnson, N; Johnson, SF; Li, YC; Liu, JF; Miron, A; Moreau, LA; Sarosiek, KA; Shapiro, GI; Swisher, EM; Wang, Y; Wickramanayake, A; Yao, W1
Beesley, VL; Butow, PN; Clavarino, AM; deFazio, A; Green, AC; Horwood, KR; O'Rourke, P; Price, MA; Webb, PM; Wockner, LF; Wyld, DK1
Burger, RA; Coleman, RL; Depasquale, SE; Gabrail, NY; Gersh, RH; Ghamande, SA; Gilbert, L; Harb, WA; Konstantinopoulos, PA; Kutarska, E; Leamon, CP; Lovejoy, CD; Messmann, RA; Morgenstern, DE; Naumann, RW; Nowara, E; Penson, RT; Sausville, EA; Symanowski, JT; Teneriello, MG1
González, A1
Duvillard, P; Gouy, S; Leary, A; Ledoux, F; Lhommé, C; Morice, P; Pautier, P; Petrella, MC; Tazi, Y; Uzan, C1
Bagnoli, M; Canevari, S; De Cecco, L; Granata, A; Iorio, E; Mezzanzanica, D; Nicoletti, R; Pisanu, ME; Podo, F; Ricci, A; Tinaglia, V1
Cui, H; Li, XP; Liu, BJ; Wang, JL; Wang, SJ; Wei, LH; Zhang, G1
Hu, P; Kang, S; Li, Y; Qi, BL; Wang, N; Zhou, RM1
Li, FY; Ren, XB; Xie, XY; Zhang, J1
Appleton, K; Brown, R; Gabra, H; Glasspool, RM; Gore, ME; Halford, SE; Hall, GD; Kaye, S; Mackean, M; McNeish, IA; Paul, J; Pledge, S; Rustin, GJ; Ullah, R; Walker, J; Wilson, RH1
Ashihara, K; Fujiwara, S; Kanemura, M; Kawaguchi, H; Ohmichi, M; Sasaki, H; Takai, M; Tanabe, A; Tanaka, T; Tanaka, Y; Terai, Y; Tsunetoh, S1
Aloisi, A; Angioli, R; Capriglione, S; Damiani, P; Guzzo, F; Luvero, D; Miranda, A; Montera, R; Plotti, F; Terranova, C1
Hasegawa, K; Ichikawa, R; Kato, R; Kawamura, K; Oe, S; Torii, Y; Udagawa, Y1
Butow, P; Donovan, H; Friedlander, ML; Gillies, K; King, MT; Martyn, J; O'Connell, R; Oza, A; Sjoquist, K; Stockler, M; Voysey, M1
Cui, Y; Gao, Y; Li, J; Li, M; Liu, H; Tian, Y; Zhang, Y1
Bec, N; Bianga, J; Bouslimani, A; Bouyssiere, B; Larroque, C; Lobinski, R; Mounicou, S; Quenet, F; Szpunar, J1
Banerjee, S; Clamp, A; Dawson-Athey, L; Earl, H; Feeney, A; Hall, G; Hall, M; James, L; Kaye, SB; Khan, I; Kristeleit, R; Lawrence, C; Ledermann, JA; McNeish, IA; Persic, M; Raja, F; Webber, L1
Dziegiel, P; Kedzia, W; Kobierzycki, C; Nowak-Markwitz, E; Olbromski, M; Pula, B; Solinski, D; Spaczynski, M; Zabel, M1
Čapkun, V; Miše, BP; Šundov, D; Telesmanić, VD; Tomić, S; Vrdoljak, E1
Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E1
Finan, MA; Madeira da Silva, L; McClellan, S; Meng, E; Mitra, A; Palle, K; Reed, E; Rocconi, RP; Scalici, J; Shevde, LA; Tripathi, K1
Li, KM; Tong, LX; Xiao, P; Xie, D; Yin, RT1
Asano, T; Hirohashi, Y; Kuroda, T; Mariya, T; Mizuuchi, M; Saito, T; Sato, N; Sonoda, T; Torigoe, T; Yasuda, K1
Li, L; Shi, L; Wang, Q; Yu, H; Zhang, W1
Liu, LH; Liu, YH; Xu, L; Yang, H1
Brachova, P; Button, AM; Carlson, MJ; Dai, D; Devor, EJ; Goodheart, MJ; Leslie, KK; Mott, SL; Mueting, SR; Thiel, KW1
Fan, G; Fu, C; Lucito, R; Pappin, DJ; Su, G; Tonks, NK; Wrzeszczynski, KO1
Kojima, A; Konishi, H; Nogawa, T; Okame, S; Shiroyama, Y; Takehara, K; Yamamoto, Y; Yokoyama, T1
Hao, D; Yuan, Y; Zhang, S1
Cho, EJ; Doh, KO; Elzey, BD; Sun, B; Torregrosa-Allen, S; Wilson, EM; Yeo, Y1
Ao, L; Fang, L; Gu, Y; Guo, Z; Liang, H; Peng, F; Zhang, M; Zhang, Y; Zhou, W1
Aloisi, A; Angioli, R; Capriglione, S; De Cicco Nardone, C; Luvero, D; Miranda, A; Montera, R; Plotti, F; Scaletta, G; Terranova, C1
Braicu, I; Olschewski, J; Sehouli, J; Vasconcelos, I1
Jansaka, N; Suprasert, P1
Bamias, A; Dimopoulos, MA; Episkopou, H; Gavalas, N; Kalampokas, T; Kyrtopoulos, SA; Likka, M; Photiou, S; Sfikakis, PP; Souliotis, VL; Stefanou, DT1
Baldwin, PJ; Brenton, JD; Cooke, SL; Earl, HM; Gale, D; Jimenez-Linan, M; Markowetz, F; Murtaza, M; Newman, S; Ng, CK; Parkinson, CA; Piskorz, AM; Rosenfeld, N; Sala, E; Sayal, K; Schwarz, RF; Temple, J1
Angioli, R; De Felice, F; Giorgini, M; Iadarola, R; Lecce, F; Marchetti, C; Monti, M; Musella, A; Muzii, L; Palaia, I; Panici, PB; Perniola, G; Vertechy, L1
Grizas, S; Janciauskiene, R; Juozaityte, E; Jureniene, K; Liutkauskiene, S; Malonyte, R1
Arcangeli, V; Brandes, AA; Cecere, SC; Cinieri, S; Daniele, G; Di Maio, M; Di Napoli, M; Gallo, C; Lorusso, D; Maltese, G; Mosconi, AM; Orditura, M; Panici, PB; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Ricci, C; Salutari, V; Sambataro, D; Scambia, G; Tamberi, S1
Chen, M; Fu, X; Han, W; Meng, Y; Nie, J; Wang, X; Wang, Y; Zhang, Y1
Chatterjee, PK; Gupta, M; Kohn, N; Metz, CN; Rosales, I; Solanki, MH; Xue, X; Yeboah, MM1
Arzuman, L; Beale, P; Huq, F; Yu, JQ2
Kaye, SB; Tan, DS1
Achatz, MI; Baiocchi, G; da Costa, AA; Guimarães, AP; Mantoan, H; Saito, A; Sanches, S; Valadares, CV1
Li, X; Liu, Y; Tian, Y; Zhang, C; Zhang, S; Zhang, Y1
de Souza, P; Scarano, W; Stenzel, MH1
Chen, DT; Chen, Z; Cheng, JQ; Fulp, WJ; Georgeades, C; Lancaster, JM; Magliocco, A; Permuth-Wey, J; Reid, BM1
Abiko, K; Baba, T; Chikuma, S; Hamanishi, J; Honjo, T; Hosoe, Y; Ikeda, T; Kanai, M; Kawaguchi, A; Konishi, I; Mandai, M; Matsumoto, S; Matsumura, N; Minami, M; Mori, Y; Morita, S; Murayama, T; Shimizu, A; Ueda, A; Yamaguchi, K; Yokode, M1
Ames, T; Blanco, E; Corte-Rodríguez, M; Espina, M; Montes-Bayón, M; Sanz-Medel, A; Sierra, LM1
Wang, Z; Xu, Z; Yiu, SM; Zhu, G1
Cianci, S; Costantini, B; De Iaco, P; Fagotti, A; Perrone, M; Petrillo, M; Ronsini, C; Scambia, G1
An, R; Matei, D; Merrill, D; Nolte, D; Sun, H; Turek, J; Yakubov, B1
Borad, MJ; Brunstein, F; Choi, Y; Colon-Otero, G; de Vries, EG; Diamond, JR; Kim, GP; Lamberts, LE; Lieu, CH; Maslyar, DJ; McWilliams, RR; Samineni, D; Scales, SJ; Verheul, HM; Voortman, J; Wang, Y; Weekes, CD1
Alkema, NG; de Jong, S; van der Zee, AG; van Vugt, MA; Wisman, GB1
Abedi, A; Amani, V; Bozorgmehr, M; Lighvan, ZM; Mirzadegan, E; Mohammadi, F; Safari, N; Shahsavar, F; Zarnani, AH1
Hanvoravongchai, P; Havanond, P; Khempech, N; Luealon, P; Vasuratna, A1
Chang, Y; Chang, YH; Chuang, CM; Lee, WH; Lu, CH; Peng, CW1
Anchora, LP; Fagotti, A; Petrillo, M; Scambia, G1
Fang, F; Huang, T; Liu, Y; Matei, D; Miller, DF; Nephew, KP; Özeş, AR; Özeş, ON1
Chen, C; Chen, J; Jia, XB; Liu, Y; Wang, HJ; Xu, P; Yang, LY1
Beck, SL; Brown, S; Kolb, NA; Mooney, K; Singleton, JR; Smith, AG; Stoddard, GJ1
Alard, A; Blank, SV; Curtin, JP; David-West, G; Musa, F; Schneider, RJ1
Barni, T; Botta, C; Camastra, C; De Marco, C; Di Cello, A; Di Vito, A; Donato, G; Franco, R; Malara, N; Mignogna, C; Morelli, M; Presta, I; Rizzuto, A; Salvino, A; Staropoli, N; Tagliaferri, P; Tassone, P1
Callegari, EA; Chien, J; Drappeau, DD; Eyster, KM; Gamarra-Luques, CD; Goyeneche, AA; Hapon, MB; Knapp, JR; Pan, B; Srinivasan, R; Telleria, CM; Terpstra, EJ; Wang, X; Zhang, L1
Almorsy, W; Elshebeiny, M1
Chi, D; Cowan, R; Kehoe, S; Leary, A; Nankivell, M1
Bamias, A; Chatziioannou, A; Dimopoulos, MA; Gavalas, NG; Haidopoulos, D; Kostouros, E; Koutsoukos, K; Liontos, M; Lykka, M; Papadodima, O; Pilalis, E; Rodolakis, A; Terpos, E; Thomakos, N; Trachana, SP; Tzannis, K; Vlachos, G1
Davies, L; García-Martínez, E; Gebski, V; Gladieff, L; Hilpert, F; Khoon Lee, C; Kristensen, G; Los, M; Mahner, S; Pujade-Lauraine, E; Savarese, A; Sehouli, J; Trillsch, F; Vuylsteke, P; Zagouri, F1
Baron, U; Braicu, EI; Dimitrova, D; Hellwag, A; Olek, S; Richter, R; Ruscito, I; Sehouli, J; Türbachova, I; Woopen, H1
Feng, Y; Li, B; Li, S; Miao, Y; Yan, Q1
Hall, MR; Rustin, GJ1
Ayhan, A; Burges, A; Creemers, GJ; Davies, L; Gebski, V; Hilpert, F; Huizing, M; Kristensen, G; Lee, CK; Lindemann, K; Lykka, M; Mirza, MR; Pujade-Lauraine, E; Raspagliesi, F; Romero, I; Rubio, MJ1
Carlier, C; Ceelen, W; Laforce, B; Tucoulou, R; Vekemans, B; Villanova, J; Vincze, L1
Li, L; Wang, Q; Wu, WJ; Zhang, W1
Fiegl, H; Marth, C; Notaro, S; Reimer, D; Rössler, J; Schmid, G; Wiedemair, A; Zeimet, AG1
Däster, S; Delko, T; Droeser, RA; Güth, U; Kraljević, M; Mechera, R; Singer, G; Stadlmann, S; Terracciano, L; Weixler, B1
Fallowfield, L; Howitt, BE; Karlan, BY; Matulonis, UA; Sehouli, J; Sood, AK1
Chiu, DS; Clarke, BA; Kroeger, DR; Lo, CS; Milne, K; Nelson, BH; Rahimi, K; Sanii, S; Shaw, PA; Talhouk, A1
Carlier, C; Ceelen, W; De Wever, O; Gremonprez, F; Laforce, B; Tucoulou, R; Van Malderen, SJM; Vanhaecke, F; Villanova, J; Vincze, L1
Berns, EM; Braicu, EI; Brown, R; Castillo-Tong, DC; Cunnea, P; Darb-Esfahani, S; Flanagan, JM; Flower, K; Gabra, H; Gallon, J; Hergovich, A; Koo, C; Kreuzinger, C; Loomis, E; Masrour, N; Paul, J; Sehouli, J; Siddiqui, N; Vanderstichele, A; Vergote, I; Wilhelm-Benartzi, C; Wilson, A; Wisman, GBA1
Bae, DS; Baek, SY; Choi, CH; Choi, HJ; Kim, BG; Kim, TJ; Lee, JW; Lee, YY; Paik, ES; Shim, M; Sohn, I1
Kojimahara, T; Kurachi, H; Liu, Z; Matsumura, S; Nagase, S; Narumi, M; Ohta, T; Seino, M; Sudo, T; Takahashi, K; Takahashi, T; Tsutsumi, S; Yamanouchi, K1
Babic, A; Rosner, BA; Shafrir, AL; Tamimi, RM; Terry, KL; Tworoger, SS1
Chan, C; Duan, X; Han, W; Lin, W; Poon, C1
Ab, O; Bartle, LM; Coccia, J; Lanieri, L; Lee, J; Pinkas, J; Ponte, JF; Ruiz-Soto, R; Themeles, M; Zhou, Y1
Allen, AR; Bell-McGuinn, KM; Brenton, JD; Coleman, RL; Cragun, JM; Floquet, A; Giordano, H; Goble, S; Harding, TC; Harrell, MI; Isaacson, J; Kaufmann, SH; Konecny, GE; Kristeleit, RS; Leary, A; Lin, KK; Ma, L; Maloney, L; Mann, E; McNeish, IA; O'Malley, DM; Oaknin, A; Oza, AM; Raponi, M; Ray-Coquard, I; Rolfe, L; Scott, CL; Sun, J; Swisher, EM; Tinker, AV; Yelensky, R1
Altintas, S; Bach, BA; Berger, R; Clamp, A; Colombo, N; Fong, PC; Hall, M; Kristeleit, R; Kurzeder, C; Lorusso, D; Ma, H; Marth, C; Mirza, MR; Monk, BJ; Oberaigner, W; Oza, A; Pignata, S; Renard, V; Rustin, G; Scambia, G; Vergote, I; Vogl, FD; Vuylsteke, P; Wenham, RM1
Cohen, C; Hanley, KZ; Horowitz, IR; Khanna, N; Rubinsak, LA1
Broggini, M; Caiola, E; Ceppi, L; Damia, G; Ganzinelli, M; Garassino, MC; Guffanti, F; Marabese, M; Piva, S; Rulli, E1
Cohen, JG; Diaz Moore, ES; Erickson, BK; Gunderson, CC; Holzapfel, M; Leath, CA; Leitao, MM; Moore, KN; Mueller, JJ; Prendergast, EN; Walsh, CS1
Hyman, DM; Iasonos, A; Schram, AM1
Bunne, M; Fosså, SD; Gundersen, POM; Osnes, T; Skalleberg, J; Småstuen, MC; Solheim, O1
Brard, L; Kim, KK; Lange, TS; McCourt, CK; Singh, RK; Strongin, RM1
Agostini, C; Aleba, A; Cretin, J; Dohollou, N; Ferrero, JM; Fric, D; Geay, JF; Gouttebel, MC; Haddad-Guichard, Z; Hardy-Bessard, AC; Lévy, E; Orfeuvre, H; Paraiso, D; Provencal, J; Pujade-Lauraine, E; Ray-Coquard, I; Salvat, J; Weber, B1
de Kroon, AI; de Kruijff, B; Hamelers, IH; Reedijk, J; Staffhorst, RW; van Bergen en Henegouwen, PM; Voortman, J1
Duan, R; Hambley, TW; New, EJ; Zhang, JZ1
Ansari, J; Buckley, L; Fernando, I; Tanguay, JS1
Brouwer, J; den Dulk, H; Marqués-Gallego, P; Mutikainen, I; Reedijk, J; Tanase, S; Turpeinen, U1
Güth, U; Huang, DJ; Schötzau, A; Wight, E1
Ballardini, M; Carpi, A; Conte, P; Favalli, G; Gadducci, A; Katsaros, D; Nanni, O; Panici, PB; Pecorelli, S; Scambia, G1
Al-Attar, A; Chan, S; Deen, S; Durrant, LG; Mukherjee, A; Shehata, M1
Farshchi-Heydari, S; Howell, SB; Jandial, DD; Messer, K; Pu, M1
Brard, L; Kim, KK; Lange, TS; Singh, RK1
Bhore, R; Heffernan, TP; Lea, JS; Schorge, JO; Wingo, SN1
Barbieri, P; Brienza, S; Carminati, P; Colombo, N; du Bois, A; Frigerio, L; Guastalla, JP; Katsaròs, D; Lhommé, C; Lissoni, AA; Parma, G; Pecorelli, S; Poveda, A; Ray-Coquard, I; Tisi, G; Tredan, O; Vermorken, JB1
Del Conte, G; Sessa, C1
Fujiwara, H; Hatae, M; Inoue, I; Katabuchi, H; Kodama, S; Kotera, K; Kudo, Y; Masuzaki, H; Onishi, Y; Sueyoshi, K; Suzuki, M; Tajima, A; Tanaka, K; Tashiro, H; Yahata, T; Yoshihara, K1
Alexandre, J; Cottu, P; Falandry, C; Floquet, A; Lebrun, D; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Weber, B1
Aavall-Lundqvist, E; Brown, C; du Bois, A; Ferrero, A; Gebski, V; Heywood, M; Jackisch, C; Joly, F; Kristensen, G; Le Fur, N; Lortholary, A; Pignata, S; Pujade-Lauraine, E; Sehouli, J; Vasey, PA; Vergote, I; Volgger, B; Wagner, U1
Bendas, G; Jaehde, U; Kalayda, GV; Krieger, ML; Schneider, V1
Groenewegen, G; Kronemeijer, RH; Los, M; van der Mijn, KJ; Voest, EE; Witteveen, PO1
Aghajanian, CA; Barakat, RR; Bell-McGuinn, KM; Bhatia, J; Gallagher, DJ; Kauff, ND; Konner, JA; Offit, K; Sabbatini, P; Spriggs, DR1
Fan, D; Guo, Z; Lin, M; Wang, X; Zhang, J; Zhang, Y; Zhu, J1
Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK1
Begent, RH; Boxer, GM; Elmasry, K; Maclean, AB; Morris, RW; Rashid, M; Siddiqui, GK; Wong te Fong, A1
Iramaneerat, K; Khemapech, N; Mutirangura, A; Rattanatunyong, P; Triratanachat, S1
Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T1
Mao, N; Pan, L; Shan, Y; Yan, X; Yang, Y; Yao, X; Yin, J; Zhang, Y1
Murphy, M; Stordal, B1
Buss, I; Galanski, MS; Garmann, D; Jaehde, U; Kalayda, GV; Keppler, BK; Weber, G1
Bronich, TK; Cohen, SM; Kabanov, AV; Nukolova, NV; Oberoi, HS1
Berchuck, A; Havrilesky, LJ; Higgins, RV; Kohler, MF; Myers, ER; Nycum, LR; Pokrzywinski, R; Revicki, D; Secord, AA1
Bruzzone, M; Centurioni, MG; Cosso, M; Cristoforoni, P; Ferrarini, M; Giannelli, F; Giglione, P; Gualco, M; Merlo, DF; Miglietta, L1
Coleman, RL; Naumann, RW1
Arnold, AG; Grisham, RN; Hyman, DM; Iasonos, A; Kauff, ND; Spriggs, D; Zhou, Q1
Foretová, L; Fridrichová, P; Laco, J; Melichar, B; Papajík, T; Simkovič, M1
Aghajanian, CA; Berlin, S; Hensley, ML; Iasonos, A; Jia, X; Kravetz, S; Pereira, L; Sabbatini, P; Tew, W; Whalen, C; Zarwan, C1
Bischofs, E; Eichbaum, M; Eickhoff, R; Fehm, T; Fersis, N; Fricke, HC; Gebauer, G; Lenz, F; Mayer, C; Schmidt, M; Schneeweiss, A; Sohn, C; Solomayer, E; Wallwiener, M1
Alvarez Secord, A; Berchuck, A; Havrilesky, LJ; Higgins, RV; Holloway, RW; Kohler, MF; Lewandowski, GS; Nycum, LR; Puls, LE; Valea, FA1
Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K1
Broggini, M; Caiola, E; Fruscio, R; Giuliani, D; Marabese, M; Milani, R; Porcu, L; Torri, V1
Liu, GY; Zhang, W1
Beale, P; Deqnah, N; Fisher, K; Huq, F; Yu, JQ1
Hai-Yan, S; Na, W; Rong-Miao, Z; Shan, K; Shu-Ying, Y; Yan, L; Yip, BH1
Enomoto, T; Kim, A; Naka, T; Ueda, Y1
Lai, TL; Lavori, PW; Shih, MC; Sikic, BI1
Aoki, D; Chiyoda, T; Kataoka, F; Nomura, H; Susumu, N; Tominaga, E; Tsuda, H; Yamagami, W1
Boran, N; Celik, B; Hizli, D; Isikdogan, Z; Karabuk, E; Kose, MF; Tulunay, G; Turan, T; Yilmaz, S1
Altınbaş, SK; Boran, N; Celik, B; Hızlı, D; Köse, MF; Turan, T; Yılmaz, S1
Aboagye, EO; Gabra, H; Perumal, M; Stronach, EA1
Abdul-Karim, FW; Abulafia, O; Bonebrake, AJ; Fanning, J; Kunos, C; Radivoyevitch, T; Usha, L1
Connor, JP; Felder, M; Kapur, A; Onujiogu, N1
Barash, I; Baumgartner, R; Blank, S; Curtin, JP; Gabizon, A; Kopolovic, J; Kwa, M; Michael, J; Muggia, F; Puzanov, I; Rosengarten, O; Shavit, L1
Bertoni, F; Catapano, CV; Colombo, N; Del Conte, G; Gadducci, A; Hess, D; Katsaros, D; Mancari, R; Marsoni, S; Parma, G; Rinaldi, A; Scambia, G; Sessa, C; van de Velde, H; Vitali, A1
Blank, S; Boyd, L; Czok, S; Eberhardt, S; Lee, SJ; Muggia, F; Muller, CY; Pothuri, B; Rutledge, T; Verschraegen, CF1
Chen, HH; Fu, S; Gagea-Iurascu, M; Hennessy, BT; Kuo, MT; Kurzrock, R; Liang, ZD; Long, Y; Mills, GB; Savaraj, N; Tsai, WB; Zhang, F1
du Bois, A; Harter, P; Heitz, F1
Li, JX; Qi, C; Zhang, QH1
Pujade-Lauraine, E1
Costantini, B; Fagotti, A; Fanfani, F; Margariti, PA; Petrillo, M; Piovano, E; Scambia, G; Turco, LC; Vizzielli, G1
Beale, P; Deqnah, N; Fisher, K; Huq, F; Qing Yu, J1
Bryce, NS; Chen, CK; de Jonge, MD; Hambley, TW; Howard, DL; Lanzirotti, A; Paterson, D; Zhang, JZ1
Buyukberber, S; Elkiran, ET; Gumusay, O; Inal, A; Isikdogan, A; Kaplan, MA; Kucukoner, M; Ozdemir, N; Ulas, A; Unal, O; Urakci, Z; Yaman, S1
Baumann, K; Belau, A; Bentley, J; Berton-Rigaud, D; Brown, C; Canzler, U; Friedlander, M; Gebski, V; Kristensen, G; Kurzeder, C; Ledermann, JA; Lee, CK; Lord, SJ; Nankivell, M; Parma, G; Pfisterer, J; Pisano, C; Plante, M; Pujade-Lauraine, E; Schauer, C; Simes, RJ; Skeie-Jensen, T; Swart, AM; Vergote, I1
Conner, M; Dobbin, ZC; Han, HD; Katre, AA; Landen, CN; Lopez-Berestein, G; Nowsheen, S; Shah, MM; Sood, AK; Steg, AD; Yang, ES; Ziebarth, AJ1
Biason, P; Campagnutta, E; Giorda, G; Lucia, E; Stopar, A; Talamini, R; Toffoli, G; Visentin, M1
Ahn, SE; Bazer, FW; Chung, HH; Han, JY; Jeong, W; Kim, HS; Kim, J; Kim, MA; Kim, MK; Kim, YB; Lim, W; Song, G; Song, YS1
Abbotts, R; Abdel-Fatah, T; Chan, S; Hawkes, C; Madhusudan, S; Seedhouse, C; Sultana, R1
Forster, RJ; Keyes, TE; Venkatanarayanan, A1
Agarwal, R; Blagden, S; Diamantis, N; Gabra, H; Shaboodien, R1
Baekelandt, M; Kaern, J; Tropé, CG1
Cosio, S; Gadducci, A; Genazzani, AR; Muraca, S1
Atkinson, RJ; Beale, P; Bougnoux, P; Cure, H; Dirix, L; Gore, ME; Rischin, D; Smit, WM; Thomas, H1
Beale, PJ; Foran, GJ; Hall, MD; Hambley, TW; Zhang, M1
Goff, BA; Greer, BE; Jacobs, A; Storer, B; Thompson, T1
Couzin, J1
Berman, ML; Cappuccini, F; Chan, JK; DiSaia, PJ; Loizzi, V; Osann, K1
Bamias, A; Diakomanolis, E; Dimopoulos, AM; Markaki, S; Michalas, S; Milingos, S; Papadimitriou, C; Protopapas, A1
Goodman, M; Holzer, AK; Howell, SB; Katano, K; Rochdi, M; Safaei, R; Samimi, G; Tomioka, M1
Belinson, J; Kulp, B; Markman, J; Markman, M; Peterson, G; Webster, K; Zanotti, K1
Fujii, K; Kikuchi, Y; Kita, T; Okamoto, S; Sasaki, N; Takano, M1
Sugiyama, T1
Lage, H; Liedert, B; Materna, V; Thomale, J1
Engelholm, SA; Gronlund, B; Horvath, G; Mäenpää, J; Ridderheim, M1
Abu-Rustum, N; Barakat, RR; Chi, DS; Eitan, R; Franklin, CC; Huh, JN; Levine, DA; Sonoda, Y; Stevens, TA1
Bast, RC; Clark, EA; Cliby, WA; Damokosh, AI; Gershenson, D; Hartmann, LC; Hoersch, S; Iartchouk, N; Kalli, KR; Kaufmann, SH; Lillie, J; Linette, GP; Lu, KH; Ross, JS; Shridhar, V; Smith, DI; Stec, J1
Baron, M; Blanchot, J; Bonnier, P; Castaigne, D; Classe, JM; Duvillard, P; Leblanc, E; Lhommé, C; Morice, P; Querleu, D; Rey, A1
Hiyama, E; Hiyama, K; Kigawa, J; Komatsu, M; Kudo, Y; Nagai, N; Nishiyama, M; Ohtaki, M; Ohwada, M; Otani, K; Suzuki, M; Tanimoto, K; Yunokawa, M1
Alvarez, RD; Barnes, MN; Huh, WK; Kilgore, LC; Leath, CA; Partridge, EE; Rocconi, RP; Straughn, JM1
Fernández-Botello, A; García-Friaza, G; Moreno, V; Pérez, JM; Prieto, MJ1
Case, AS; Estes, JM; Partridge, EE; Rocconi, RP; Straughn, JM1
Ferrandina, G; Martinelli, E; Paglia, A; Ranelletti, FO; Scambia, G; Zannoni, GF1
Angioli, R; Basile, S; Bellati, F; Benedetti Panici, P; De Vivo, A; Manci, N; Muzii, L; Perniola, G1
Björn, E; Ericson, C; Naredi, P; Nguyen, TT; Nöjd, M; Nygren, Y1
Brabec, V; Christofis, P; Gibson, D; Kaspárková, J; Kostrhunová, H; Najajreh, Y; Nováková, O; Slámová, M1
He, SR; Wei, FH; Yang, L; Zhang, Y; Zhao, XD1
Basuyau, JP; Dalifard, I; Eche, N; Hacene, K; Pichon, MF; Riedinger, JM1
Brard, L; Kim, KK; Lange, TS; Shaw, SK; Singh, RK1
Andrews, PA; Howell, SB; Wung, WE1
Berek, JS; Butler, TA; Ford, LC; Hacker, NF; Hoeschele, JD; Lagasse, LD; Pretorius, RG1
Gall, HE; Klein, I; Pinedo, HM; van der Vijgh, WJ; Vermorken, JB1
Pinedo, HM; van der Vijgh, WJ; Vermorken, JB1
Henkel, H; Nagel, GA; von Heyden, HW; Weinstock, N1
Bosl, GJ; Motzer, RJ; Parker, RJ; Perera, F; Poirier, MC; Reed, E; Shamkhani, H; Tang, D; Tsai, WY1
Barnard, CF; Kelland, LR; Mellish, KJ; Murrer, BA1
Ichii, M; Minami, T; Okazaki, Y1
Li, M; Liu, J1
Plaxe, SC1
Hoskins, WJ; Jones, WB; Lewis, JL; Rubin, SC; Vaccarello, L; Vlamis, V; Wong, G1
Chang, J; Fisher, C; Fryatt, I; Gore, ME; Ponder, B1
Apostoli, P; Bonetti, A; Cetto, GL; Franceschi, T; Leone, R; Messori, A; Molino, A; Sperotto, L1
Balat, O; Burk, K; Edwards, CL; Finnegan, MB; Franklin, JL; Freedman, RS; Hord, M; Kavanagh, JJ; Loechner, S; Tresukosol, D1
Hashii, K; Ichii, M; Kadota, E; Minami, T; Namikawa, K; Tateyama, I; Tohno, S; Tohno, Y; Utsumi, M; Yamada, MO1
Kikkawa, F; Kojima, M; Maeda, O; Oguchi, H; Suganuma, N; Tamakoshi, K; Tomoda, Y1
Groshen, S; Jeffers, S; Morris, M; Muderspach, L; Muggia, F; Roman, L; Russell, C; Uziely, B1
Adams, M; Fish, RG; Griffiths, H; James, K; Mason, M; Shelley, MD1
Bonneterre, J; Dauplat, J; Fumoleau, P; Guastalla, JP; Kerbrat, P; Lhommé, C; Namer, M; Oberling, F; Pouillart, P; Tubiana, N1
Hayase, R; Kodama, J; Kudoh, T; Tamada, T; Yamamoto, J; Yamamoto, M1
Barnard, CF; Harrap, KR; Kelland, LR; Mellish, KJ1
Kelland, LR; Mellish, KJ1
Cooper, KG; Kitchener, HC; Parkin, DE1
Andrews, PA; Jennerwein, M1
Bugat, R; Canal, P; Chevreau, C; Jozan, S; Julia, AM; Nehme, A1
Gore, ME; Taylor, AE1
Eisenhauer, E; Swenerton, K; ten Bokkel Huinink, WW1
Cho, T; Ikarashi, H; Kaneko, T; Kodama, S; Kurata, H; Suzuki, E; Suzuki, K; Tanaka, K; Yoshiya, N; Yoshizawa, H1
Godwin, AK; Hamilton, TC; Handel, LM; Johnson, SW; Ozols, RF; Perez, RP; Yeung, AT1
Alberts, DS; Garcia, DJ1
Hoskins, PJ; Swenerton, KD1
Abel, G; Harrap, KR; Kelland, LR; McKeage, MJ1
Almadrones, L; Barakat, R; Curtin, J; Hakes, T; Hoskins, W; Jones, W; Lewis, JL; Markman, M; Reichman, B; Rubin, S1
al-Baker, S; Han, I; Khokhar, AR; Ling, YH; Perez-Soler, R1
Khokhar, AR; Kido, Y; Siddik, ZH1
Baur, M; Dittrich, C; Fazeny, B; Grunt, T; Hudec, M; Marth, C; Salzer, H; Sevelda, P; Vavra, N1
Barakat, RR; Curtin, JP; Hakes, TB; Hoskins, WJ; Rubin, SC; Wong, GY1
Barakat, RR; Benjamin, I; Curtin, JP; Hoskins, WJ; Lewis, JL; Saigo, PE1
Calvert, AH; Ghazal-Aswad, S; Newell, DR1
Barnard, CF; Donaghue, A; Harrap, KR; Kelland, LR; Mistry, P; Murrer, BA; Poon, GK; Raynaud, FI1
Chan, KK; Formenti, SC; Jeffers, S; Jozsef, G; Morrow, PC; Muggia, FM; Sapozink, M; Shrivastava, PN1
Benard, J; Fajac, A; Llabador, Y; Moretto, P; Ortega, R; Simonoff, M1
Cumber-Walsweer, Y; Kelland, LR; O'Neill, CF; Ormerod, MG; Robertson, D; Titley, JC1
Francis, PA; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC; Walcher, V1
Kucera, E; Mayerhofer, K; Reinthaller, A; Sevelda, P; Speiser, P; Zeisler, H1
Bugat, R; Caliaro, MJ; Canal, P; Jozan, S; Lafon, C; Lochon, I; Néhmé, A; Valette, A; Vitaux, P1
Armstrong, D; Carmichael, J; Gordon, A; Malfetano, J; ten Bokkel Huinink, W1
Boven, E; Fichtinger-Schepman, AM; Korst, AE; van der Sterre, ML; van der Vijgh, WJ2
Allain, P; Buquet-Fagot, C; Cvitkovic, E; Djelloul, S; Gespach, C; Louvet, C; Mester, J; Raymond, E1
Fluellen, L; Fusco, N; Rodriguez, M; Rose, PG1
Holford, J; Kelland, LR; Rogers, P1
Sabbatini, P; Spriggs, D1
Ball, H; Blessing, JA; Lentz, SS; Markman, M; Moore, D1
Belinson, J; Ernst, S; Homesley, H; Kennedy, A; Lichtman, SM; Markman, M; Omura, G; Webster, K1
Kelland, LR; Rogers, PM; Sharp, SY1
Barletta, A; Coluccia, M; Nassi, A; Pardiso, A1
Bernhardt, G; Gust, R; Hummel, E; Koch, M; Krauser, R; Schmid, B; Schnurr, B; Schönenberger, H1
Amoroso, M; Bolis, G; Parazzini, F; Pirletti, E; Polatti, A; Rabaiotti, E; Reina, S; Scarfone, G; Villa, A1
Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; van der Vijgh, WJ; van Moorsel, CJ; Veerman, G; Vermorken, JB1
abd-Elkawy, E; Ali, HS; Fayed, ST; Kassim, SK; Khalifa, A; Sallam, MM; Seada, LS; Seada, MA1
Barletta, A; Boccarelli, A; Cardellicchio, N; Coluccia, M; Giordano, D; Intini, FP; Nassi, A; Natile, G; Paradiso, A1
Hunakova, L; Kelland, LR; O'Neill, CF1
Kaye, SB1
Bicher, A; Bostick-Bruton, F; Ma, YK; Reed, E; Yu, JJ1
Brès, J; Constans, B; Cupissol, D; Gau, F; Gory-Delabaere, G; Nouguier-Soulé, J1
Fujiwara, K1
Comerci, JT; Edwards, RP; Kanbour-Shakir, A; Kelley, JL; Kunschner, AJ; Price, FV; Sit, AS1
Bostick-Bruton, F; Dabholkar, M; Reed, E; Thornton, K; Vionnet, J; Yu, JJ1
Fujiwara, K; Fujiwara, M; Ishikawa, H; Kohno, I; Suzuki, S; Tanaka, Y; Yamauchi, H1
Cohen, SM; Lippard, SJ; Silverman, AP; Wei, M1
Kehoe, S; Selman, T1
Christian, MC; Trimble, EL; Wright, J1
Isonishi, S; Saitou, M; Tanaka, T; Yasuda, M1
Aghajanian, C; Barakat, RR; Bhaskaran, D; Brown, C; Hensley, M; Hoskins, WJ; Markman, M; Revzin, M; Sabbatini, P; Smith, A; Soignet, S; Soslow, R; Spriggs, D; Venkatraman, E1
Long, HJ; Peethambaram, PP1
Cannistra, SA1
Aghajanian, C; Dizon, DS; Hensley, ML; Hummer, A; Poynor, EA; Sabbatini, P; Spriggs, DR; Venkatraman, E1
Armstrong, DK; Bristow, RE; Montz, FJ; Tomacruz, RS; Trimble, EL1
Alvarez-Valdés, A; Amo-Ochoa, P; Camazón, MJ; Continente, JM; Font-Bardía, M; Lannegrand, R; López-Solera, I; Navarro-Ranninger, C; Pérez, JM; Solans, X1
Brubaker, LH1
Bull, JM; Cysyk, R; Gormley, PE; LeRoy, AF1
Soutter, WP1
Guthrie, D; Parmar, M; Stewart, L; Williams, CJ1
Klys, HS; Matheson, LM; McKay, K; Smyth, JF; Tothill, P1
Allegra, C; Jacob, J; Ozols, RF; Reed, E; Young, RC1
Izard, M1
Alexander, ND; Hunter, RW; Soutter, WP1
Hoskins, W; Markman, M1
Almadrones, L; Hakes, T; Hoskins, W; Jones, W; Lewis, JL; Markman, M; Pizzuto, F; Reichman, B; Rubin, S1
Abel, G; Giandomenico, CM; Harrap, KR; Kelland, LR; Mistry, P; Murrer, BA1
Hill, BT; Hosking, LK; Shellard, SA1
Hasegawa, E; Hirakawa, S; Machida, K; Momose, K; Ohmura, G; Watanabe, H1
Crowther, D; Lind, MJ; McAuliffe, CA; Murphy, DJ; Sharma, H; Smith, A; Tinker, N1
Dempke, WC; Fichtinger-Schepman, AM; Hill, BT; Shellard, SA1
Daoud, SS; Forde, NH1
Cavaletti, G; Minoia, A; Pizzini, G; Tredici, G1
Frühauf, S; Zeller, WJ1
Barr, W; Cordiner, J; Harding, M; Hole, D; Kaye, S; Kennedy, J; Milsted, R; Soukop, M; Soutter, WP1
Ostchega, Y; Ozols, RF; Poirier, MC; Reed, E; Steinberg, SM; Young, RC; Yuspa, SH1
Chambers, JT; Chambers, SK; Schwartz, PE; Voynick, IM1
Andrews, PA; Howell, SB; Jones, JA; Varki, NM1
de Vries, EG; Sleijfer, DT; Uges, DR; van der Zee, AG1
Chen, JT; Fujimoto, I; Hamada, T; Hasumi, K; Hirai, Y; Nakayama, K; Shimizu, Y; Teshima, H; Yamauchi, K; Yokosuka, K1
Canetta, RM; Colombo, N; Deeb, G; Farmen, RH; Gaver, RC; George, AM; Green, MD; Morris, AD; Muggia, FM; Speyer, JL1
Elferink, F; Gall, HE; Klein, I; Pinedo, HM; van der Vijgh, WJ; Vermorken, JB1
Andrews, PA; Howell, SB; Mann, SC; Velury, S1
Chambers, JT; Chambers, SK; Kohorn, EI; Lawrence, R; Schwartz, PE1
Amarin, J; Blackie, RG; Farmer, JG; Harding, M; Harland, SJ; Kaye, SB; Kerr, DJ1
Andrews, PA; Howell, SB; Murphy, MP1
Fish, RG; Griffiths, H; Shelley, MD1
Gorbunova, VA; Grigorova, TM; Kozachenko, VP; Marenich, AF; Perevodchikova, NI1
Erlichman, C; Fine, S; Soldin, SJ; Sturgeon, JF; Thiessen, JJ1
Issell, BF; Krikorian, JG; Lee, FH; Lopez, JA; Reich, SD; Smyth, RD1
Adams, M; Fish, RG; Kerby, I; Shelley, MD1
Bachur, NR; Costanza, ME; Dodion, P; Egan, PC; Egorin, MJ1
Boven, E; Elferink, F; Nauta, MM; Pinedo, HM; Schluper, HM; van der Vijgh, WJ1

Reviews

56 review(s) available for platinum and Cancer of Ovary

ArticleYear
Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab Therapy.
    Current oncology reports, 2021, 11-09, Volume: 23, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Europe; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; United States

2021
Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer.
    International journal of molecular sciences, 2021, Dec-20, Volume: 22, Issue:24

    Topics: Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Prognosis

2021
Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022, Volume: 30, Issue:9

    Topics: Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Quality of Life; Taxoids

2022
Survival Outcomes of Epithelial Ovarian Cancer Patients Following Dose-dense Versus 3-Weekly Platinum-Paclitaxel Chemotherapy: A Meta-Analysis.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2023, Volume: 35, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Proportional Hazards Models

2023
Targeting NaPi2b in ovarian cancer.
    Cancer treatment reviews, 2023, Volume: 112

    Topics: Biomarkers; Breast Neoplasms; Female; Humans; Immunoconjugates; Immunohistochemistry; Ovarian Neoplasms; Platinum

2023
Predicting Prognosis and Platinum Resistance in Ovarian Cancer: Role of Immunohistochemistry Biomarkers.
    International journal of molecular sciences, 2023, Jan-19, Volume: 24, Issue:3

    Topics: Biomarkers; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Quality of Life; Tumor Microenvironment

2023
Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2023, Volume: 40, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Hyperthermic Intraperitoneal Chemotherapy; Ovarian Neoplasms; Platinum; Prognosis

2023
Overcoming PARP inhibitor resistance in ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2023, 03-06, Volume: 33, Issue:3

    Topics: Antineoplastic Agents; Drug Delivery Systems; Female; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2023
Ovarian Cancer-Insights into Platinum Resistance and Overcoming It.
    Medicina (Kaunas, Lithuania), 2023, Mar-10, Volume: 59, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Tumor Microenvironment

2023
Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients With Platinum Resistance: A Narrative Review.
    JAMA oncology, 2023, Jun-01, Volume: 9, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2023
Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
    PloS one, 2023, Volume: 18, Issue:5

    Topics: China; DNA-Binding Proteins; Endonucleases; Female; Genotype; Humans; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide

2023
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis.
    Cancer treatment reviews, 2023, Volume: 118

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Network Meta-Analysis; Ovarian Neoplasms; Platinum; Polyethylene Glycols

2023
Mini-review: Immunology in ovarian cancer.
    The journal of obstetrics and gynaecology research, 2023, Volume: 49, Issue:9

    Topics: B7-H1 Antigen; Female; Humans; Immunotherapy; Ovarian Neoplasms; Platinum; Programmed Cell Death 1 Receptor

2023
Clinical and translational advances in ovarian cancer therapy.
    Nature cancer, 2023, Volume: 4, Issue:9

    Topics: Aggression; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum

2023
Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 09-20, Volume: 37, Issue:27

    Topics: Disease Management; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis

2019
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 09-20, Volume: 37, Issue:27

    Topics: Antineoplastic Agents; Disease Management; Drug Design; Drug Discovery; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Salvage Therapy

2019
RNA splicing alteration in the response to platinum chemotherapy in ovarian cancer: A possible biomarker and therapeutic target.
    Medicinal research reviews, 2021, Volume: 41, Issue:1

    Topics: Biomarkers; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; RNA Splicing

2021
Meta-analysis of excision repair cross complementary gene 1 (ERCC1) expression and platinum chemosensitivity in patients with ovarian cancer.
    Annals of palliative medicine, 2020, Volume: 9, Issue:5

    Topics: China; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Humans; Ovarian Neoplasms; Platinum

2020
The fetal outcomes after neoadjuvant platinum and paclitaxel chemotherapy during pregnancy: analysis of three cases and review of the literature.
    Archives of gynecology and obstetrics, 2022, Volume: 305, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Fetus; Humans; Infant; Infant, Newborn; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Platinum; Pregnancy

2022
ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis.
    Journal of ovarian research, 2021, Jun-21, Volume: 14, Issue:1

    Topics: DNA-Binding Proteins; Endonucleases; Female; Humans; Ovarian Neoplasms; Platinum; Polymorphism, Genetic

2021
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
    Medical oncology (Northwood, London, England), 2017, Volume: 34, Issue:6

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum

2017
When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer.
    Future oncology (London, England), 2017, Volume: 13, Issue:23s

    Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Recurrence; Retreatment; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2017
Platinum or nonplatinum in recurrent ovarian cancer: that is the question.
    Future oncology (London, England), 2017, Volume: 13, Issue:23s

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Platinum; Recurrence; Treatment Outcome

2017
Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
    Investigational new drugs, 2018, Volume: 36, Issue:2

    Topics: Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Neoplasm Grading; Ovarian Neoplasms; Platinum; Prognosis; RNA, Long Noncoding; RNA, Messenger

2018
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.
    Future oncology (London, England), 2018, Volume: 14, Issue:2

    Topics: Antibodies, Monoclonal, Humanized; Drug Resistance, Neoplasm; Female; Folate Receptor 1; Humans; Immunoconjugates; Maytansine; Ovarian Neoplasms; Platinum

2018
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:4

    Topics: Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2018
Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment.
    Endocrine-related cancer, 2018, Volume: 25, Issue:5

    Topics: Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum

2018
Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.
    Current cancer drug targets, 2019, Volume: 19, Issue:3

    Topics: Bridged-Ring Compounds; Drug Resistance, Neoplasm; Female; Focal Adhesion Kinase 1; Humans; Molecular Targeted Therapy; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Taxoids

2019
MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.
    Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:12

    Topics: Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; TOR Serine-Threonine Kinases

2018
Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
    Hematology/oncology clinics of North America, 2018, Volume: 32, Issue:6

    Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Taxoids

2018
Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review.
    Biochimica et biophysica acta. General subjects, 2019, Volume: 1863, Issue:2

    Topics: Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Tumor Microenvironment

2019
The Evolving Arena of Ovarian Cancer Maintenance Therapy.
    Oncology, 2019, Volume: 97, Issue:4

    Topics: Bevacizumab; Drug Therapy; Female; Humans; Medical Oncology; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Randomized Controlled Trials as Topic; Treatment Outcome

2019
Optimizing treatment of the partially platinum-sensitive ovarian cancer patient.
    Future oncology (London, England), 2013, Volume: 9, Issue:12 Suppl

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Tetrahydroisoquinolines; Trabectedin

2013
Increasing the chances for platinum-sensitive ovarian cancer patients.
    Future oncology (London, England), 2013, Volume: 9, Issue:12 Suppl

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Recurrence; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome

2013
Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:12

    Topics: Antineoplastic Agents; DNA-Binding Proteins; Endonucleases; Female; Humans; Ovarian Neoplasms; Platinum; Prognosis

2013
A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants.
    The oncologist, 2015, Volume: 20, Issue:2

    Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Drug Implants; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Treatment Outcome

2015
Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2015

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Treatment Outcome

2015
Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2016, Volume: 24

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Humans; Mice; Models, Theoretical; Neoplasm Grading; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2016
Primary Surgery or Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: The Debate Continues….
    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2016, Volume: 35

    Topics: Cytoreduction Surgical Procedures; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Patient Selection; Platinum; Quality of Life

2016
Ovarian cancer.
    Nature reviews. Disease primers, 2016, 08-25, Volume: 2

    Topics: Antineoplastic Agents; BRCA2 Protein; CA-125 Antigen; Contraceptives, Oral, Hormonal; Early Detection of Cancer; Female; Genetic Predisposition to Disease; Gynecologic Surgical Procedures; Humans; Mass Screening; Membrane Proteins; Ovarian Neoplasms; Ovariectomy; Parity; Platinum; Risk Factors; Sterilization, Tubal; Ubiquitin-Protein Ligases

2016
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2011, Volume: 14, Issue:3

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome

2011
Management strategies for recurrent platinum-resistant ovarian cancer.
    Drugs, 2011, Jul-30, Volume: 71, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Discovery; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Recurrence

2011
Therapeutic strategies in epithelial ovarian cancer.
    Journal of experimental & clinical cancer research : CR, 2012, Feb-13, Volume: 31

    Topics: Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Taxoids

2012
Molecular mechanisms of apoptosis and chemosensitivity to platinum and paclitaxel in ovarian cancer: biological data and clinical implications.
    European journal of gynaecological oncology, 2002, Volume: 23, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Resistance, Neoplasm; Female; Genes, p53; Humans; Molecular Biology; Mutation; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Proto-Oncogene Proteins c-bcl-2; Sensitivity and Specificity; Survival Analysis; Treatment Outcome

2002
Consolidation/maintenance chemotherapy for ovarian cancer.
    Current oncology reports, 2003, Volume: 5, Issue:6

    Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Women's Health

2003
[Second-line chemotherapy for recurrent ovarian cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Taxoids

2005
Total platinum dose versus platinum dose intensification in ovarian cancer treatment.
    Seminars in oncology, 1994, Volume: 21, Issue:2 Suppl 2

    Topics: Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Ovarian Neoplasms; Platinum

1994
Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
    Seminars in oncology, 1997, Volume: 24, Issue:1 Suppl 5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Multicenter Studies as Topic; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Remission Induction; Safety; Survival Rate; Topoisomerase I Inhibitors; Topotecan

1997
Salvage therapy for ovarian cancer.
    Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:6

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Forecasting; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Salvage Therapy; Treatment Failure

1998
Progress in the treatment of ovarian cancer. Scottish Gynaecological Cancer Trials Group.
    Anti-cancer drugs, 1999, Volume: 10 Suppl 1

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Taxoids

1999
Treatment of platinum-resistant ovarian cancer.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:8

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Quality of Life

2001
Second-line and subsequent therapy for ovarian carcinoma.
    Current oncology reports, 2002, Volume: 4, Issue:2

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Female; Genetic Therapy; Hematopoietic Stem Cell Mobilization; Humans; Immunotherapy; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Treatment Outcome

2002
Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-01, Volume: 20, Issue:5

    Topics: Aged; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Regression Analysis

2002
Chemotherapy in advanced ovarian cancer.
    BMJ (Clinical research ed.), 1992, Jan-11, Volume: 304, Issue:6819

    Topics: Female; Humans; Meta-Analysis as Topic; Ovarian Neoplasms; Platinum; Research Design

1992
Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?
    American journal of obstetrics and gynecology, 1992, Volume: 166, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Meta-Analysis as Topic; Ovarian Neoplasms; Platinum; Prognosis; Regression Analysis; Survival Rate

1992
Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
    BMJ (Clinical research ed.), 1991, Oct-12, Volume: 303, Issue:6807

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Infant, Newborn; Meta-Analysis as Topic; Ovarian Neoplasms; Platinum; Randomized Controlled Trials as Topic; Survival Rate

1991

Trials

85 trial(s) available for platinum and Cancer of Ovary

ArticleYear
Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    Gynecologic oncology, 2022, Volume: 164, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phenylurea Compounds; Platinum; Pyridines; Response Evaluation Criteria in Solid Tumors; Tamoxifen; Treatment Outcome

2022
Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy.
    International journal of clinical pharmacology and therapeutics, 2022, Volume: 60, Issue:1

    Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Survival Rate

2022
A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.
    Journal of gynecologic oncology, 2022, Volume: 33, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Republic of Korea

2022
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
    Gynecologic oncology, 2022, Volume: 164, Issue:3

    Topics: BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Germ Cells; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum

2022
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
    Gynecologic oncology, 2022, Volume: 165, Issue:1

    Topics: Aniline Compounds; Carcinoma, Ovarian Epithelial; Female; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Thrombocytopenia

2022
Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
    British journal of cancer, 2022, Volume: 126, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Epothilones; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum

2022
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
    Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Female; Humans; Lymphopenia; Nausea; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Seizures; Triple Negative Breast Neoplasms

2022
Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 08-10, Volume: 40, Issue:23

    Topics: Antibodies, Bispecific; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; RNA; Tumor Microenvironment; Vascular Endothelial Growth Factor A

2022
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial.
    BMJ open, 2022, 05-24, Volume: 12, Issue:5

    Topics: Adenocarcinoma, Clear Cell; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Quality of Life; Tumor Microenvironment

2022
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab.
    Gynecologic oncology, 2022, Volume: 166, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Indazoles; Maintenance Chemotherapy; Ovarian Neoplasms; Piperidines; Platinum

2022
Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial.
    Cell reports. Medicine, 2022, 07-19, Volume: 3, Issue:7

    Topics: Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Immune Checkpoint Inhibitors; Indoles; Ovarian Neoplasms; Platinum; Quinolines

2022
A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 01-01, Volume: 41, Issue:1

    Topics: Adenosine Diphosphate Ribose; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Transitional Cell; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerases; Urinary Bladder Neoplasms

2023
Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer.
    JCI insight, 2022, 09-22, Volume: 7, Issue:18

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Purines

2022
Patient self-reporting of tolerability using PRO-CTCAE in a randomized double-blind, placebo-controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in patients with platinum resistant or refractory epithelial ovarian ca
    Gynecologic oncology, 2022, Volume: 167, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fatigue; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum

2022
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial.
    ESMO open, 2022, Volume: 7, Issue:5

    Topics: Bevacizumab; Carboplatin; Female; Homologous Recombination; Humans; Mangifera; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerases

2022
A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer.
    Gynecologic oncology, 2022, Volume: 167, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
    Gynecologic oncology, 2022, Volume: 167, Issue:3

    Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2022
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
    British journal of cancer, 2023, Volume: 128, Issue:2

    Topics: BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2023
INOVATYON/ ENGOT-ov5 study: Randomized phase III international study comparing trabectedin/pegylated liposomal doxorubicin (PLD) followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 month
    British journal of cancer, 2023, Volume: 128, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Doxorubicin; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Trabectedin

2023
Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer: results of a multicentre, open label phase I/II study (TOPAZ).
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Leukopenia; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Topotecan

2023
Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 08-01, Volume: 29, Issue:15

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Treatment Outcome

2023
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023, 10-20, Volume: 41, Issue:30

    Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Quality of Life

2023
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2023, 09-04, Volume: 33, Issue:9

    Topics: Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Prospective Studies; Tumor Microenvironment; Viral Vaccines

2023
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Future oncology (London, England), 2019, Volume: 15, Issue:32

    Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival

2019
An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION.
    Japanese journal of clinical oncology, 2019, Aug-01, Volume: 49, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pilot Projects; Platinum; Republic of Korea

2019
A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics.
    CPT: pharmacometrics & systems pharmacology, 2020, Volume: 9, Issue:3

    Topics: Biomarkers, Tumor; CA-125 Antigen; Decision Making; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Membrane Proteins; Models, Theoretical; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Predictive Value of Tests; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Sodium-Phosphate Cotransporter Proteins, Type IIb; Software; Topoisomerase II Inhibitors; Treatment Outcome; Tumor Burden

2020
Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial.
    Journal of gynecologic oncology, 2021, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Ovarian Neoplasms; Platinum

2021
Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m² versus 40 mg/m² in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial.
    Journal of gynecologic oncology, 2021, Volume: 32, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols

2021
An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 05-01, Volume: 27, Issue:9

    Topics: Adult; Aged; Disease Management; Female; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Retreatment; Treatment Outcome

2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
    Nature communications, 2021, 05-03, Volume: 12, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; DNA Methylation; DNA-Binding Proteins; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Promoter Regions, Genetic

2021
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
    PloS one, 2021, Volume: 16, Issue:6

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CA-125 Antigen; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Progression-Free Survival; Survival Rate; Treatment Outcome

2021
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind
    Journal of gynecologic oncology, 2021, Volume: 32, Issue:5

    Topics: Administration, Intravenous; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Pharmaceutical Preparations; Platinum; Quality of Life; Randomized Controlled Trials as Topic; Selenium

2021
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial.
    Gynecologic oncology, 2021, Volume: 163, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Platinum; Quinolines

2021
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jun-01, Volume: 28, Issue:6

    Topics: Aged; Antineoplastic Agents; Carbolines; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Ovarian Neoplasms; Platinum; Topotecan

2017
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.
    Future oncology (London, England), 2018, Volume: 14, Issue:17

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoconjugates; Maytansine; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Survival Rate

2018
Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.
    Future oncology (London, England), 2018, Volume: 14, Issue:21

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; B7-H1 Antigen; Biomarkers; Clinical Protocols; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Research Design

2018
An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizuma
    BMC cancer, 2018, Jul-31, Volume: 18, Issue:1

    Topics: Antineoplastic Agents; Bevacizumab; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Progression-Free Survival

2018
Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status.
    Cancer treatment and research communications, 2018, Volume: 14

    Topics: Adenocarcinoma; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Germ-Line Mutation; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prospective Studies; Recurrence; Topotecan

2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    British journal of cancer, 2018, Volume: 119, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Capsules; Cystadenocarcinoma, Serous; Disease-Free Survival; Double-Blind Method; Female; Humans; Maintenance Chemotherapy; Middle Aged; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Treatment Outcome; Young Adult

2018
Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study.
    The oncologist, 2019, Volume: 24, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Ovarian Neoplasms; Platinum; Prognosis; Prospective Studies; Survival Rate

2019
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Dec-10, Volume: 31, Issue:35

    Topics: Administration, Intravenous; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Folic Acid; Humans; Kaplan-Meier Estimate; Middle Aged; Nausea; Neutropenia; Oligopeptides; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Treatment Outcome; Vinca Alkaloids

2013
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
    British journal of cancer, 2014, Apr-15, Volume: 110, Issue:8

    Topics: Adaptor Proteins, Signal Transducing; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Decitabine; DNA Methylation; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; MutL Protein Homolog 1; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Platinum

2014
A randomised, placebo-controlled trial of weekly paclitaxel and saracatinib (AZD0530) in platinum-resistant ovarian, fallopian tube or primary peritoneal cancer†.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Quinazolines; Retroperitoneal Neoplasms

2014
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Lenalidomide; Membrane Proteins; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Thalidomide

2014
Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer.
    PloS one, 2015, Volume: 10, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line, Tumor; Disease-Free Survival; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Survival Rate

2015
Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
    Annals of surgical oncology, 2015, Volume: 22, Issue:13

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Rate

2015
Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Italy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrimidines; Sulfonamides; Treatment Outcome

2015
Low Dose Decitabine Combined with Taxol and Platinum Chemotherapy to Treat Refractory/Recurrent Ovarian Cancer: An Open-Label, Single-Arm, Phase I/II Study.
    Current protein & peptide science, 2015, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Decitabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Safety

2015
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Dec-01, Volume: 33, Issue:34

    Topics: Adenocarcinoma, Clear Cell; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Cohort Studies; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Programmed Cell Death 1 Receptor; Salvage Therapy; Survival Rate

2015
Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; GPI-Linked Proteins; Humans; Immunoconjugates; Immunohistochemistry; Mesothelin; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Ovarian Neoplasms; Platinum; Retreatment; Tomography, X-Ray Computed; Treatment Outcome

2016
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:9

    Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Treatment Outcome

2016
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Response Evaluation Criteria in Solid Tumors

2016
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
    The Lancet. Oncology, 2017, Volume: 18, Issue:1

    Topics: Aged; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Germ-Line Mutation; Humans; Indoles; International Agencies; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate

2017
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 70

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Recombinant Fusion Proteins

2017
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.
    British journal of cancer, 2009, Feb-24, Volume: 100, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Taxoids

2009
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-01, Volume: 27, Issue:28

    Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epithelial Cells; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Proportional Hazards Models; Treatment Outcome; Young Adult

2009
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Recurrence; Taxoids

2010
Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jul-10, Volume: 28, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Recurrence

2010
Phase 1/2 study of atrasentan combined with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.
    Neoplasia (New York, N.Y.), 2010, Volume: 12, Issue:11

    Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Pyrrolidines; Survival Analysis; Treatment Outcome; Vomiting

2010
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.
    Cancer, 2012, Jan-15, Volume: 118, Issue:2

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Quality of Life; Recurrence; Taxoids

2012
Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study.
    Oncology, 2011, Volume: 80, Issue:3-4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Survival Analysis; Treatment Outcome

2011
Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.
    Cancer, 2012, May-01, Volume: 118, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Furans; Humans; Ketones; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Retreatment; Tubulin Modulators

2012
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.
    BMC cancer, 2011, Oct-20, Volume: 11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Pyrimidines; Sulfonamides

2011
A multicenter, randomized, phase 2 clinical trial to evaluate the efficacy and safety of combination docetaxel and carboplatin and sequential therapy with docetaxel then carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
    Cancer, 2012, Jul-01, Volume: 118, Issue:13

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Quality of Life; Recurrence; Taxoids

2012
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
    International journal of clinical oncology, 2013, Volume: 18, Issue:1

    Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids

2013
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study.
    Journal of translational medicine, 2012, Apr-27, Volume: 10

    Topics: Adult; Aged; Cell Line, Tumor; Cell Survival; Deoxycytosine Nucleotides; DNA Damage; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gynecology; Histones; Humans; Immunoblotting; Medical Oncology; Middle Aged; Ovarian Neoplasms; Platinum; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones; Treatment Outcome

2012
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2012, Volume: 22, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; CA-125 Antigen; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Pyrazines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult

2012
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Taxoids; Treatment Outcome

2012
A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients.
    European journal of gynaecological oncology, 2002, Volume: 23, Issue:5

    Topics: Adult; Aged; Analysis of Variance; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Probability; Remission Induction; Risk Assessment; Survival Rate; Treatment Outcome

2002
A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:18

    Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Treatment Failure; Vomiting

2002
Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
    American journal of obstetrics and gynecology, 2003, Volume: 188, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome; Washington

2003
Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
    Cancer, 2005, Apr-01, Volume: 103, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Administration Schedule; Etoposide; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Taxoids; Topotecan

2005
Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors.
    Therapeutic drug monitoring, 1995, Volume: 17, Issue:1

    Topics: Adolescent; Adult; Cisplatin; Drug Administration Schedule; Female; Germinoma; Half-Life; Humans; Male; Middle Aged; Ovarian Neoplasms; Platinum; Testicular Neoplasms

1995
A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.
    Gynecologic oncology, 1995, Volume: 58, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Cyclobutanes; Drug Resistance; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Platinum

1995
Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:9

    Topics: Adult; Aged; Bacterial Infections; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Premedication; Risk Factors; Survival Analysis

1994
A dosing scheme for carboplatin in adult cancer patients based upon pre-infusion renal function and platelet count.
    Anti-cancer drugs, 1994, Volume: 5, Issue:5

    Topics: Adenocarcinoma; Aged; Carboplatin; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Kidney Function Tests; Male; Middle Aged; Monte Carlo Method; Ovarian Neoplasms; Platelet Count; Platinum; Risk Factors; Teratoma; Testicular Neoplasms; Thrombocytopenia

1994
Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: an interim analysis of a phase II multicenter study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5 Suppl 6

    Topics: Adult; Aged; Chlorpheniramine; Cimetidine; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Prednisolone; Premedication; Prospective Studies; Salvage Therapy; Stereoisomerism

1994
Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group.
    Cancer treatment reviews, 1993, Volume: 19 Suppl C

    Topics: Blood Pressure; Dose-Response Relationship, Drug; Female; Heart Rate; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Premedication

1993
Oral etoposide is active against platinum-resistant epithelial ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1

    Topics: Administration, Oral; Adult; Aged; Carcinoma; Drug Resistance; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Treatment Outcome

1994
In vitro and in vivo evaluation of the combination of cisplatin and its analogue carboplatin for platinum dose intensification in ovarian carcinoma.
    Cancer, 1993, May-15, Volume: 71, Issue:10

    Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Leukocyte Count; Ovarian Neoplasms; Pilot Projects; Platelet Count; Platinum; Tumor Cells, Cultured

1993
Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.
    Gynecologic oncology, 1996, Volume: 63, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome

1996
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
    Gynecologic oncology, 1998, Volume: 69, Issue:3

    Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Agents, Alkylating; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Treatment Outcome

1998
Phase 2 trial of moderately high dose single agent mitoxantrone in platinum and paclitaxel-refractory ovarian cancer.
    Gynecologic oncology, 1998, Volume: 70, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Paclitaxel; Platinum

1998
Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer.
    Gynecologic oncology, 1999, Volume: 72, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Failure

1999
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:2

    Topics: Acute Kidney Injury; Adult; Aged; Carcinoma; Drug Evaluation; Drug Resistance; Female; Humans; Ifosfamide; Mesna; Middle Aged; Ovarian Neoplasms; Platinum

1992

Other Studies

492 other study(ies) available for platinum and Cancer of Ovary

ArticleYear
Photochemistry and
    Chemical communications (Cambridge, England), 2021, Oct-26, Volume: 57, Issue:85

    Topics: Antineoplastic Agents; Apoptosis; Cell Membrane Permeability; Computational Biology; Coordination Complexes; Drug Screening Assays, Antitumor; Female; HeLa Cells; Humans; Light; Optical Imaging; Ovarian Neoplasms; Photochemotherapy; Platinum; Rhenium; Spectrometry, X-Ray Emission

2021
Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2022, 01-01, Volume: 28, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tubes; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Pyrazoles; Pyrimidinones

2022
The expression and clinical significance of ERβ/ERα in ovarian cancer: can we predict the effectiveness of platinum plus taxane therapy?
    Irish journal of medical science, 2022, Volume: 191, Issue:5

    Topics: Bridged-Ring Compounds; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Humans; Ovarian Neoplasms; Platinum; Receptors, Estrogen; Taxoids

2022
Adjuvant taxane plus platinum chemotherapy for stage I ovarian clear cell carcinoma with complete surgical staging: are more than three cycles necessary?
    International journal of clinical oncology, 2022, Volume: 27, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Retrospective Studies; Taxoids

2022
Discovery of metabolomic biomarkers for discriminating platinum-sensitive and platinum-resistant ovarian cancer by using GC-MS.
    European journal of mass spectrometry (Chichester, England), 2021, Volume: 27, Issue:6

    Topics: Biomarkers; Gas Chromatography-Mass Spectrometry; Humans; Metabolome; Metabolomics; Ovarian Neoplasms; Platinum

2021
Applicability of the Histoculture Drug Response Assay to Predict Platinum Sensitivity and Prognosis in Ovarian Cancer.
    Anticancer research, 2021, Volume: 41, Issue:12

    Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Analysis

2021
Chronic stress induces platinum and Niraparib resistance in mouse models of ovarian cancer.
    Experimental cell research, 2022, 01-15, Volume: 410, Issue:2

    Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Indazoles; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Models, Biological; Ovarian Neoplasms; Piperidines; Platinum; Stress, Psychological

2022
THE QUALITY OF LIFE OF OVARIAN CANCER PATIENTS AS AN INDICATION OF THE EFFECTIVENESS OF PLATINUM-BASED ADJUVANT CHEMOTHERAPY.
    Georgian medical news, 2021, Issue:320

    Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Humans; Ovarian Neoplasms; Platinum; Quality of Life

2021
Identification of potent SENP1 inhibitors that inactivate SENP1/JAK2/STAT signaling pathway and overcome platinum drug resistance in ovarian cancer.
    Clinical and translational medicine, 2021, Volume: 11, Issue:12

    Topics: Cysteine Endopeptidases; Drug Resistance; Female; Humans; Ovarian Neoplasms; Platinum; Signal Transduction

2021
Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer.
    International journal of clinical oncology, 2022, Volume: 27, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Ovarian Neoplasms; Platinum

2022
TFEB Regulates ATP7B Expression to Promote Platinum Chemoresistance in Human Ovarian Cancer Cells.
    Cells, 2022, 01-10, Volume: 11, Issue:2

    Topics: Base Sequence; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line, Tumor; Copper-Transporting ATPases; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Platinum; Transcription, Genetic

2022
Design, synthesis and biological evaluation of antitumor platinum(II) agents conjugated with non-steroidal anti-inflammatory drug species.
    Bioorganic chemistry, 2022, Volume: 120

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Screening Assays, Antitumor; Female; Humans; Inflammation; Organoplatinum Compounds; Ovarian Neoplasms; Platinum

2022
Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Ovarian Cancer Treated With Primary Surgery Followed by Platinum-based Chemotherapy: A Single-center Italian Study.
    Anticancer research, 2022, Volume: 42, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Italy; Middle Aged; Muscle, Skeletal; Neoplasm, Residual; Ovarian Neoplasms; Ovariectomy; Platinum; Prognosis; Progression-Free Survival; Retrospective Studies; Sarcopenia; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome

2022
Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum-based chemotherapy.
    The journal of obstetrics and gynaecology research, 2022, Volume: 48, Issue:5

    Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Retrospective Studies

2022
    Molecules (Basel, Switzerland), 2022, Jan-19, Volume: 27, Issue:3

    Topics: Antineoplastic Agents; Cisplatin; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Platinum

2022
2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion.
    Molecules (Basel, Switzerland), 2022, Jan-26, Volume: 27, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Female; Humans; MAP Kinase Signaling System; Mesenchymal Stem Cells; Organoplatinum Compounds; Ovarian Neoplasms; Platinum

2022
Survival in recurrent ovarian cancer patients before and after the bevacizumab era: an observational single-centre study.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2022, Volume: 42, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2022
Platinum-Based Chemotherapy 'Rechallenge' in Advanced Non-ovarian Solid Malignancies.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2022, Volume: 34, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Platinum; Quality of Life

2022
Significance of platinum distribution to predict platinum resistance in ovarian cancer after platinum treatment in neoadjuvant chemotherapy.
    Scientific reports, 2022, 03-16, Volume: 12, Issue:1

    Topics: Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum

2022
Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.
    Oncoimmunology, 2022, Volume: 11, Issue:1

    Topics: Animals; Carcinoma, Ovarian Epithelial; Cellular Senescence; Female; Mice; Ovarian Neoplasms; Platinum; Tumor Microenvironment

2022
Synthesis and characterization of thiocarbonato-linked platinum(IV) complexes.
    Dalton transactions (Cambridge, England : 2003), 2022, Apr-05, Volume: 51, Issue:14

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Platinum

2022
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2022, 06-06, Volume: 32, Issue:6

    Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Mangifera; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Ribose

2022
Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2022, 07-04, Volume: 32, Issue:7

    Topics: Adenosine Diphosphate Ribose; Antineoplastic Agents; Australia; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Retrospective Studies

2022
A risk model of gene signatures for predicting platinum response and survival in ovarian cancer.
    Journal of ovarian research, 2022, Mar-31, Volume: 15, Issue:1

    Topics: China; DNA Copy Number Variations; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Intermediate Filament Proteins; Ovarian Neoplasms; Platinum; Ribonucleases; Sodium-Glucose Transporter 1

2022
Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions.
    Cytopathology : official journal of the British Society for Clinical Cytology, 2022, Volume: 33, Issue:4

    Topics: Biomarkers, Tumor; Carcinoma; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Platinum; Pleural Effusion, Malignant; Prognosis; Retrospective Studies

2022
Synthesis and In Vitro Studies of Photoactivatable Semisquaraine-type Pt(II) Complexes.
    Inorganic chemistry, 2022, May-23, Volume: 61, Issue:20

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Female; HeLa Cells; Humans; Ligands; Ovarian Neoplasms; Platinum

2022
Novel MicroRNA-Regulated Transcript Networks Are Associated with Chemotherapy Response in Ovarian Cancer.
    International journal of molecular sciences, 2022, Apr-28, Volume: 23, Issue:9

    Topics: Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Gene Regulatory Networks; Humans; MicroRNAs; Ovarian Neoplasms; Platinum; RNA, Messenger

2022
Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
    BMC cancer, 2022, May-16, Volume: 22, Issue:1

    Topics: BRCA2 Protein; Carcinoma, Ovarian Epithelial; Female; Homologous Recombination; Humans; Ovarian Neoplasms; Platinum; Recombinational DNA Repair

2022
Anaphylactic reaction to carboplatin diagnosed by skin testing-a reliable tool in platinum-based immediate-type hypersensitivity reactions.
    Wiener medizinische Wochenschrift (1946), 2023, Volume: 173, Issue:11-12

    Topics: Anaphylaxis; Antineoplastic Agents; Carboplatin; Cisplatin; Drug Hypersensitivity; Erythema; Female; Humans; Melanoma; Middle Aged; Ovarian Neoplasms; Platinum

2023
Alantolactone-Loaded Pegylated Prodrug Nanocarriers for Synergistic Treatment of Cisplatin-Resistant Ovarian Cancer via Reactivating Mitochondrial Apoptotic Pathway.
    ACS biomaterials science & engineering, 2022, 06-13, Volume: 8, Issue:6

    Topics: Antineoplastic Agents; Cisplatin; Female; Humans; Lactones; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prodrugs; Sesquiterpenes, Eudesmane

2022
A Rationally Designed Bimetallic Platinum (II)-Ferrocene Antitumor Agent Induces Non-Apoptotic Cell Death and Exerts in Vivo Efficacy.
    Chemistry (Weinheim an der Bergstrasse, Germany), 2022, Aug-16, Volume: 28, Issue:46

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Female; Humans; Metallocenes; Organoplatinum Compounds; Ovarian Neoplasms; Platinum

2022
Effects of Pegylated Liposomal Doxorubicin and CA125 Level Variability Analysis in Platinum-refractory/resistant Recurrent Ovarian Cancer.
    Anticancer research, 2022, Volume: 42, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies

2022
Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.
    Journal of translational medicine, 2022, 05-31, Volume: 20, Issue:1

    Topics: Animals; Cisplatin; Female; Humans; Mitochondria; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Ovarian Neoplasms; Oxidative Phosphorylation; Platinum; Sirtuin 1

2022
Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.
    International journal of clinical pharmacology and therapeutics, 2022, Volume: 60, Issue:8

    Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2022
Case report: Response to platinum agents and poly (adenosine diphosphate-ribose) polymerase inhibitor in a patient with BRCA1 c.5096G>A (R1699Q) intermediate-risk variant.
    Cancer treatment and research communications, 2022, Volume: 32

    Topics: Adenosine Diphosphate; Aged; BRCA1 Protein; Female; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Ribose

2022
Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma.
    Computational and mathematical methods in medicine, 2022, Volume: 2022

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carbohydrates; Carcinoma, Ovarian Epithelial; Female; Humans; MicroRNAs; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life

2022
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer.
    British journal of cancer, 2022, Volume: 127, Issue:7

    Topics: Ataxia Telangiectasia Mutated Proteins; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; Drug Resistance; Female; Fibroblast Growth Factor 1; Fibroblast Growth Factors; Humans; Ovarian Neoplasms; Platinum; Recombinational DNA Repair; Replication Protein A; RNA, Small Interfering

2022
The Immune Subtype Contributes to Distinct Overall Survival for Ovarian Cancer Patients With Platinum-Based Adjuvant Therapy.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Tumor Microenvironment

2022
Efficacy and safety of olaparib maintenance monotherapy for Japanese patients with platinum-sensitive relapsed ovarian, fallopian tube, and primary peritoneal cancer.
    International journal of clinical oncology, 2022, Volume: 27, Issue:10

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Japan; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Retrospective Studies

2022
Genomic and epigenomic
    Science translational medicine, 2022, 07-06, Volume: 14, Issue:652

    Topics: BRCA1 Protein; BRCA2 Protein; Carcinoma; Epigenomics; Female; Genomics; Humans; Mutation; Ovarian Neoplasms; Platinum; Triple Negative Breast Neoplasms

2022
Assessment of Tumor Heterogeneity in High-Grade Serous Ovarian Cancer: Mass Cytometry to Understand the Complex Tumor Biology.
    Methods in molecular biology (Clifton, N.J.), 2022, Volume: 2535

    Topics: Biology; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2022
A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Gynecologic oncology, 2022, Volume: 167, Issue:1

    Topics: Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Tumor Microenvironment

2022
Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
    PloS one, 2022, Volume: 17, Issue:8

    Topics: Carcinoma, Ovarian Epithelial; Cell Line; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Single-Cell Analysis; Transcriptome

2022
Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells.
    Nature communications, 2022, 08-05, Volume: 13, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Fatty Acids; Female; Glucose; Glycolysis; Humans; Ovarian Neoplasms; Platinum

2022
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers.
    Nature communications, 2022, 08-05, Volume: 13, Issue:1

    Topics: Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Serine

2022
Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report.
    Reproductive sciences (Thousand Oaks, Calif.), 2023, Volume: 30, Issue:2

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Recurrence

2023
Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2022, Volume: 33, Issue:10

    Topics: BRCA1 Protein; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2022
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
    Anticancer research, 2022, Volume: 42, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies

2022
Mutational Footprint of Platinum Chemotherapy in a Secondary Thyroid Cancer.
    JCO precision oncology, 2022, Volume: 6

    Topics: Carboplatin; Female; Humans; Ovarian Neoplasms; Platinum; Thyroid Neoplasms

2022
NANOG regulates epithelial-mesenchymal transition via AMPK/mTOR signalling pathway in ovarian cancer SKOV-3 and A2780 cells.
    Journal of cellular and molecular medicine, 2022, Volume: 26, Issue:20

    Topics: AMP-Activated Protein Kinases; Biomarkers; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Nanog Homeobox Protein; Ovarian Neoplasms; Platinum; RNA, Small Interfering; TOR Serine-Threonine Kinases

2022
Role of salvage radiotherapy for recurrent ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2023, 01-03, Volume: 33, Issue:1

    Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies; Salvage Therapy

2023
Potent Chlorambucil-Platinum(IV) Prodrugs.
    International journal of molecular sciences, 2022, Sep-09, Volume: 23, Issue:18

    Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Chlorambucil; Cisplatin; Female; Humans; Male; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Prodrugs; Reactive Oxygen Species

2022
Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study).
    International journal of clinical oncology, 2022, Volume: 27, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Progression-Free Survival; Retrospective Studies

2022
Whole-exome sequencing of epithelial ovarian carcinomas differing in resistance to platinum therapy.
    Life science alliance, 2022, 10-13, Volume: 5, Issue:12

    Topics: Carcinoma, Ovarian Epithelial; Exome Sequencing; Female; Humans; Ovarian Neoplasms; Platinum; Precision Medicine

2022
IDO1 Modulates the Sensitivity of Epithelial Ovarian Cancer Cells to Cisplatin through ROS/p53-Dependent Apoptosis.
    International journal of molecular sciences, 2022, Oct-09, Volume: 23, Issue:19

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Female; Heme; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Ovarian Neoplasms; Platinum; Reactive Oxygen Species; Tumor Suppressor Protein p53

2022
Novel Platinum Nanoclusters Activate PI3K/AKT/mTOR Signaling Pathway-Mediated Autophagy for Cisplatin-Resistant Ovarian Cancer Therapy.
    ACS applied materials & interfaces, 2022, Nov-02, Volume: 14, Issue:43

    Topics: Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; Cisplatin; Female; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases

2022
A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Antineoplastic Agents, Immunological; Apoptosis; B7-H1 Antigen; Carcinoma, Ovarian Epithelial; Female; HLA-B44 Antigen; Humans; Immune Checkpoint Inhibitors; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Programmed Cell Death 1 Receptor

2022
A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models.
    International journal of molecular sciences, 2022, Oct-15, Volume: 23, Issue:20

    Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Female; Heterografts; Humans; Immunoconjugates; Immunoglobulin G; Maytansine; Mice; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Xenograft Model Antitumor Assays

2022
Bioactive Platinum(IV) Complexes Incorporating Halogenated Phenylacetates.
    Molecules (Basel, Switzerland), 2022, Oct-21, Volume: 27, Issue:20

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Female; Glioblastoma; Humans; Ovarian Neoplasms; Phenylacetates; Platinum; Reactive Oxygen Species

2022
NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer.
    Biomarkers in medicine, 2022, Volume: 16, Issue:14

    Topics: Biomarkers; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Neurocalcin; Ovarian Neoplasms; Platinum; Prognosis

2022
The efficacy and safety of platinum-based chemotherapy for ovarian cancer in pregnancy: A protocol for systematic review and meta-analysis.
    Medicine, 2022, Nov-25, Volume: 101, Issue:47

    Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Meta-Analysis as Topic; Ovarian Neoplasms; Platinum; Pregnancy; Systematic Reviews as Topic

2022
Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
    Journal of translational medicine, 2022, 12-03, Volume: 20, Issue:1

    Topics: Aldehyde Reductase; Carboplatin; Carcinoma, Ovarian Epithelial; CD8-Positive T-Lymphocytes; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Ovarian Neoplasms; Platinum; Proteomics; RNA, Messenger; Tumor Microenvironment

2022
High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer.
    BJOG : an international journal of obstetrics and gynaecology, 2022, Volume: 129 Suppl 2

    Topics: Amino Acid Transport System y+; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Platinum; Prognosis; Retrospective Studies

2022
Computer-aided identification, synthesis, and biological evaluation of DNA polymerase η inhibitors for the treatment of cancer.
    European journal of medicinal chemistry, 2023, Feb-15, Volume: 248

    Topics: Apoptosis; Cell Line, Tumor; DNA Damage; DNA Replication; Female; Humans; Ovarian Neoplasms; Platinum

2023
N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase.
    Molecular cancer therapeutics, 2023, 03-02, Volume: 22, Issue:3

    Topics: Adenosine; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Female; Humans; Nicotinamide N-Methyltransferase; Ovarian Neoplasms; Platinum; RNA

2023
Dye-cored polylysine dendrimer as luminescent nanoplatform for imaging-guided anticancer drug delivery.
    Colloids and surfaces. B, Biointerfaces, 2023, Volume: 222

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Dendrimers; Doxorubicin; Female; Humans; Ovarian Neoplasms; Platinum; Polylysine

2023
LRRC superfamily expression in stromal cells predicts the clinical prognosis and platinum resistance of ovarian cancer.
    BMC medical genomics, 2023, 01-18, Volume: 16, Issue:1

    Topics: Female; Humans; Leucine; Membrane Proteins; Ovarian Neoplasms; Platinum; Prognosis; Stromal Cells; Tumor Microenvironment

2023
Effectiveness and safety of nab-paclitaxel and platinum as first-line chemotherapy for ovarian cancer: a retrospective study.
    Journal of gynecologic oncology, 2023, Volume: 34, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies

2023
The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome.
    British journal of cancer, 2023, Volume: 128, Issue:9

    Topics: Carcinoma, Ovarian Epithelial; DNA Damage; Female; Humans; Machine Learning; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2023
Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
    Journal of ovarian research, 2023, Feb-23, Volume: 16, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Retrospective Studies; Vascular Endothelial Growth Factor A

2023
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
    Anticancer research, 2023, Volume: 43, Issue:3

    Topics: Adenosine Diphosphate Ribose; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tubes; Female; Humans; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Thrombocytopenia

2023
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
    Gynecologic oncology, 2023, Volume: 171

    Topics: BRCA1 Protein; DNA Damage; Female; Homologous Recombination; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Rad51 Recombinase

2023
Proteomic analysis reveals CAAP1 negatively correlates with platinum resistance in ovarian cancer.
    Journal of proteomics, 2023, 04-15, Volume: 277

    Topics: Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Proteomics; RNA, Messenger

2023
A platinum(II) complex HY1-Pt overcomes cisplatin-induced resistance and attenuates metastasis of epithelial ovarian cancer by cancer cell stemness inhibition.
    The international journal of biochemistry & cell biology, 2023, Volume: 157

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Casein Kinase II; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2023
Unveiling the epigenomic mechanisms of acquired platinum-resistance in high-grade serous ovarian cancer.
    International journal of cancer, 2023, 07-01, Volume: 153, Issue:1

    Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Epigenomics; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2023
Circ_0078607 increases platinum drug sensitivity via miR-196b-5p/GAS7 axis in ovarian cancer.
    Epigenetics, 2023, Volume: 18, Issue:1

    Topics: Animals; Cell Proliferation; Cisplatin; DNA Methylation; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; MicroRNAs; Nerve Tissue Proteins; Ovarian Neoplasms; Platinum; RNA, Circular

2023
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
    Journal of ovarian research, 2023, Mar-15, Volume: 16, Issue:1

    Topics: East Asian People; Female; Homologous Recombination; Humans; Mutation; Ovarian Neoplasms; Platinum

2023
Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative chemotherapy in patients with advanced ovarian cancer.
    Medicine, 2023, Mar-17, Volume: 102, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Female; Humans; Lung Neoplasms; Ovarian Neoplasms; Platinum; Retrospective Studies; Vinblastine; Vinorelbine

2023
New Drug Treats Female Reproductive Cancers.
    The American journal of nursing, 2023, 04-01, Volume: 123, Issue:4

    Topics: Adult; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum

2023
Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies.
    Cancer, 2023, 07-01, Volume: 129, Issue:13

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cystadenocarcinoma, Serous; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies

2023
Synthesis, Characterization and Biological Investigation of the Platinum(IV) Tolfenamato Prodrug-Resolving Cisplatin-Resistance in Ovarian Carcinoma Cell Lines.
    International journal of molecular sciences, 2023, Mar-16, Volume: 24, Issue:6

    Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Female; Humans; Ovarian Neoplasms; Platinum; Prodrugs

2023
The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
    Cancer research communications, 2023, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Animals; BRCA2 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Disease Models, Animal; Female; Heterografts; Humans; Mice; Ovarian Neoplasms; Platinum; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors

2023
Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
    The journal of gene medicine, 2023, Volume: 25, Issue:10

    Topics: Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; DNA-Binding Proteins; Female; Humans; Ovarian Neoplasms; Platinum; RNA; Transcriptome; Tumor Microenvironment

2023
hMSH2 coordinated with the expression of E2F1 promotes platinum response in epithelial ovarian cancer.
    The Journal of international medical research, 2023, Volume: 51, Issue:3

    Topics: Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Female; Humans; Kaplan-Meier Estimate; MutS Homolog 2 Protein; Ovarian Neoplasms; Platinum

2023
ROS-mediated SRMS activation confers platinum resistance in ovarian cancer.
    Oncogene, 2023, Volume: 42, Issue:20

    Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Reactive Oxygen Species; src-Family Kinases

2023
RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2023, 07-05, Volume: 29, Issue:13

    Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Rad51 Recombinase

2023
BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report.
    Pathologica, 2023, Volume: 115, Issue:2

    Topics: BRCA1 Protein; BRCA2 Protein; Carcinoma; Female; Gene Amplification; Humans; Mutation; Ovarian Neoplasms; Platinum

2023
Outcomes and Prognostic Factors of Patients with Platinum- Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2023, Apr-01, Volume: 24, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis

2023
Enhancement of sonodynamic treatment of ovarian cancer based on Pt-B-P ternary nanoparticles.
    Nanomedicine : nanotechnology, biology, and medicine, 2023, Volume: 51

    Topics: Animals; Cell Line, Tumor; Female; Humans; Hydrogen Peroxide; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Nanoparticles; Ovarian Neoplasms; Oxygen; Platinum; Reactive Oxygen Species; Tumor Microenvironment

2023
Targeting homologous recombination deficiency in uterine leiomyosarcoma.
    Journal of experimental & clinical cancer research : CR, 2023, May-04, Volume: 42, Issue:1

    Topics: Female; Homologous Recombination; Humans; Leiomyosarcoma; Ovarian Neoplasms; Piperazines; Platinum; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair; Uterine Neoplasms

2023
Metabolic modulation of CtBP dimeric status impacts the repression of DNA damage repair genes and the platinum sensitivity of ovarian cancer.
    International journal of biological sciences, 2023, Volume: 19, Issue:7

    Topics: Animals; Cell Line, Tumor; Cisplatin; DNA Damage; Drug Resistance, Neoplasm; Female; Humans; Metformin; Mice; Ovarian Neoplasms; Platinum

2023
Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells.
    International journal of molecular sciences, 2023, Apr-23, Volume: 24, Issue:9

    Topics: Animals; Carboplatin; Drug Resistance, Neoplasm; Female; Humans; Mesenchymal Stem Cells; Mice; Ovarian Neoplasms; Platinum; Tumor Microenvironment

2023
Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum-refractory/resistant ovarian cancer.
    Cancer medicine, 2023, Volume: 12, Issue:13

    Topics: Adipose Tissue; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies

2023
Impact of the number of cycles of platinum-based chemotherapy for early stage ovarian clear cell carcinoma on survival: a retrospective study.
    BMC women's health, 2023, 05-15, Volume: 23, Issue:1

    Topics: Adenocarcinoma, Clear Cell; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Retrospective Studies

2023
Anti-Cancer and Radio-Sensitizing Properties of New Bimetallic (
    Journal of medicinal chemistry, 2023, 05-25, Volume: 66, Issue:10

    Topics: Amines; Cell Line, Tumor; Female; Humans; Ovarian Neoplasms; Platinum; Radiation-Sensitizing Agents

2023
Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial.
    JAMA oncology, 2023, 07-01, Volume: 9, Issue:7

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Smallpox; Vaccinia

2023
Cost-Effectiveness Analysis of Biomarker Testing to Guide First-Line PARP Inhibitor Maintenance for Patients with Advanced Ovarian Cancer After Response to First-Line Platinum Chemotherapy in the USA.
    Targeted oncology, 2023, Volume: 18, Issue:4

    Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Ovarian Epithelial; Cost-Effectiveness Analysis; Female; Humans; Maintenance Chemotherapy; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2023
Clinical perspectives of rare ovarian tumors: clear cell ovarian cancer.
    Japanese journal of clinical oncology, 2023, Jul-31, Volume: 53, Issue:8

    Topics: Adenocarcinoma, Clear Cell; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Quality of Life

2023
Mechanisms of autophagy and endoplasmic reticulum stress in the reversal of platinum resistance of epithelial ovarian cancer cells by naringin.
    Molecular biology reports, 2023, Volume: 50, Issue:8

    Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases

2023
Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience.
    Anticancer research, 2023, Volume: 43, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies

2023
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 190

    Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Germ Cells; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies

2023
Clinical and biomarker factors affecting survival in patients with platinum-sensitive relapsed ovarian cancer receiving olaparib monotherapy: a multicenter retrospective study.
    Scientific reports, 2023, 07-24, Volume: 13, Issue:1

    Topics: BRCA1 Protein; BRCA2 Protein; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Prospective Studies; Retrospective Studies

2023
Visible light-activatable platinum(IV) prodrugs harnessing CD36 for ovarian cancer therapy.
    Dalton transactions (Cambridge, England : 2003), 2023, Aug-08, Volume: 52, Issue:31

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Female; Humans; Light; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Prodrugs

2023
Association of UBE2L6 and ABCB6 Expression With Platinum Resistance in Serous Ovarian Carcinoma.
    Anticancer research, 2023, Volume: 43, Issue:8

    Topics: ATP-Binding Cassette Transporters; Carcinoma, Ovarian Epithelial; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Prognosis; Ubiquitin-Conjugating Enzymes

2023
Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
    Breast cancer research and treatment, 2023, Volume: 202, Issue:1

    Topics: BRCA1 Protein; BRCA2 Protein; Female; Genomic Instability; Homologous Recombination; Humans; Ovarian Neoplasms; Platinum; Triple Negative Breast Neoplasms

2023
HIPEC in Ovarian Cancer: When and to Whom?
    Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2023, Volume: 33, Issue:9

    Topics: Cisplatin; Cystadenocarcinoma, Serous; Female; Fever; Humans; Hyperthermic Intraperitoneal Chemotherapy; Middle Aged; Ovarian Neoplasms; Platinum

2023
RAD51D Secondary Mutation-Mediated Resistance to PARP-Inhibitor-Based Therapy in HGSOC.
    International journal of molecular sciences, 2023, Sep-23, Volume: 24, Issue:19

    Topics: Carcinoma, Ovarian Epithelial; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mutation; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2023
Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse.
    Journal of ovarian research, 2023, Oct-28, Volume: 16, Issue:1

    Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Disease Progression; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Recurrence; Retrospective Studies; Ribose

2023
Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer.
    Journal for immunotherapy of cancer, 2023, Volume: 11, Issue:11

    Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Lymphocytes, Tumor-Infiltrating; Ovarian Neoplasms; Platinum; T-Lymphocytes

2023
FT-Raman data analyzed by multivariate and machine learning as a new methods for detection spectroscopy marker of platinum-resistant women suffering from ovarian cancer.
    Scientific reports, 2023, Nov-26, Volume: 13, Issue:1

    Topics: Amides; Female; Humans; Ovarian Neoplasms; Platinum; Proteins; Spectrum Analysis, Raman

2023
Chemotherapy-free, but not quite free chemotherapy.
    The Lancet. Oncology, 2019, Volume: 20, Issue:10

    Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum

2019
FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.
    eLife, 2019, 09-03, Volume: 8

    Topics: Animals; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Focal Adhesion Kinase 1; Humans; Mice; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Signal Transduction; Stem Cells

2019
Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy.
    Cell death & disease, 2019, 09-10, Volume: 10, Issue:9

    Topics: Biomarkers, Tumor; Cell Line, Tumor; Databases, Nucleic Acid; Female; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Platinum

2019
Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.
    International journal of cancer, 2020, 05-01, Volume: 146, Issue:9

    Topics: Aged; Biomarkers, Tumor; Calbindin 2; Case-Control Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Longitudinal Studies; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Survival Rate

2020
Treatment of Ovarian Cancer With Intraperitoneal Platinum: Heating Up the Debate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 11-20, Volume: 37, Issue:33

    Topics: Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Heating; Humans; Ovarian Neoplasms; Platinum

2019
ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity.
    Cells, 2019, 10-18, Volume: 8, Issue:10

    Topics: Ataxia Telangiectasia Mutated Proteins; Blotting, Western; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxycycline; Female; Flow Cytometry; HeLa Cells; Humans; Ovarian Neoplasms; Plasmids; Platinum; Protein Stability; PTEN Phosphohydrolase; Real-Time Polymerase Chain Reaction; Tissue Array Analysis; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein

2019
Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis.
    Medicine, 2019, Volume: 98, Issue:44

    Topics: Antineoplastic Agents; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Ovarian Neoplasms; Platinum; Prognosis

2019
Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.
    International journal of cancer, 2020, 04-01, Volume: 146, Issue:7

    Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Genotype; Humans; Models, Biological; Mutation; Ovarian Neoplasms; Platinum; Recurrence; Transcriptome; Treatment Outcome

2020
Chemotherapy-free strategy for platinum-sensitive recurrent ovarian cancer.
    The Lancet. Oncology, 2019, Volume: 20, Issue:12

    Topics: Bevacizumab; Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum

2019
The 1,10-Phenanthroline Ligand Enhances the Antiproliferative Activity of DNA-Intercalating Thiourea-Pd(II) and -Pt(II) Complexes Against Cisplatin-Sensitive and -Resistant Human Ovarian Cancer Cell Lines.
    International journal of molecular sciences, 2019, Dec-04, Volume: 20, Issue:24

    Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Coordination Complexes; DNA; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Female; Humans; Intercalating Agents; Ligands; Ovarian Neoplasms; Palladium; Phenanthrolines; Platinum; Thiourea

2019
Virtual clinical trials identify effective combination therapies in ovarian cancer.
    Scientific reports, 2019, 12-10, Volume: 9, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Clinical Trials as Topic; Computer Simulation; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Kaplan-Meier Estimate; Models, Theoretical; Ovarian Neoplasms; Platinum; Research Design; Taxoids

2019
Identification and Characterization of a New Platinum-Induced TP53 Mutation in MDAH Ovarian Cancer Cells.
    Cells, 2019, 12-21, Volume: 9, Issue:1

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Mitosis; Mutation; Ovarian Neoplasms; Ovary; Platinum; Tumor Suppressor Protein p53

2019
Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.
    EBioMedicine, 2020, Volume: 51

    Topics: Cohort Studies; Computational Biology; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Kaplan-Meier Estimate; Lymphocyte Subsets; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Support Vector Machine; Treatment Outcome

2020
Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 127

    Topics: Chemotherapy, Adjuvant; Female; Humans; Lymphocytes, Tumor-Infiltrating; Ovarian Neoplasms; Platinum

2020
The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 07-01, Volume: 26, Issue:13

    Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Cytidine Deaminase; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Minor Histocompatibility Antigens; Ovarian Neoplasms; Platinum; Prognosis; Synthetic Lethal Mutations; Xenograft Model Antitumor Assays

2020
Prediction of Platinum-based Chemotherapy Response in Advanced High-grade Serous Ovarian Cancer: ADC Histogram Analysis of Primary Tumors.
    Academic radiology, 2021, Volume: 28, Issue:3

    Topics: Diffusion Magnetic Resonance Imaging; Female; Humans; Ovarian Neoplasms; Platinum; Retrospective Studies

2021
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer.
    International journal of cancer, 2020, 07-15, Volume: 147, Issue:2

    Topics: Adult; Aged; Cyclic GMP-Dependent Protein Kinase Type I; Cystadenocarcinoma, Serous; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Middle Aged; Myosin-Light-Chain Phosphatase; Neoplasm Grading; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome

2020
Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
    Scientific reports, 2020, 02-25, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; BRCA1 Protein; BRCA2 Protein; Decision Making; Female; Germ-Line Mutation; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; United Kingdom

2020
Simple
    International journal of molecular sciences, 2020, Mar-19, Volume: 21, Issue:6

    Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Survival; Cisplatin; Female; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Ligands; Molecular Structure; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Structure-Activity Relationship; Survivin

2020
Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer.
    JCO global oncology, 2020, Volume: 6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Female; Humans; Indazoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Pyrimidines; Retrospective Studies; Sulfonamides

2020
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:5

    Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2020
Platinum-sensitive ovarian cancer: liminal advances.
    The Lancet. Oncology, 2020, Volume: 21, Issue:5

    Topics: Bevacizumab; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2020
miRNa signature in small extracellular vesicles and their association with platinum resistance and cancer recurrence in ovarian cancer.
    Nanomedicine : nanotechnology, biology, and medicine, 2020, Volume: 28

    Topics: Biomarkers; Drug Resistance, Neoplasm; Exosomes; Female; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Ovarian Neoplasms; Platinum

2020
Expanding use of rucaparib as maintenance therapy in recurrent ovarian cancer: updates from the ARIEL3 trial.
    The Lancet. Oncology, 2020, Volume: 21, Issue:5

    Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Indoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
    The Lancet. Oncology, 2020, Volume: 21, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Double-Blind Method; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Treatment Outcome

2020
Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
    Gynecologic oncology, 2020, Volume: 157, Issue:3

    Topics: Adolescent; Adult; Humans; Lymph Node Excision; Middle Aged; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Platinum; Young Adult

2020
Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer.
    Anticancer research, 2020, Volume: 40, Issue:5

    Topics: Aged; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Logistic Models; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Platinum

2020
The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53.
    Cell death & disease, 2020, 05-07, Volume: 11, Issue:5

    Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase 6; Humans; Lung Neoplasms; Mice, SCID; Mutation; Ovarian Neoplasms; Platinum; Protein Binding; Protein Stability; Signal Transduction; Substrate Specificity; Tumor Suppressor Protein p53; Ubiquitin Thiolesterase; Ubiquitination; Xenograft Model Antitumor Assays

2020
Influence of Ligand and Nuclearity on the Cytotoxicity of Cyclometallated C^N^C Platinum(II) Complexes.
    Chemistry (Weinheim an der Bergstrasse, Germany), 2020, Nov-20, Volume: 26, Issue:65

    Topics: Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Ligands; Ovarian Neoplasms; Platinum; Platinum Compounds

2020
Has dose-dense chemotherapy met an ICONic end?
    The Lancet. Oncology, 2020, Volume: 21, Issue:7

    Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Ovarian Neoplasms; Platinum; Quality of Life

2020
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
    International journal of cancer, 2020, 12-15, Volume: 147, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cohort Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Disease Progression; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis; Survival Analysis; Treatment Outcome; Up-Regulation

2020
Potentially functional variants in nucleotide excision repair pathway genes predict platinum treatment response of Chinese ovarian cancer patients.
    Carcinogenesis, 2020, 09-24, Volume: 41, Issue:9

    Topics: Asian People; Biomarkers, Tumor; Cell Cycle Proteins; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Genotype; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide; Prognosis; ROC Curve; Transcription Factors

2020
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
    Nature communications, 2020, 07-24, Volume: 11, Issue:1

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cyclins; Drug Combinations; Drug Resistance, Neoplasm; Female; Gene Knockout Techniques; Humans; Mice, Inbred NOD; Mice, SCID; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Rad51 Recombinase; Stem Cells; Xenograft Model Antitumor Assays

2020
The identification of six risk genes for ovarian cancer platinum response based on global network algorithm and verification analysis.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Cell Line, Tumor; Disease-Free Survival; DNA Polymerase III; Drug Resistance, Neoplasm; Fanconi Anemia; Fanconi Anemia Complementation Group A Protein; Fanconi Anemia Complementation Group G Protein; Female; Gene Expression Regulation, Neoplastic; Histone Demethylases; Homologous Recombination; Humans; Middle Aged; Ovarian Neoplasms; Platinum; RecQ Helicases; Risk Factors

2020
Serum D-dimer, albumin and systemic inflammatory response markers in ovarian clear cell carcinoma and their prognostic implications.
    Journal of ovarian research, 2020, Aug-08, Volume: 13, Issue:1

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; CA-125 Antigen; Female; Fibrin Fibrinogen Degradation Products; Humans; Leukocyte Count; Lymphocyte Count; Middle Aged; Monocytes; Neoplasm Staging; Ovarian Neoplasms; Platelet Count; Platinum; Preoperative Period; Prognosis; Retrospective Studies; Serum Albumin; Survival Analysis; Treatment Outcome

2020
Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer.
    Molecular cancer research : MCR, 2020, Volume: 18, Issue:11

    Topics: Animals; Female; Histones; Humans; Ovarian Neoplasms; Phosphorylation; Platinum; Polycomb Repressive Complex 1; Ubiquitination

2020
Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks.
    BMC medicine, 2020, 08-18, Volume: 18, Issue:1

    Topics: Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis

2020
Dihydrotanshinone I inhibits ovarian cancer cell proliferation and migration by transcriptional repression of PIK3CA gene.
    Journal of cellular and molecular medicine, 2020, Volume: 24, Issue:19

    Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Furans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Ovarian Neoplasms; Phenanthrenes; Phosphatidylinositol 3-Kinases; Platinum; Proto-Oncogene Proteins c-akt; Quinones; Signal Transduction; Transcription, Genetic; Zebrafish

2020
A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer.
    Journal of ovarian research, 2020, Aug-31, Volume: 13, Issue:1

    Topics: Aged; Algorithms; Antineoplastic Agents; Cohort Studies; Databases, Factual; Female; Humans; Insurance Claim Review; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Survival Analysis; Taxoids; Time-to-Treatment; Treatment Outcome; United States

2020
N-Glycome changes reflecting resistance to platinum-based chemotherapy in ovarian cancer.
    Journal of proteomics, 2021, 01-06, Volume: 230

    Topics: Female; Glycosylation; Humans; Ovarian Neoplasms; Platinum; Polysaccharides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2021
Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
    International journal of molecular sciences, 2020, Sep-07, Volume: 21, Issue:18

    Topics: 3T3-L1 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; MAP Kinase Signaling System; Mice; Ovarian Neoplasms; Paclitaxel; Platinum; Tumor Microenvironment

2020
Synthesis and antiproliferative activity of hindered, chiral 1,2-diaminodiamantane platinum(II) complexes.
    Dalton transactions (Cambridge, England : 2003), 2020, Oct-20, Volume: 49, Issue:40

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Coordination Complexes; Drug Design; Drug Resistance, Neoplasm; Female; Guanosine Monophosphate; Humans; Isomerism; Ligands; Molecular Conformation; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Structure-Activity Relationship

2020
ERCC1 expression and platinum chemosensitivity in patients with ovarian cancer: A meta-analysis.
    The International journal of biological markers, 2020, Volume: 35, Issue:4

    Topics: DNA-Binding Proteins; Endonucleases; Female; Humans; Ovarian Neoplasms; Platinum

2020
[Efficacy of Olaparib Treatment for Platinum-Sensitive Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:10

    Topics: Fallopian Tube Neoplasms; Fallopian Tubes; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum

2020
A functional polymorphism in the poly(ADP-ribose) polymerase-1 gene is associated with platinum-based chemotherapeutic response and prognosis in epithelial ovarian cancer patients.
    European journal of obstetrics, gynecology, and reproductive biology, 2020, Volume: 255

    Topics: Carcinoma, Ovarian Epithelial; Case-Control Studies; Female; Genotype; Humans; Ovarian Neoplasms; Platinum; Poly (ADP-Ribose) Polymerase-1; Polymorphism, Single Nucleotide; Prognosis

2020
Survival impact of extended cycles of second-line chemotherapy in platinum-sensitive relapsed ovarian cancer patients with residual tumor after six cycles.
    BMC cancer, 2020, Dec-07, Volume: 20, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2020
HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.
    Molecular oncology, 2021, Volume: 15, Issue:4

    Topics: Animals; Antineoplastic Agents; Benzoquinones; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Platinum; Proteomics; Triazoles; Xenograft Model Antitumor Assays

2021
Cytotoxicity and DNA interaction in a series of aryl terminated iminopyridine Pt(II) complexes.
    Journal of inorganic biochemistry, 2021, Volume: 216

    Topics: A549 Cells; Coordination Complexes; Cytotoxins; DNA, Neoplasm; Female; HeLa Cells; HT29 Cells; Humans; Ovarian Neoplasms; Platinum; Pyridines

2021
A source of hope for platinum-resistant ovarian cancer?
    Lancet (London, England), 2021, 01-23, Volume: 397, Issue:10271

    Topics: Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Pyrazoles; Pyrimidinones

2021
A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer.
    Drug design, development and therapy, 2021, Volume: 15

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Indoles; Middle Aged; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinolines

2021
WEE1 inhibition after platinum resistance.
    Nature reviews. Clinical oncology, 2021, Volume: 18, Issue:4

    Topics: Cell Cycle Proteins; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones

2021
Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with
    Journal of gynecologic oncology, 2021, Volume: 32, Issue:2

    Topics: Cost-Benefit Analysis; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Singapore

2021
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer.
    EMBO molecular medicine, 2021, 05-07, Volume: 13, Issue:5

    Topics: Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Rad51 Recombinase

2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
    Gynecologic oncology, 2021, Volume: 161, Issue:3

    Topics: Administration, Oral; Aged; Area Under Curve; BRCA1 Protein; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2021
SENP1-mediated deSUMOylation of JAK2 regulates its kinase activity and platinum drug resistance.
    Cell death & disease, 2021, 04-01, Volume: 12, Issue:4

    Topics: Cell Nucleus; Cysteine Endopeptidases; Cytoplasm; Drug Resistance; Female; Humans; Janus Kinase 2; Ovarian Neoplasms; Platinum; Signal Transduction

2021
Chloroxine overrides DNA damage tolerance to restore platinum sensitivity in high-grade serous ovarian cancer.
    Cell death & disease, 2021, 04-14, Volume: 12, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chloroquinolinols; Cisplatin; Cystadenocarcinoma, Serous; DNA Damage; Drug Resistance, Neoplasm; Female; Humans; Mice, Transgenic; Ovarian Neoplasms; Platinum

2021
Treatment-related leukemia after taxane and platinum therapy in gynecological cancer patients (Gynecologic Oncology Trial and Investigation Consortium 011).
    The journal of obstetrics and gynaecology research, 2021, Volume: 47, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Genital Neoplasms, Female; Humans; Leukemia; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Taxoids

2021
Platinum-based chemotherapy and bevacizumab instigate the destruction of human ovarian cancers via different signaling pathways.
    Biochemical pharmacology, 2021, Volume: 188

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Signal Transduction; Tumor Cells, Cultured

2021
Nano-assembly of ursolic acid with platinum prodrug overcomes multiple deactivation pathways in platinum-resistant ovarian cancer.
    Biomaterials science, 2021, Jun-04, Volume: 9, Issue:11

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Female; Humans; Mice; Ovarian Neoplasms; Platinum; Prodrugs; Triterpenes; Ursolic Acid

2021
DNA-Intercalative Platinum Anticancer Complexes Photoactivated by Visible Light.
    Chemistry (Weinheim an der Bergstrasse, Germany), 2021, Jul-21, Volume: 27, Issue:41

    Topics: Antineoplastic Agents; Cell Line, Tumor; DNA; Female; Humans; Light; Organoplatinum Compounds; Ovarian Neoplasms; Platinum

2021
The Platelet to Lymphocyte and Neutrophil to Lymphocyte Ratios in Predicting Response to Platinum-based Chemotherapy for Epithelial Ovarian Cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2021, May-01, Volume: 22, Issue:5

    Topics: Adult; Biomarkers, Tumor; Blood Platelets; Carcinoma, Ovarian Epithelial; Case-Control Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Indonesia; Lymphocytes; Middle Aged; Neutrophils; Ovarian Neoplasms; Platinum; Prognosis

2021
Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization.
    Journal of experimental & clinical cancer research : CR, 2021, Jun-03, Volume: 40, Issue:1

    Topics: Animals; Autophagy; Cell Proliferation; Cell Survival; CRISPR-Cas Systems; Female; Gene Expression Regulation, Neoplastic; Group III Phospholipases A2; Heterografts; Humans; Lipid Droplets; Lipogenesis; Mice; Microscopy, Electron, Transmission; Neoplasm Metastasis; Ovarian Neoplasms; Platinum; Pyridines; Quinolines

2021
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
    BMC cancer, 2021, Jun-17, Volume: 21, Issue:1

    Topics: Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Humans; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Platinum

2021
The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer.
    Cancer research, 2021, 08-01, Volume: 81, Issue:15

    Topics: Female; Humans; MicroRNAs; Ovarian Neoplasms; Platinum

2021
Transcriptome-based stemness indices analysis reveals platinum-based chemo-theraputic response indicators in advanced-stage serous ovarian cancer.
    Bioengineered, 2021, Volume: 12, Issue:1

    Topics: Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Gene Expression Profiling; Genetic Association Studies; Humans; Ovarian Neoplasms; Platinum; Prognosis; Transcriptome

2021
The Plasticity of Circulating Tumor Cells in Ovarian Cancer During Platinum-containing Chemotherapy.
    Current cancer drug targets, 2021, Volume: 21, Issue:11

    Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Epithelial Cell Adhesion Molecule; Humans; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Ovarian Neoplasms; Platinum

2021
Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer.
    Gynecologic oncology, 2021, Volume: 163, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; BRCA1 Protein; BRCA2 Protein; Female; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Retrospective Studies; Young Adult

2021
Epithelial Ovarian Cancer and Cancer Stem Cells.
    Advances in experimental medicine and biology, 2021, Volume: 1330

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Neoplastic Stem Cells; Ovarian Neoplasms; Platinum

2021
Comparisons of survival outcomes between bevacizumab and olaparib in
    Journal of gynecologic oncology, 2021, Volume: 32, Issue:6

    Topics: Bevacizumab; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Republic of Korea

2021
The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples.
    PLoS genetics, 2017, Volume: 13, Issue:4

    Topics: Cell Line, Tumor; Chromosomal Instability; Drug Resistance, Neoplasm; Female; Genetic Heterogeneity; Humans; In Situ Hybridization, Fluorescence; Neoplasm Staging; Ovarian Neoplasms; Platinum; Single-Cell Analysis

2017
Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression.
    European review for medical and pharmacological sciences, 2017, Volume: 21, Issue:6

    Topics: ADAM17 Protein; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Nivolumab; Ovarian Neoplasms; Platinum

2017
EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.
    Oncotarget, 2017, Jul-25, Volume: 8, Issue:30

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Count; Chemotherapy, Adjuvant; Class Ia Phosphatidylinositol 3-Kinase; Epithelial-Mesenchymal Transition; Female; Humans; Immunophenotyping; Kaplan-Meier Estimate; Neoplastic Cells, Circulating; Ovarian Neoplasms; Phenotype; Platinum; Prognosis; Twist-Related Protein 1

2017
Cutting costs and standardizing care: Once-per-cycle complete blood count monitoring may be safe for patients undergoing platinum-based chemotherapy.
    The journal of obstetrics and gynaecology research, 2017, Volume: 43, Issue:4

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Chemotherapy-Induced Febrile Neutropenia; Endometrial Neoplasms; Female; Hospitalization; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Retrospective Studies

2017
Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy Response.
    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2018, Volume: 37, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Carcinoma; Carcinoma, Ovarian Epithelial; Claudin-4; Cohort Studies; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Sweden; Tissue Array Analysis

2018
Platinum-induced mitochondrial DNA mutations confer lower sensitivity to paclitaxel by impairing tubulin cytoskeletal organization.
    Human molecular genetics, 2017, 08-01, Volume: 26, Issue:15

    Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cytoskeleton; DNA, Mitochondrial; Drug Resistance, Neoplasm; Female; Humans; Mutation; Ovarian Neoplasms; Paclitaxel; Platinum; Tubulin

2017
Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017, Volume: 27, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Female; Forkhead Box Protein M1; Humans; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; RNA, Messenger; Thiostrepton

2017
Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
    Molecular cancer, 2017, 05-30, Volume: 16, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Mice; Mutation; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays

2017
CDK6 protects epithelial ovarian cancer from platinum-induced death via FOXO3 regulation.
    EMBO molecular medicine, 2017, Volume: 9, Issue:10

    Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase 6; DNA Damage; Female; Forkhead Box Protein O3; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Piperazines; Platinum; Primary Cell Culture; Protein Kinase Inhibitors; Pyridines; Survival Analysis; Xenograft Model Antitumor Assays

2017
Targeted therapies: SOLO2 confirms olaparib maintenance in ovarian cancer.
    Nature reviews. Clinical oncology, 2017, Volume: 14, Issue:10

    Topics: Double-Blind Method; Female; Humans; Mutation; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Tablets

2017
Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer.
    Oxidative medicine and cellular longevity, 2017, Volume: 2017

    Topics: Adult; Aged; Antioxidants; Ascites; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Inflammation; Interleukin-6; Isoprostanes; Lipid Peroxides; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Oxidative Stress; Platinum; Tumor Necrosis Factor-alpha

2017
Optimal treatment for platinum-sensitive recurrent ovarian cancer.
    Clinical advances in hematology & oncology : H&O, 2017, Volume: 15, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Ovarian Neoplasms; Platinum; Recurrence; Retreatment; Treatment Outcome

2017
CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
    Scientific reports, 2017, 12-04, Volume: 7, Issue:1

    Topics: Animals; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Cell Survival; CRISPR-Cas Systems; Cystadenocarcinoma, Serous; Disease Models, Animal; Female; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Grading; Neurofibromin 1; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; PTEN Phosphohydrolase; Survival Rate; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2017
Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.
    Cancer research, 2018, 02-01, Volume: 78, Issue:3

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; Epigenomics; Female; Genomics; Humans; Ovarian Neoplasms; Platinum; Prognosis; Promoter Regions, Genetic; Tumor Cells, Cultured

2018
Chemotherapy weakly contributes to predicted neoantigen expression in ovarian cancer.
    BMC cancer, 2018, 01-22, Volume: 18, Issue:1

    Topics: Aged; Animals; Antigens, Neoplasm; Caenorhabditis elegans; CD8-Positive T-Lymphocytes; Chickens; Female; Gene Expression Regulation, Neoplastic; Genome; High-Throughput Nucleotide Sequencing; Humans; Macrophages; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplastic Stem Cells; Ovarian Neoplasms; Platinum

2018
Enhancer of zeste homolog 2 promotes cisplatin resistance by reducing cellular platinum accumulation.
    Cancer science, 2018, Volume: 109, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Boron Compounds; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Ovarian Neoplasms; Platinum; RNA Interference

2018
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 09-01, Volume: 24, Issue:17

    Topics: Aged; BRCA1 Protein; BRCA2 Protein; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Risk Assessment

2018
Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance.
    Oncogene, 2018, Volume: 37, Issue:29

    Topics: Autocrine Communication; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Imidazoles; Immunotherapy; Interleukin-11; Janus Kinase 2; Ovarian Neoplasms; Platinum; Prognosis; Proto-Oncogene Proteins c-fos; Pyrazoles; Pyridazines; Reactive Oxygen Species; Signal Transduction

2018
A panel of 7 prognosis-related long non-coding RNAs to improve platinum-based chemoresistance prediction in ovarian cancer.
    International journal of oncology, 2018, Volume: 53, Issue:2

    Topics: Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Platinum; Prognosis; RNA, Long Noncoding; Sequence Analysis, RNA; Survival Analysis

2018
Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine.
    The journal of obstetrics and gynaecology research, 2018, Volume: 44, Issue:7

    Topics: Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2018
Clinical analysis of chemo-resistance risk factors in endometriosis associated ovarian cancer.
    Journal of ovarian research, 2018, May-29, Volume: 11, Issue:1

    Topics: Adult; Aged; Breast Neoplasms; CA-125 Antigen; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Endometriosis; Female; Humans; Membrane Proteins; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Risk Factors

2018
A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 09-15, Volume: 24, Issue:18

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Disease-Free Survival; DNA Damage; Drug Resistance, Neoplasm; Female; Homologous Recombination; Humans; Loss of Heterozygosity; Middle Aged; Mutation; Ovarian Neoplasms; Platinum

2018
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 09-01, Volume: 24, Issue:17

    Topics: Female; Humans; Indazoles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors

2018
Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy.
    European journal of gynaecological oncology, 2016, Volume: 37, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies

2016
Identifying disease-associated copy number variations by a doubly penalized regression model.
    Biometrics, 2018, Volume: 74, Issue:4

    Topics: Biometry; Computer Simulation; DNA Copy Number Variations; Drug Resistance, Neoplasm; Female; Genome, Human; Humans; Outcome Assessment, Health Care; Ovarian Neoplasms; Platinum; Regression Analysis

2018
Apatinib and etoposide: surprising efficacy of an oral combination.
    The Lancet. Oncology, 2018, Volume: 19, Issue:9

    Topics: Etoposide; Female; Humans; Ovarian Neoplasms; Platinum; Prospective Studies; Pyridines

2018
Treatment of platinum refractory or resistant ovarian cancer.
    The Lancet. Oncology, 2018, Volume: 19, Issue:9

    Topics: Double-Blind Method; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sorafenib; Topotecan

2018
BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    British journal of cancer, 2018, Volume: 119, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Mutation; Ovarian Neoplasms; Platinum; Prognosis; Treatment Outcome; Up-Regulation

2018
Maintenance PARP inhibitor therapy: is maintaining quality of life enough?
    The Lancet. Oncology, 2018, Volume: 19, Issue:10

    Topics: Female; Humans; Mutation; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Quality of Life

2018
Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    British journal of cancer, 2018, Volume: 119, Issue:9

    Topics: Adult; Aged; BRCA1 Protein; BRCA2 Protein; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Disease Progression; DNA Methylation; Female; High-Throughput Nucleotide Sequencing; Homologous Recombination; Humans; Loss of Heterozygosity; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Sequence Analysis, DNA; Young Adult

2018
Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
    Gynecologic oncology, 2019, Volume: 152, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Topotecan

2019
Extracellular vesicle-associated miRNAs in ovarian cancer - design of an integrated NGS-based workflow for the identification of blood-based biomarkers for platinum-resistance.
    Clinical chemistry and laboratory medicine, 2019, 06-26, Volume: 57, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Coordination Complexes; Drug Resistance, Neoplasm; Extracellular Vesicles; Female; High-Throughput Nucleotide Sequencing; Humans; MicroRNAs; Middle Aged; Ovarian Neoplasms; Pilot Projects; Platinum; Progression-Free Survival; Research Design; Sequence Analysis, RNA; Workflow

2019
Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer.
    Cancer research and treatment, 2019, Volume: 51, Issue:3

    Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Humans; Internet; Middle Aged; Nomograms; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; ROC Curve; Survival Rate; Tertiary Care Centers; Treatment Outcome

2019
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells.
    Nature, 2018, Volume: 563, Issue:7732

    Topics: BRCA1 Protein; Cell Line, Tumor; Chromosome Aberrations; CRISPR-Cas Systems; Cytoplasmic Dyneins; DNA; DNA Damage; Drug Resistance, Neoplasm; Female; Gene Editing; Genes, BRCA1; Genomic Instability; Homologous Recombination; Humans; MRE11 Homologue Protein; Mutation; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Protein Binding; Recombinational DNA Repair; Transcription Factors

2018
Trabectedin for reversing platinum resistance and resensitization to platinum in patients with recurrent ovarian cancer.
    Future oncology (London, England), 2019, Volume: 15, Issue:3

    Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies; Trabectedin

2019
IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells.
    JCI insight, 2018, 12-06, Volume: 3, Issue:23

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Azacitidine; Cell Line, Tumor; Cytokines; Disease Progression; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Therapy; Epigenomics; Female; Humans; Immunotherapy; Interleukin-6; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Neoplastic Stem Cells; Ovarian Neoplasms; Platinum; Retinal Dehydrogenase; Signal Transduction; STAT3 Transcription Factor; Tumor Microenvironment; Up-Regulation

2018
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
    Journal of medical economics, 2019, Volume: 22, Issue:2

    Topics: Antineoplastic Agents; Budgets; Female; Health Expenditures; Humans; Indazoles; Models, Econometric; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Survival Analysis; United States

2019
Seven Genes Based Novel Signature Predicts Clinical Outcome and Platinum Sensitivity of High Grade IIIc Serous Ovarian Carcinoma.
    International journal of biological sciences, 2018, Volume: 14, Issue:14

    Topics: Cell Movement; Cell Proliferation; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Platinum; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Transcriptome

2018
Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.
    Proceedings of the National Academy of Sciences of the United States of America, 2019, 01-29, Volume: 116, Issue:5

    Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal; Disease Progression; Epoxide Hydrolases; Female; Inflammation; Lipids; Macrophages; Mice; Mice, Inbred C57BL; Mice, SCID; Ovarian Neoplasms; Platinum; Signal Transduction; Taxoids

2019
Reannotation and Analysis of Clinical and Chemotherapy Outcomes in the Ovarian Data Set From The Cancer Genome Atlas.
    JCO clinical cancer informatics, 2018, Volume: 2

    Topics: Adult; Aged; Aged, 80 and over; Algorithms; Cystadenoma, Serous; Data Curation; Databases, Genetic; Female; Genomics; Humans; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Platinum; Proteomics; Survival Analysis; Treatment Failure

2018
Selectivity of Terpyridine Platinum Anticancer Drugs for G-quadruplex DNA.
    Molecules (Basel, Switzerland), 2019, 01-23, Volume: 24, Issue:3

    Topics: Anticarcinogenic Agents; Cisplatin; Drug Resistance, Neoplasm; Female; Fluorescence Resonance Energy Transfer; Fluorescent Dyes; G-Quadruplexes; Humans; Ligands; Nucleic Acid Conformation; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-myc; Pyridines

2019
TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers.
    Journal of ovarian research, 2019, Feb-13, Volume: 12, Issue:1

    Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies

2019
Stromal cell ratio based on automated image analysis as a predictor for platinum-resistant recurrent ovarian cancer.
    BMC cancer, 2019, Feb-18, Volume: 19, Issue:1

    Topics: Aged; Biomarkers, Tumor; CA-125 Antigen; Chi-Square Distribution; Drug Resistance, Neoplasm; Drug Therapy; Female; Humans; Image Processing, Computer-Assisted; Logistic Models; Membrane Proteins; Neoplasm Recurrence, Local; Odds Ratio; Ovarian Neoplasms; Platinum; Stromal Cells; Tumor Microenvironment

2019
Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study
    Asian Pacific journal of cancer prevention : APJCP, 2019, Feb-26, Volume: 20, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Middle Aged; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Rate; United States; Young Adult

2019
Chemotherapy-free treatments: are we ready for prime time?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2019, 04-01, Volume: 30, Issue:4

    Topics: Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Progression-Free Survival; Quinazolines; Time

2019
Radiotherapy for isolated recurrent epithelial ovarian cancer: A single institutional experience.
    The journal of obstetrics and gynaecology research, 2019, Volume: 45, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Ovarian Neoplasms; Platinum; Radiotherapy; Retrospective Studies; Survival Analysis

2019
Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.
    International journal of molecular sciences, 2019, Mar-07, Volume: 20, Issue:5

    Topics: Cluster Analysis; Computational Biology; Cystadenocarcinoma, Serous; Databases, Genetic; DNA Methylation; Epigenesis, Genetic; Female; Gene Dosage; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Middle Aged; Mutation; Neoplasm Staging; Ovarian Neoplasms; Platinum; Unsupervised Machine Learning

2019
[Ⅲ.Surgery for Platinum Sensitive Recurrent Epithelial Ovarian Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum

2019
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer.
    Anti-cancer drugs, 2019, Volume: 30, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Retrospective Studies; Survival Rate; Trabectedin

2019
Early experiences with PD-1 inhibitor treatment of platinum resistant epithelial ovarian cancer.
    Journal of gynecologic oncology, 2019, Volume: 30, Issue:4

    Topics: Administration, Intravenous; Aged; Antineoplastic Agents, Immunological; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Nivolumab; Ovarian Neoplasms; Platinum; Programmed Cell Death 1 Receptor; Prospective Studies

2019
USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability.
    Science advances, 2019, Volume: 5, Issue:5

    Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Coordination Complexes; Drug Resistance, Neoplasm; Female; Gene Editing; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Platinum; RNA Interference; RNA, Small Interfering; Snail Family Transcription Factors; Ubiquitin-Specific Proteases; Ubiquitination; Xenograft Model Antitumor Assays

2019
Downregulation of LINC00515 in high-grade serous ovarian cancer and its relationship with platinum resistance.
    Biomarkers in medicine, 2019, Volume: 13, Issue:7

    Topics: Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Platinum; RNA, Long Noncoding

2019
New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
    Journal of experimental & clinical cancer research : CR, 2019, Jun-03, Volume: 38, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Decision-Making; Disease Management; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Molecular Diagnostic Techniques; Neoplastic Stem Cells; Ovarian Neoplasms; Platinum; Prognosis; Proportional Hazards Models; Treatment Outcome

2019
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
    Cells, 2019, 06-14, Volume: 8, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Cystadenocarcinoma, Serous; Female; Genetic Heterogeneity; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Mutation; Mutation Rate; Neoplasm Staging; Ovarian Neoplasms; Platinum; Treatment Outcome; Tumor Suppressor Protein p53

2019
miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer.
    Cell death & disease, 2019, 06-24, Volume: 10, Issue:7

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Comet Assay; DNA Damage; Female; Humans; Immunohistochemistry; In Situ Hybridization; In Vitro Techniques; Mice; Mice, Nude; MicroRNAs; Ovarian Neoplasms; Phosphoric Diester Hydrolases; Platinum

2019
Peritoneal Surface Disease Severity Score (PSDSS), AGO-score and TIAN model in patients with platinum-sensitive recurrent ovarian cancer treated by cytoreductive surgery plus HIPEC.
    Clinical & experimental metastasis, 2019, Volume: 36, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Middle Aged; Models, Statistical; Neoplasm Recurrence, Local; Nomograms; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prognosis; Prospective Studies; Severity of Illness Index; Survival Rate; Taxoids

2019
Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
    Journal of cellular biochemistry, 2019, Volume: 120, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Cystadenocarcinoma, Serous; Desmosomal Cadherins; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Ovarian Neoplasms; Ovary; Platinum; Prognosis; Proteomics

2019
Ovarian Cancer Treatment Stratification Using
    Anticancer research, 2019, Volume: 39, Issue:8

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Platinum

2019
Expression of Bcl-2 and the antiapoptotic BAG family proteins in ovarian cancer.
    Applied immunohistochemistry & molecular morphology : AIMM, 2013, Volume: 21, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; DNA-Binding Proteins; Female; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Taxoids; Transcription Factors

2013
Immune escape of AKT overexpressing ovarian cancer cells.
    International journal of oncology, 2013, Volume: 42, Issue:5

    Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Killer Cells, Natural; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-akt; Ubiquitin-Protein Ligases

2013
Increased sensitivity to chemotherapy induced by CpG-ODN treatment is mediated by microRNA modulation.
    PloS one, 2013, Volume: 8, Issue:3

    Topics: Animals; Cisplatin; Computational Biology; Drug Therapy; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Luciferases; Mice; MicroRNAs; Oligodeoxyribonucleotides; Ovarian Neoplasms; Plasmids; Platinum; Real-Time Polymerase Chain Reaction; Transcriptome

2013
Novel monofunctional platinum (II) complex Mono-Pt induces apoptosis-independent autophagic cell death in human ovarian carcinoma cells, distinct from cisplatin.
    Autophagy, 2013, Volume: 9, Issue:7

    Topics: Apoptosis; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cisplatin; DNA Damage; Female; Humans; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; TOR Serine-Threonine Kinases

2013
Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
    Journal of experimental & clinical cancer research : CR, 2013, Apr-30, Volume: 32

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Female; Gene Expression; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; tau Proteins; Treatment Outcome

2013
The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Gynecologic oncology, 2013, Volume: 130, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Genome-Wide Association Study; Genotype; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide; Transcription Factors

2013
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:5

    Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Mutation; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Survival Rate

2013
Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endostatins; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Survival Rate

2013
Integrative prediction of gene function and platinum-free survival from genomic and epigenetic features in ovarian cancer.
    Methods in molecular biology (Clifton, N.J.), 2013, Volume: 1049

    Topics: Cell Line, Tumor; DNA Copy Number Variations; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Platinum; Survival Analysis

2013
Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Oct-15, Volume: 19, Issue:20

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Case-Control Studies; Female; Genetic Association Studies; Genotype; Humans; Nervous System Diseases; Odds Ratio; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide; Taxoids

2013
Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Oct-15, Volume: 19, Issue:20

    Topics: Antineoplastic Combined Chemotherapy Protocols; CpG Islands; Cystadenocarcinoma, Serous; Disease Progression; DNA Methylation; Female; Humans; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Promoter Regions, Genetic; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A

2013
Analysis of failures and clinical outcome of advanced epithelial ovarian cancer in patients with microscopic residual disease at second-look reassessment following primary cytoreductive surgery and first-line platinum-based chemotherapy.
    European journal of gynaecological oncology, 2013, Volume: 34, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Retrospective Studies; Second-Look Surgery; Treatment Failure; Treatment Outcome

2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
    Proceedings of the National Academy of Sciences of the United States of America, 2013, Oct-15, Volume: 110, Issue:42

    Topics: Antineoplastic Agents; Benzoquinones; BRCA1 Protein; BRCA2 Protein; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group N Protein; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mutation; Nuclear Proteins; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Structure, Tertiary; Rad51 Recombinase; Tumor Suppressor Proteins

2013
Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis.
    Gynecologic oncology, 2014, Volume: 132, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Prospective Studies; Quality of Life

2014
Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants.
    Gynecologic oncology, 2014, Volume: 132, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Retrospective Studies; Treatment Outcome

2014
Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.
    British journal of cancer, 2014, Jan-21, Volume: 110, Issue:2

    Topics: Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Choline; Choline Kinase; Down-Regulation; Doxorubicin; Female; Humans; Lipid Metabolism; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Phosphorylcholine; Platinum; RNA Interference; Signal Transduction; Transcriptome

2014
Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
    Chinese medical journal, 2013, Volume: 126, Issue:23

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Retrospective Studies

2013
[Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Zhonghua fu chan ke za zhi, 2013, Volume: 48, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Genotype; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide; Prognosis; Young Adult

2013
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
    Journal of ovarian research, 2014, Apr-09, Volume: 7

    Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-akt; Signal Transduction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2014
Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer?
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:7

    Topics: Adult; Aged; Biomarkers, Pharmacological; Biomarkers, Tumor; CA-125 Antigen; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis; Proteins; WAP Four-Disulfide Core Domain Protein 2

2014
Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Archives of gynecology and obstetrics, 2014, Volume: 290, Issue:5

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Neutropenia; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome

2014
Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014, Volume: 24, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Palliative Care; Peritoneal Neoplasms; Platinum; Prognosis; Quality of Life; Severity of Illness Index; Surveys and Questionnaires

2014
Downregulation of HNF1 homeobox B is associated with drug resistance in ovarian cancer.
    Oncology reports, 2014, Volume: 32, Issue:3

    Topics: Cell Line, Tumor; Cystadenocarcinoma, Serous; Down-Regulation; Drug Resistance, Neoplasm; Female; Hepatocyte Nuclear Factor 1-beta; Humans; MicroRNAs; Ovarian Neoplasms; Platinum

2014
Complementarity of MALDI and LA ICP mass spectrometry for platinum anticancer imaging in human tumor.
    Metallomics : integrated biometal science, 2014, Volume: 6, Issue:8

    Topics: Cisplatin; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2014
SOX18 expression predicts response to platinum-based chemotherapy in ovarian cancer.
    Anticancer research, 2014, Volume: 34, Issue:8

    Topics: Cell Line, Tumor; Female; Humans; Immunohistochemistry; Ovarian Neoplasms; Platinum; SOXF Transcription Factors

2014
Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
    Pathology oncology research : POR, 2015, Volume: 21, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Drug Therapy; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Platinum; Prognosis; Survival Rate; Treatment Outcome

2015
ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signaling.
    PloS one, 2014, Volume: 9, Issue:9

    Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Disease-Free Survival; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Isoenzymes; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Neoplastic Stem Cells; Ovarian Neoplasms; Phenotype; Platinum; Retinal Dehydrogenase; Signal Transduction

2014
[Effects of hyperthermia combined platinum-based drugs on ovarian cancer cell lines SKOV3].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2014, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Carboplatin; Cell Line; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Endonucleases; Female; Hot Temperature; Humans; Inhibitor of Apoptosis Proteins; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; RNA, Messenger; Survivin

2014
Prognostic impact of human leukocyte antigen class I expression and association of platinum resistance with immunologic profiles in epithelial ovarian cancer.
    Cancer immunology research, 2014, Volume: 2, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class I; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Risk Factors

2014
[Establishment and biological characteristics of a platinum-resistance nude mouse model in epithelial ovarian cancer].
    Zhonghua fu chan ke za zhi, 2014, Volume: 49, Issue:7

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Repair; Drug Resistance, Neoplasm; Female; Genes, BRCA1; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum

2014
Efficacy of permanent iodine-125 seed implants and gemcitabine chemotherapy in patients with platinum- resistant recurrent ovarian carcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:20

    Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Brachytherapy; Chemoradiotherapy; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Tomography, X-Ray Computed

2014
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    International journal of oncology, 2015, Volume: 46, Issue:2

    Topics: Adult; Aged; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Taxoids; Tumor Suppressor Protein p53

2015
A quantitative proteomics-based signature of platinum sensitivity in ovarian cancer cell lines.
    The Biochemical journal, 2015, Feb-01, Volume: 465, Issue:3

    Topics: Cell Line, Tumor; DNA Damage; Female; Humans; Ovarian Neoplasms; Platinum; Proteomics

2015
[A case of platinum-resistant, recurrent ovarian clear cell adenocarcinoma successfully treated with irinotecan (CPT-11) and paclitaxel (PTX) chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:11

    Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Ovarian Neoplasms; Paclitaxel; Platinum; Recurrence

2014
A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Female; Genes, BRCA1; Genes, BRCA2; Genomic Instability; Homologous Recombination; Humans; Middle Aged; Mutation; Ovarian Neoplasms; Platinum; Prognosis; Survival Analysis; Treatment Outcome

2014
Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer.
    Biomaterials, 2015, Volume: 37

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Cross-Linking Reagents; Drug Carriers; Drug Delivery Systems; Endocytosis; Female; Fluorescent Dyes; Gels; Humans; Hyaluronan Receptors; Hyaluronic Acid; Injections, Intraperitoneal; Kinetics; Luminescence; Maximum Tolerated Dose; Mice, Inbred BALB C; Nanoparticles; Ovarian Neoplasms; Platinum; Tumor Burden

2015
The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.
    Oncotarget, 2015, Feb-10, Volume: 6, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Disease-Free Survival; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genotype; Humans; MicroRNAs; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Platinum; Prognosis; Proportional Hazards Models

2015
Quality of Life in Platinum-Sensitive Recurrent Ovarian Cancer: Chemotherapy Versus Surgery Plus Chemotherapy.
    Annals of surgical oncology, 2015, Volume: 22, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Prospective Studies; Quality of Life; Survival Rate

2015
Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Survival Rate; Tertiary Care Centers

2014
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.
    PLoS medicine, 2015, Volume: 12, Issue:2

    Topics: Aged; Algorithms; Alleles; Carcinoma, Ovarian Epithelial; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Genetic Variation; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phylogeny; Platinum

2015
Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients.
    BMC cancer, 2015, Mar-07, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Platinum; Treatment Outcome; Young Adult

2015
Magnesium protects against cisplatin-induced acute kidney injury without compromising cisplatin-mediated killing of an ovarian tumor xenograft in mice.
    American journal of physiology. Renal physiology, 2015, Jul-01, Volume: 309, Issue:1

    Topics: Acute Kidney Injury; Animals; Antineoplastic Agents; Carcinoma; Cation Transport Proteins; Cell Line, Tumor; Cisplatin; Dietary Supplements; Female; Gene Expression; Humans; Kidney; Magnesium; Mice, Nude; Ovarian Neoplasms; Platinum; Xenograft Model Antitumor Assays

2015
Monofunctional Platinum-containing Pyridine-based Ligand Acts Synergistically in Combination with the Phytochemicals Curcumin and Quercetin in Human Ovarian Tumour Models.
    Anticancer research, 2015, Volume: 35, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Curcumin; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Ovarian Neoplasms; Phytochemicals; Platinum; Pyridines; Quercetin

2015
Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
    Annals of surgical oncology, 2015, Volume: 22 Suppl 3

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Risk Factors; Survival Rate

2015
[eIF3a gene polymorphism and chemo-sensitivity to platinum-based drugs in ovarian cancer].
    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2015, Volume: 40, Issue:6

    Topics: Antineoplastic Agents; Eukaryotic Initiation Factor-3; Female; Genotype; Humans; Mutation; Ovarian Neoplasms; Platinum; Polymorphism, Genetic; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2015
Dual-drug delivery of curcumin and platinum drugs in polymeric micelles enhances the synergistic effects: a double act for the treatment of multidrug-resistant cancer.
    Biomaterials science, 2015, Volume: 3, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Curcumin; Drug Carriers; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Micelles; Ovarian Neoplasms; Platinum; Polymers

2015
STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.
    International journal of cancer, 2016, Feb-01, Volume: 138, Issue:3

    Topics: Carcinoma, Ovarian Epithelial; Case-Control Studies; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polymorphism, Single Nucleotide; Receptor, Notch1; STAT3 Transcription Factor

2016
Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugs.
    Biochemical pharmacology, 2015, Nov-01, Volume: 98, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; DNA; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum

2015
Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
    Dalton transactions (Cambridge, England : 2003), 2015, Dec-14, Volume: 44, Issue:46

    Topics: Antineoplastic Agents; Bromosuccinimide; Carboplatin; Cell Line, Tumor; Cisplatin; Female; Halogenation; Humans; Models, Molecular; Organoplatinum Compounds; Ovarian Neoplasms; Ovary; Oxaliplatin; Oxidation-Reduction; Platinum; Prodrugs

2015
Long-Term Survival for Platinum-Sensitive Recurrent Ovarian Cancer Patients Treated with Secondary Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Annals of surgical oncology, 2016, Volume: 23, Issue:5

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Combined Modality Therapy; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Rate

2016
Intracellular Doppler Signatures of Platinum Sensitivity Captured by Biodynamic Profiling in Ovarian Xenografts.
    Scientific reports, 2016, Jan-06, Volume: 6

    Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Heterografts; Humans; Mice; Molecular Imaging; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured; Ultrasonography, Doppler

2016
A Novel Platinum-based Compound with Preferential Cytotoxic Activity against a Panel of Cancer Cell Lines.
    Anti-cancer agents in medicinal chemistry, 2016, Volume: 16, Issue:3

    Topics: 2,2'-Dipyridyl; Amniotic Fluid; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cisplatin; Dimethylformamide; DNA; Drug Resistance, Neoplasm; Epithelial Cells; Female; Humans; Intercalating Agents; Male; MCF-7 Cells; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Prostatic Neoplasms; Spectrophotometry

2016
Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Topotecan

2016
Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study.
    Chemotherapy, 2016, Volume: 61, Issue:5

    Topics: Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Databases, Factual; Disease-Free Survival; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Propensity Score

2016
Cytoreductive Surgery Plus Platinum-Based Hyperthermic Intraperitoneal Chemotherapy in Epithelial Ovarian Cancer: A Promising Integrated Approach to Improve Locoregional Control.
    The oncologist, 2016, Volume: 21, Issue:5

    Topics: Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum

2016
NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer.
    Oncogene, 2016, 10-13, Volume: 35, Issue:41

    Topics: Carrier Proteins; Cell Line, Tumor; Cellular Senescence; DNA Breaks, Double-Stranded; DNA Damage; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Ovarian Neoplasms; Platinum; RNA, Long Noncoding; Signal Transduction; Transcriptional Elongation Factors

2016
[Expression of MiR-130a in Serum Samples of Patients with Epithelial Ovarian Cancer and Its Association with Platinum Resistance].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2016, Volume: 47, Issue:1

    Topics: Apoptosis; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Humans; MicroRNAs; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase

2016
The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
    JAMA neurology, 2016, 07-01, Volume: 73, Issue:7

    Topics: Accidental Falls; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Chi-Square Distribution; Female; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Ovarian Neoplasms; Peripheral Nervous System Diseases; Platinum; Prospective Studies; Severity of Illness Index; Taxoids

2016
Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:7

    Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Carboplatin; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2016
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
    Journal of ovarian research, 2016, May-21, Volume: 9, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aurora Kinase A; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis

2016
Mifepristone increases mRNA translation rate, triggers the unfolded protein response, increases autophagic flux, and kills ovarian cancer cells in combination with proteasome or lysosome inhibitors.
    Molecular oncology, 2016, Volume: 10, Issue:7

    Topics: Activating Transcription Factor 4; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cinnamates; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lysosomes; Mifepristone; Ovarian Neoplasms; Platinum; Proteasome Inhibitors; Protein Biosynthesis; Puromycin; RNA, Messenger; Signal Transduction; Thiourea; Tunicamycin; Unfolded Protein Response

2016
Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
    Journal of the Egyptian National Cancer Institute, 2016, Volume: 28, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum

2016
The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling.
    PloS one, 2016, Volume: 11, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Ascitic Fluid; Carboplatin; Female; Humans; Middle Aged; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Prognosis; Vascular Endothelial Growth Factor A

2016
Synthesis of tris(quinoline)monochloroplatinum(II) Chloride and its Activity Alone and in Combination with Capsaicin and Curcumin in Human Ovarian Cancer Cell Lines.
    Anticancer research, 2016, Volume: 36, Issue:6

    Topics: Antineoplastic Agents; Capsaicin; Cell Line, Tumor; Curcumin; DNA; Drug Synergism; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Platinum

2016
Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:9

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; DNA Mutational Analysis; Exons; Female; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Platinum; Treatment Outcome; Young Adult

2016
Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy.
    Cancer biomarkers : section A of Disease markers, 2016, Jun-07, Volume: 17, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Leukocyte Count; Lymphocytes; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Neutrophils; Ovarian Neoplasms; Platelet Count; Platinum; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Treatment Outcome

2016
Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:8

    Topics: CA-125 Antigen; Female; Humans; Ovarian Neoplasms; Platinum

2016
Assessment of Ovarian Cancer Tumors Treated with Intraperitoneal Cisplatin Therapy by Nanoscopic X-ray Fluorescence Imaging.
    Scientific reports, 2016, 07-21, Volume: 6

    Topics: Animals; Cell Line, Tumor; Cisplatin; Computer Simulation; Data Mining; Diagnostic Imaging; Female; Fluorescence; Injections, Intraperitoneal; Mice, Nude; Monte Carlo Method; Nanotechnology; Ovarian Neoplasms; Platinum; X-Rays

2016
[Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
    Zhonghua fu chan ke za zhi, 2016, Jul-25, Volume: 51, Issue:7

    Topics: Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; China; Computational Biology; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Proteomics; ROC Curve; Treatment Outcome

2016
Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.
    BMC cancer, 2016, 08-02, Volume: 16

    Topics: Aged; DNA Methylation; Female; Folate Receptor 1; Gene Expression Regulation, Neoplastic; Humans; Long Interspersed Nucleotide Elements; Middle Aged; Ovarian Neoplasms; Platinum; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Up-Regulation

2016
MPO density in primary cancer biopsies of ovarian carcinoma enhances the indicative value of IL-17 for chemosensitivity.
    BMC cancer, 2016, 08-17, Volume: 16

    Topics: Adult; Aged; Biomarkers, Tumor; Female; Humans; Interleukin-17; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peroxidase; Platinum; Regression Analysis; Survival Analysis; Tissue Array Analysis; Treatment Outcome

2016
Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Feb-15, Volume: 23, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Bridged-Ring Compounds; CD8-Positive T-Lymphocytes; Female; Humans; Immunotherapy; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Platinum; Prognosis; T-Lymphocytes; Taxoids; Tumor Microenvironment

2017
Nanoscopic tumor tissue distribution of platinum after intraperitoneal administration in a xenograft model of ovarian cancer.
    Journal of pharmaceutical and biomedical analysis, 2016, Nov-30, Volume: 131

    Topics: Animals; Calcium; Cisplatin; Copper; Disease Models, Animal; Female; Fever; Heterografts; Injections, Intraperitoneal; Mass Spectrometry; Mice; Ovarian Neoplasms; Phosphorus; Platinum; Spectrometry, X-Ray Emission; Sulfur; Tissue Distribution; Zinc

2016
Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, May-01, Volume: 23, Issue:9

    Topics: Aged; Cell Line, Tumor; DNA Adducts; DNA Damage; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Promoter Regions, Genetic

2017
Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Cancer research and treatment, 2017, Volume: 49, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Blood Cell Count; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Nomograms; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult

2017
Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.
    Cancer biology & therapy, 2017, Sep-02, Volume: 18, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Humans; MAP Kinase Signaling System; Ovarian Neoplasms; Phosphorylation; Platinum; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering

2017
Reproductive and hormonal factors in relation to survival and platinum resistance among ovarian cancer cases.
    British journal of cancer, 2016, Nov-22, Volume: 115, Issue:11

    Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Menarche; Menopause; Middle Aged; Ovarian Neoplasms; Platinum; Survival Analysis; Survival Rate

2016
Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.
    Molecular pharmaceutics, 2016, 11-07, Volume: 13, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms; Platinum; Polymers; Treatment Outcome

2016
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Neoplasia (New York, N.Y.), 2016, Volume: 18, Issue:12

    Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Folate Receptor 1; Humans; Immunoconjugates; Maytansine; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Xenograft Model Antitumor Assays

2016
Folate Receptor Alpha Expression in Platinum Resistant/Refractory Ovarian Carcinomas and Primary Endocervical Adenocarcinomas.
    Applied immunohistochemistry & molecular morphology : AIMM, 2018, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Adolescent; Adult; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Female; Folate Receptor 1; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Ovarian Neoplasms; Platinum; Uterine Cervical Neoplasms

2018
The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
    Scientific reports, 2016, 12-14, Volume: 6

    Topics: 5' Untranslated Regions; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; DNA-Binding Proteins; Endonucleases; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Nuclear Proteins; Ovarian Neoplasms; Pharmacogenomic Variants; Platinum; Polymorphism, Genetic; Survival Analysis; Transcription Factors; Treatment Outcome

2016
Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort.
    Gynecologic oncology, 2017, Volume: 144, Issue:2

    Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Retrospective Studies

2017
Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 12-20, Volume: 34, Issue:36

    Topics: Carboplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Ovarian Neoplasms; Platinum

2016
Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer.
    Gynecologic oncology, 2017, Volume: 145, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Audiometry, Pure-Tone; Bleomycin; Case-Control Studies; Chemotherapy, Adjuvant; Child; Cisplatin; Etoposide; Female; Hearing Loss; Humans; Longitudinal Studies; Middle Aged; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Ovariectomy; Platinum; Vinblastine; Young Adult

2017
Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells.
    PloS one, 2008, May-28, Volume: 3, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Ferric Compounds; Humans; Ovarian Neoplasms; Platinum; Rats; Rats, Wistar

2008
High cytotoxicity of cisplatin nanocapsules in ovarian carcinoma cells depends on uptake by caveolae-mediated endocytosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-15, Volume: 15, Issue:4

    Topics: Antineoplastic Agents; Biological Transport; Caveolae; Caveolin 1; Cell Line, Tumor; Cisplatin; Endocytosis; Female; Humans; Nanocapsules; Ovarian Neoplasms; Platinum

2009
Investigations using fluorescent ligands to monitor platinum(IV) reduction and platinum(II) reactions in cancer cells.
    Dalton transactions (Cambridge, England : 2003), 2009, Apr-28, Issue:16

    Topics: Cell Line, Tumor; Cell Survival; Coumarins; DNA; Female; Fluorescent Dyes; Humans; Ligands; Molecular Structure; Ovarian Neoplasms; Oxidation-Reduction; Platinum

2009
Epithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatment.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:3

    Topics: CA-125 Antigen; Carcinoma, Papillary; Cohort Studies; Cystadenocarcinoma, Serous; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome

2009
Cytotoxic activity and cellular processing in human ovarian carcinoma cell lines of a new platinum(II) compound containing a fluorescent substituted propylene diamine ligand.
    Biochemical pharmacology, 2009, Aug-15, Volume: 78, Issue:4

    Topics: Alkenes; Cisplatin; Crystallography, X-Ray; Diamines; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Fluorescence; Humans; Ovarian Neoplasms; Photochemical Processes; Platinum; Tumor Cells, Cultured

2009
Is the current concept of recurrent ovarian carcinoma as a chronic disease also applicable in platinum resistant patients?
    Archives of gynecology and obstetrics, 2010, Volume: 281, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Cohort Studies; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Retrospective Studies

2010
Human leukocyte antigen class I expression is an independent prognostic factor in advanced ovarian cancer resistant to first-line platinum chemotherapy.
    British journal of cancer, 2009, Oct-20, Volume: 101, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Histocompatibility Antigens Class I; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis

2009
Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model.
    Gynecologic oncology, 2009, Volume: 115, Issue:3

    Topics: Animals; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Platinum; Transplantation, Heterologous

2009
Chemotherapy: Topotecan or treosulfan--that is the question.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:10

    Topics: Antineoplastic Agents; Busulfan; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance; Drug Therapy; Female; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Survival Analysis; Time Factors; Topotecan

2009
A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells.
    Investigational new drugs, 2011, Volume: 29, Issue:1

    Topics: Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Survival; Coumarins; Cyclic S-Oxides; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Membrane Potential, Mitochondrial; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-bcl-2; Signal Transduction

2011
Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2010, Volume: 108, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Platinum; Reoperation; Retrospective Studies

2010
Targeted therapies: tailored treatment for ovarian cancer: are we there yet?
    Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:2

    Topics: Antineoplastic Agents; Bridged-Ring Compounds; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Taxoids; Treatment Outcome

2010
Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.
    PloS one, 2010, Mar-12, Volume: 5, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Japan; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis; Proportional Hazards Models; Taxoids; Treatment Outcome

2010
Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:12

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cystadenocarcinoma, Mucinous; Databases, Factual; Disease Progression; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Young Adult

2010
Intracellular ATP depletion leads to reduced platinum accumulation in ovarian cancer cells.
    International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:7

    Topics: Adenosine Triphosphate; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Female; Humans; Ovarian Neoplasms; Platinum

2010
Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:5

    Topics: Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Genetic Association Studies; Humans; INDEL Mutation; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum

2011
Cellular and biomolecular responses of human ovarian cancer cells to cytostatic dinuclear platinum(II) complexes.
    Apoptosis : an international journal on programmed cell death, 2011, Volume: 16, Issue:3

    Topics: Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Shape; Cell Size; Checkpoint Kinase 1; Checkpoint Kinase 2; Cisplatin; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Humans; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Platinum; Protein Kinases; Protein Serine-Threonine Kinases

2011
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome

2011
Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.
    Angiogenesis, 2011, Volume: 14, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Demography; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult

2011
HERV-K hypomethylation in ovarian clear cell carcinoma is associated with a poor prognosis and platinum resistance.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adult; Biomarkers; Carcinoma; DNA Methylation; Drug Resistance, Neoplasm; Endogenous Retroviruses; Female; Gene Expression; Humans; Kaplan-Meier Estimate; Long Interspersed Nucleotide Elements; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis; Restriction Mapping; Survival Analysis

2011
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome

2012
Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients.
    Journal of cellular and molecular medicine, 2012, Volume: 16, Issue:2

    Topics: Aged; Annexin A3; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Culture Media, Conditioned; Drug Resistance, Neoplasm; Exocytosis; Exosomes; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum

2012
Enhancing lipophilicity as a strategy to overcome resistance against platinum complexes?
    Journal of inorganic biochemistry, 2011, Volume: 105, Issue:5

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Survival; Cisplatin; DNA; Drug Resistance, Neoplasm; Endocytosis; Humans; Ligands; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Platinum

2011
Folate-decorated nanogels for targeted therapy of ovarian cancer.
    Biomaterials, 2011, Volume: 32, Issue:23

    Topics: Animals; Antineoplastic Agents; Biological Availability; Body Weight; Cell Line, Tumor; Cell Survival; Cisplatin; Doxorubicin; Drug Delivery Systems; Endocytosis; Female; Folic Acid; Humans; Hydrogels; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Light; Mice; Mice, Nude; Microscopy, Atomic Force; Nanoparticles; Osmolar Concentration; Ovarian Neoplasms; Particle Size; Platinum; Polyethylene Glycols; Polymethacrylic Acids; Scattering, Radiation; Static Electricity; Surface Properties; Survival Analysis; Water; Xenograft Model Antitumor Assays

2011
Role of chemotherapy in epithelial ovarian cancer.
    Minerva ginecologica, 2011, Volume: 63, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Taxoids

2011
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
    Gynecologic oncology, 2011, Volume: 123, Issue:2

    Topics: Adult; Aged; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Humans; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Retrospective Studies; Topoisomerase I Inhibitors; Topotecan

2011
Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ovarian Epithelial; Cystadenocarcinoma, Serous; Fatal Outcome; Female; Genes, BRCA1; Heterozygote; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Neoplasms, Glandular and Epithelial; Neoplasms, Second Primary; Ovarian Neoplasms; Paclitaxel; Platinum

2012
DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer.
    The pharmacogenomics journal, 2013, Volume: 13, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Disease-Free Survival; DNA Damage; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Genetic Association Studies; Humans; Middle Aged; Nuclear Proteins; Ovarian Neoplasms; Platinum; Polymorphism, Genetic; Prognosis; Promoter Regions, Genetic; Proto-Oncogene Proteins c-mdm2; Transcription Factors; Treatment Outcome

2013
Will Chinese ovarian cancer patients benefit from knowing the BRCA2 mutation status?
    Chinese journal of cancer, 2012, Volume: 31, Issue:1

    Topics: Age Factors; Asian People; Disease-Free Survival; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Genetic Testing; Humans; Mutation; Ovarian Neoplasms; Platinum; Remission Induction; Risk; Survival Rate

2012
Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
    Anticancer research, 2012, Volume: 32, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Magnetic Resonance Spectroscopy; Mass Spectrometry; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Pyridines; Spectrophotometry, Infrared

2012
Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.
    Pharmacogenomics, 2012, Volume: 13, Issue:4

    Topics: Adult; Biomarkers, Pharmacological; Carcinoma, Ovarian Epithelial; China; DNA-Binding Proteins; Endonucleases; Female; Genotype; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polymorphism, Genetic; Prognosis; Survival Analysis

2012
Clinical trial designs for testing biomarker-based personalized therapies.
    Clinical trials (London, England), 2012, Volume: 9, Issue:2

    Topics: Bayes Theorem; Biomarkers; Clinical Trials as Topic; Drug Resistance; Early Termination of Clinical Trials; Female; Humans; Models, Statistical; Ovarian Neoplasms; Platinum; Precision Medicine; Randomized Controlled Trials as Topic; Research Design; Sample Size

2012
Retrospective study comparing irinotecan and pegylated liposomal doxorubicin in treatment of recurrent platinum-refractory/resistant epithelial ovarian cancer.
    European journal of gynaecological oncology, 2012, Volume: 33, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Mucositis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Retrospective Studies; Salvage Therapy

2012
Secondary cytoreductive surgery outcomes of selected patients with paclitaxel/platinum sensitive recurrent epithelial ovarian cancer.
    Journal of surgical oncology, 2012, Sep-15, Volume: 106, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome

2012
Best predictors of survival outcome after tertiary cytoreduction in patients with recurrent platinum-sensitive epithelial ovarian cancer.
    European journal of obstetrics, gynecology, and reproductive biology, 2012, Volume: 163, Issue:1

    Topics: Adult; Aged; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome

2012
Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.
    Molecular imaging and biology, 2012, Volume: 14, Issue:6

    Topics: Animals; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Chlorpropamide; Dideoxynucleosides; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Ki-67 Antigen; Mice; Ovarian Neoplasms; Platinum; Positron-Emission Tomography; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays

2012
DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.
    BMC cancer, 2012, May-14, Volume: 12

    Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Heparan Sulfate Proteoglycans; Humans; Ligands; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Protein Binding; Receptors, Tumor Necrosis Factor, Member 6b

2012
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?
    The oncologist, 2012, Volume: 17, Issue:12

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Creatinine; Deoxycytidine; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Quality of Life; Recurrence; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Taxoids; Thrombosis; Topotecan

2012
Mechanistic basis for overcoming platinum resistance using copper chelating agents.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:11

    Topics: Animals; Antineoplastic Agents; Cation Transport Proteins; Cell Line, Tumor; Chelating Agents; Cisplatin; Copper; Copper Transporter 1; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Platinum; RNA, Messenger; Stress, Physiological; Treatment Outcome; Xenograft Model Antitumor Assays

2012
Surgery for relapsed ovarian cancer: when should it be offered?
    Current oncology reports, 2012, Volume: 14, Issue:6

    Topics: Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Ovary; Platinum; Prognosis; Randomized Controlled Trials as Topic

2012
[Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2012, Volume: 32, Issue:6

    Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-bcl-2

2012
How to approach patients in relapse.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials, Phase III as Topic; Decision Making; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Ovarian Neoplasms; Platinum; Secondary Prevention

2012
Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case-control study on survival in patients with two year follow-up.
    Gynecologic oncology, 2012, Volume: 127, Issue:3

    Topics: Adult; Aged; Case-Control Studies; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Survival Analysis

2012
Synthesis of trans-(4-hydroxypyridine)(ammine)dichloroplatinum(II) and its activity in the human ovarian tumour models.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2013, Jun-01, Volume: 9, Issue:4

    Topics: Antineoplastic Agents; Cell Line, Tumor; Coordination Complexes; DNA; Drug Screening Assays, Antitumor; Female; Humans; Ligands; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Structure-Activity Relationship

2013
Getting to the core of platinum drug bio-distributions: the penetration of anti-cancer platinum complexes into spheroid tumour models.
    Metallomics : integrated biometal science, 2012, Volume: 4, Issue:11

    Topics: Anthraquinones; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Electricity; Female; Formaldehyde; Histocytological Preparation Techniques; Humans; Intracellular Space; Necrosis; Ovarian Neoplasms; Platinum; Spheroids, Cellular

2012
Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:8

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Etoposide; Female; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate

2012
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nomograms; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Sensitivity and Specificity; Treatment Outcome

2013
Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jan-01, Volume: 19, Issue:1

    Topics: Animals; Antigens, CD; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cell Survival; Disease Models, Animal; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Endoglin; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Receptors, Cell Surface; RNA Interference

2013
Polymorphic thymidylate synthase gene impacts on overall survival of patients with epithelial ovarian cancer after platinum-based chemotherapy.
    Pharmacogenomics, 2012, Volume: 13, Issue:14

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Carcinoma, Ovarian Epithelial; Female; Follow-Up Studies; Genetic Association Studies; Genotype; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Thymidylate Synthase

2012
SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Animals; Antigens, Neoplasm; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Transformation, Neoplastic; Chickens; Disease Models, Animal; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Platinum; Prognosis; Serine Proteinase Inhibitors; Serpins

2012
Clinicopathological and functional significance of XRCC1 expression in ovarian cancer.
    International journal of cancer, 2013, Jun-15, Volume: 132, Issue:12

    Topics: Animals; Antineoplastic Agents; Cell Line; Cricetinae; Disease Progression; DNA-Binding Proteins; Female; Gene Expression; Gene Silencing; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; RNA Interference; Treatment Outcome; Tumor Stem Cell Assay; X-ray Repair Cross Complementing Protein 1

2013
Label-free impedance detection of cancer cells.
    Analytical chemistry, 2013, Feb-19, Volume: 85, Issue:4

    Topics: Antibodies, Immobilized; Antigens, Neoplasm; Cell Adhesion Molecules; Cell Line, Tumor; Dielectric Spectroscopy; Electrochemical Techniques; Epithelial Cell Adhesion Molecule; Female; Humans; Microelectrodes; Neoplastic Cells, Circulating; Ovarian Neoplasms; Platinum

2013
Feasibility of trials in ovarian cancer by line of therapy and platinum sensitivity.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Patient Selection; Platinum; Prognosis; Survival Rate

2013
XANES determination of the platinum oxidation state distribution in cancer cells treated with platinum(IV) anticancer agents.
    Journal of the American Chemical Society, 2003, Jun-25, Volume: 125, Issue:25

    Topics: Antineoplastic Agents; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxidation-Reduction; Platinum; Spectrometry, X-Ray Emission; Tumor Cells, Cultured

2003
Choices--and uncertainties--for women with BRCA mutations.
    Science (New York, N.Y.), 2003, Oct-24, Volume: 302, Issue:5645

    Topics: Antineoplastic Agents; Breast Neoplasms; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Heterozygote; Humans; Mastectomy; Mutation; Ovarian Neoplasms; Ovariectomy; Platinum; Risk Assessment; Tamoxifen

2003
Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy.
    American journal of obstetrics and gynecology, 2003, Volume: 189, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Survival Analysis; Treatment Outcome

2003
The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy.
    European journal of gynaecological oncology, 2004, Volume: 25, Issue:2

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cathepsin D; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Humans; Immunohistochemistry; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Survival Analysis; Tumor Suppressor Protein p53

2004
Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jul-15, Volume: 10, Issue:14

    Topics: Adenosine Triphosphatases; Antineoplastic Agents; Biological Transport; Carboplatin; Cation Transport Proteins; Cell Line, Tumor; Cisplatin; Copper; Copper-Transporting ATPases; DNA Adducts; Drug Resistance, Neoplasm; Female; Humans; Kinetics; Microscopy, Confocal; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Recombinant Fusion Proteins; Time Factors

2004
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Aug-01, Volume: 22, Issue:15

    Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Research Design; Retrospective Studies; Time Factors

2004
[Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Serous; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Quality of Life

2004
Protection of platinum-DNA adduct formation and reversal of cisplatin resistance by anti-MRP2 hammerhead ribozymes in human cancer cells.
    International journal of cancer, 2005, Jun-20, Volume: 115, Issue:3

    Topics: Adrenocortical Carcinoma; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Base Sequence; Caspase 3; Caspases; Cisplatin; Cross-Linking Reagents; DNA Adducts; DNA Repair; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Kinetics; Melanoma; Molecular Sequence Data; Ovarian Neoplasms; Platinum; RNA, Catalytic; Skin Neoplasms; Tumor Cells, Cultured

2005
The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
    Cancer, 2005, Apr-01, Volume: 103, Issue:7

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Pleural Effusion, Malignant; Prognosis; Retrospective Studies; Survival Rate

2005
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-15, Volume: 11, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate

2005
Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique).
    Human reproduction (Oxford, England), 2005, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents; Female; Fertility; Follow-Up Studies; Humans; Hysterectomy; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Platinum; Pregnancy; Retrospective Studies; Survival Rate

2005
Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:3

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Genes, Neoplasm; Humans; Inhibitory Concentration 50; Models, Biological; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Platinum; Prognosis; Treatment Outcome

2006
Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients.
    The oncologist, 2006, Volume: 11, Issue:4

    Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Polyethylene Glycols; Time Factors

2006
Synthesis and characterization of palladium(II) and platinum(II) complexes with Schiff bases derivatives of 2-pyridincarboxyaldehyde. Study of their interaction with DNA.
    Journal of inorganic biochemistry, 2006, Volume: 100, Issue:8

    Topics: Aldehydes; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; DNA; DNA Adducts; Female; Humans; Inhibitory Concentration 50; Mass Spectrometry; Microscopy, Atomic Force; Molecular Structure; Organic Chemicals; Ovarian Neoplasms; Palladium; Platinum; Pyridines; Schiff Bases

2006
Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
    Cancer, 2006, Aug-01, Volume: 107, Issue:3

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum

2006
Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer.
    BMC cancer, 2006, Jul-11, Volume: 6

    Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase 2; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate

2006
Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer.
    Annals of surgical oncology, 2007, Volume: 14, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Observation; Ovarian Neoplasms; Platinum; Prognosis; Prospective Studies

2007
Determination of platinum in human subcellular microsamples by inductively coupled plasma mass spectrometry.
    Analytical biochemistry, 2007, Apr-01, Volume: 363, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; DNA Adducts; DNA, Neoplasm; Female; Humans; Mass Spectrometry; Melanoma; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Sensitivity and Specificity; Subcellular Fractions

2007
DNA interactions of new cytotoxic tetrafunctional dinuclear platinum complex trans,trans-[{PtCl2(NH3)}2(piperazine)].
    Biochemical pharmacology, 2007, Jun-15, Volume: 73, Issue:12

    Topics: Animals; Antineoplastic Agents; Base Sequence; Cattle; Cell Line, Tumor; Cisplatin; Cross-Linking Reagents; DNA; DNA Adducts; DNA-Binding Proteins; DNA, Superhelical; Female; Humans; Inhibitory Concentration 50; Kinetics; Ligands; Magnetic Resonance Spectroscopy; Models, Chemical; Molecular Sequence Data; Molecular Structure; Ovarian Neoplasms; Piperazine; Piperazines; Platinum; Platinum Compounds; Polarography; Spectrometry, Fluorescence; Temperature; Transcription, Genetic

2007
[The predictive factors for the response to platinum/paclitaxel based first-line adjuvant chemotherapy in advanced ovarian cancer].
    Zhonghua yi xue za zhi, 2007, May-08, Volume: 87, Issue:17

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Immunohistochemistry; Middle Aged; Ovarian Neoplasms; Ovary; Paclitaxel; Platinum; Prognosis; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53

2007
Prognostic value of serum CA 125 bi-exponential decrease during first line paclitaxel/platinum chemotherapy: a French multicentric study.
    Gynecologic oncology, 2008, Volume: 109, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Kinetics; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies

2008
A novel indole ethyl isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant human ovarian cancer cells.
    Gynecologic oncology, 2008, Volume: 109, Issue:2

    Topics: Adenocarcinoma; Apoptosis; Biomarkers; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Female; Humans; Indoles; Isocyanates; Male; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Pancreatic Neoplasms; Platinum; Prostatic Neoplasms

2008
A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate.
    Analytical biochemistry, 1984, Nov-15, Volume: 143, Issue:1

    Topics: Chromatography, High Pressure Liquid; Cisplatin; Ditiocarb; Female; Graphite; Humans; Kinetics; Ovarian Neoplasms; Platinum; Spectrophotometry, Atomic; Ultrafiltration

1984
Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma.
    Cancer treatment reports, 1983, Volume: 67, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Injections, Intraperitoneal; Kidney; Laparoscopy; Laparotomy; Metabolic Clearance Rate; Ovarian Neoplasms; Peritoneum; Platinum

1983
Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications.
    European journal of cancer & clinical oncology, 1982, Volume: 18, Issue:11

    Topics: Aged; Carcinoma, Squamous Cell; Cisplatin; Female; Humans; Infusions, Parenteral; Kinetics; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Tongue Neoplasms

1982
Pharmacokinetic evidence for an enterohepatic circulation in a patient treated with cis-dichlorodiammineplatinum (II).
    Research communications in chemical pathology and pharmacology, 1980, Volume: 28, Issue:2

    Topics: Adenocarcinoma, Papillary; Adult; Cisplatin; Enterohepatic Circulation; Female; Humans; Kinetics; Models, Biological; Ovarian Neoplasms; Platinum; Spectrophotometry, Atomic; Time Factors

1980
[Pharmacokinetic of platin in plasma and urine of man under 1-, 8-, and 24 h-infusion with cis-dichlorodiamine-platin (II) (cis-DDP) (author's transl)].
    Klinische Wochenschrift, 1982, Mar-01, Volume: 60, Issue:5

    Topics: Adult; Carcinoma, Squamous Cell; Cisplatin; Female; Head and Neck Neoplasms; Humans; Infusions, Parenteral; Kinetics; Lung Neoplasms; Lymphoma; Male; Middle Aged; Ovarian Neoplasms; Platinum; Testicular Neoplasms

1982
Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay.
    Cancer, 1994, Jun-01, Volume: 73, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Cyclophosphamide; Dactinomycin; DNA; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Germinoma; Humans; Leukocytes; Male; Middle Aged; Ovarian Neoplasms; Platinum; Spectrophotometry, Atomic; Testicular Neoplasms; Vinblastine

1994
DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
    International journal of cancer, 1995, Sep-15, Volume: 62, Issue:6

    Topics: Antineoplastic Agents; Cell Division; DNA Damage; DNA, Neoplasm; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1995
Comparison of three different methods for measurement of tissue platinum level.
    Biological trace element research, 1995, Volume: 48, Issue:1

    Topics: Adenocarcinoma; Animals; Cadmium; Cisplatin; Female; Humans; Injections, Intravenous; Kidney; Lumbar Vertebrae; Male; Mass Spectrometry; Mice; Ovarian Neoplasms; Platinum; Spectrophotometry, Atomic; Tissue Distribution

1995
[The study of platinum concentration in retroperitoneal lymph nodes after intraperitoneal carboplatin in ovarian tumors].
    Zhonghua fu chan ke za zhi, 1995, Volume: 30, Issue:5

    Topics: Adult; Aged; Carboplatin; Carcinoma; Cystadenocarcinoma, Mucinous; Female; Humans; Infusions, Parenteral; Lymph Nodes; Middle Aged; Ovarian Neoplasms; Platinum; Retroperitoneal Space

1995
Ovarian cancer.
    Medical Section proceedings : the ... annual Meeting of the Medical Section of the American Council of Life Insurance. American Council of Life Insurance. Medical Section. Meeting, 1994

    Topics: Female; Humans; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Platinum; Survival Rate; United States

1994
Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response.
    Gynecologic oncology, 1995, Volume: 57, Issue:1

    Topics: Abdominal Neoplasms; Adult; Aged; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Laparotomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Pelvic Neoplasms; Platinum; Reoperation; Retrospective Studies; Survival Analysis

1995
A matched control study of familial epithelial ovarian cancer: patient characteristics, response to chemotherapy and outcome.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; Child; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Prognosis; Survival Rate

1995
Accumulation of platinum in the intervertebral discs and vertebrae of ovarian tumor-bearing patients treated with cisplatin.
    Biological trace element research, 1994, Volume: 42, Issue:3

    Topics: Adenocarcinoma; Cisplatin; Female; Humans; Intervertebral Disc; Isotope Labeling; Lumbar Vertebrae; Mass Spectrometry; Ovarian Neoplasms; Platinum

1994
Potentiation of cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) by amphotericin B in BALB/c nude mice bearing human ovarian carcinoma cells.
    Japanese journal of cancer research : Gann, 1994, Volume: 85, Issue:11

    Topics: Amphotericin B; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Synergism; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Ovarian Neoplasms; Platinum

1994
[Pt levels following the infusion of daily low-dose cisplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:4

    Topics: Cisplatin; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Platinum; Uterine Cervical Neoplasms

1995
Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
    International journal of cancer, 1994, Oct-01, Volume: 59, Issue:1

    Topics: Antineoplastic Agents; Cadmium; Cadmium Chloride; Chlorides; Cross-Linking Reagents; DNA, Neoplasm; Drug Resistance; Female; Glutathione; Humans; Metallothionein; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1994
Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
    Cancer research, 1994, Dec-01, Volume: 54, Issue:23

    Topics: Administration, Oral; Antineoplastic Agents; DNA; DNA Repair; Drug Resistance; Female; Glutathione; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1994
Cerebral metastases from epithelial ovarian carcinoma treated with carboplatin.
    Gynecologic oncology, 1994, Volume: 55, Issue:2

    Topics: Adenocarcinoma, Papillary; Adult; Aged; Brain Neoplasms; Carboplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum

1994
Drug accumulation and DNA platination in cells exposed to aquated cisplatin species.
    Cancer letters, 1994, Jun-30, Volume: 81, Issue:2

    Topics: Cisplatin; DNA; Female; Humans; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1994
Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:4

    Topics: Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Interferon-gamma; Ovarian Neoplasms; Platinum; Recombinant Proteins; Tumor Cells, Cultured

1994
Chlorambucil for platinum-refractory ovarian cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1994, Volume: 6, Issue:3

    Topics: Adult; Aged; Carcinoma; Chlorambucil; Combined Modality Therapy; Drug Resistance; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Remission Induction; Retrospective Studies; Survival Rate

1994
[Pharmacokinetics of carboplatin in a patient under hemodialysis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:4

    Topics: Carboplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Middle Aged; Ovarian Neoplasms; Platinum; Renal Dialysis

1994
Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.
    Biochemical pharmacology, 1994, Feb-11, Volume: 47, Issue:4

    Topics: Cisplatin; DNA; DNA Repair; Drug Resistance; Female; Humans; Ovarian Neoplasms; Platinum; RNA, Ribosomal; Time Factors; Tumor Cells, Cultured

1994
Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    British journal of cancer, 1994, Volume: 69, Issue:1

    Topics: Antineoplastic Agents; Cisplatin; DNA Probes; DNA, Neoplasm; Drug Resistance; Female; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1994
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.
    Gynecologic oncology, 1993, Volume: 50, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance; Female; Fluorouracil; Humans; Infusions, Intravenous; Middle Aged; Mitomycin; Ovarian Neoplasms; Platinum; Salvage Therapy

1993
Cellular pharmacology of liposomal cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum(II) in A2780/S and A2780/PDD cells.
    Cancer research, 1993, Oct-15, Volume: 53, Issue:20

    Topics: Antineoplastic Agents; Biological Transport; Cell Survival; Cisplatin; Dimyristoylphosphatidylcholine; DNA, Neoplasm; Drug Carriers; Drug Resistance; Female; Humans; Kinetics; Liposomes; Organoplatinum Compounds; Ovarian Neoplasms; Phosphatidylglycerols; Platinum; Spectrophotometry, Atomic; Tumor Cells, Cultured

1993
Differential cytotoxicity, uptake and DNA binding of tetraplatin and analogous isomers in sensitive and resistant cancer cell lines.
    Anti-cancer drugs, 1993, Volume: 4, Issue:2

    Topics: Animals; Antineoplastic Agents; Cell Division; Cisplatin; Colony-Forming Units Assay; DNA; Drug Resistance; Female; Humans; Isomerism; Leukemia L1210; Mice; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1993
Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging.
    Obstetrics and gynecology, 1993, Volume: 82, Issue:1

    Topics: Adolescent; Adult; Aged; Carcinoma; Cisplatin; Combined Modality Therapy; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Retrospective Studies; Survival Rate

1993
Platinum-based chemotherapy for advanced-stage serous ovarian carcinoma of low malignant potential.
    Gynecologic oncology, 1995, Volume: 59, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cystadenoma, Serous; Female; Humans; Laparotomy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Reoperation; Treatment Outcome

1995
A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve.
    Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carboplatin; Female; Humans; Linear Models; Male; Middle Aged; Ovarian Neoplasms; Platinum; Prospective Studies; Protein Binding; Regression Analysis; Reproducibility of Results; Retrospective Studies

1996
Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:2

    Topics: Administration, Oral; Antineoplastic Agents; Cell Death; Chromatography, High Pressure Liquid; Female; Humans; Molecular Structure; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1996
Abdomino-pelvic hyperthermia and intraperitoneal carboplatin in epithelial ovarian cancer: feasibility, tolerance and pharmacology.
    International journal of radiation oncology, biology, physics, 1996, Jul-15, Volume: 35, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Cohort Studies; Combined Modality Therapy; Feasibility Studies; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Treatment Outcome

1996
Quantitative mapping of platinum and essential trace metal in cisplatin resistant and sensitive human ovarian adenocarcinoma cells.
    Cellular and molecular biology (Noisy-le-Grand, France), 1996, Volume: 42, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Ovarian Neoplasms; Platinum; Spectrometry, X-Ray Emission; Trace Elements; Tumor Cells, Cultured

1996
Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
    British journal of cancer, 1996, Volume: 74, Issue:7

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; DNA, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Humans; Isomerism; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Time Factors; Tumor Cells, Cultured

1996
Taxol as second-line treatment in patients with advanced ovarian cancer after platinum-based first-line chemotherapy.
    Gynecologic oncology, 1997, Volume: 64, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Survival Rate

1997
Multifactorial mechanism for the potentiation of cisplatin (CDDP) cytotoxicity by all-trans retinoic acid (ATRA) in human ovarian carcinoma cell lines.
    British journal of cancer, 1997, Volume: 75, Issue:3

    Topics: Antineoplastic Agents; Cell Line; Cell Survival; Cisplatin; DNA Adducts; DNA Primers; Drug Synergism; ErbB Receptors; Female; Glutathione; Glutathione Transferase; Humans; Kinetics; Metallothionein; Ovarian Neoplasms; Platinum; Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Tretinoin; Tumor Cells, Cultured; Tumor Stem Cell Assay

1997
Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
    British journal of cancer, 1997, Volume: 75, Issue:10

    Topics: Amifostine; Animals; Antineoplastic Agents; Body Temperature; Carboplatin; DNA Adducts; Drug Administration Schedule; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Platinum; Radiation-Protective Agents; Transplantation, Heterologous

1997
Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
    Anti-cancer drugs, 1997, Volume: 8, Issue:9

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cell Survival; Colonic Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Thymidylate Synthase; Tumor Cells, Cultured

1997
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Treatment Outcome

1998
ras mutation and platinum resistance in human ovarian carcinomas in vitro.
    International journal of cancer, 1998, Jul-03, Volume: 77, Issue:1

    Topics: Carcinoma; Drug Resistance, Neoplasm; Female; Genes, ras; Humans; Mutation; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1998
Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:3

    Topics: Amifostine; Animals; Antineoplastic Agents; Cisplatin; Drug Combinations; Drug Synergism; Female; Humans; Kidney; Liver; Mice; Neoplasm Transplantation; Ovarian Neoplasms; Platinum; Radiation-Protective Agents; Transplantation, Heterologous

1998
Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:9

    Topics: Antineoplastic Agents; Cell Membrane; Cisplatin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Organoplatinum Compounds; Ouabain; Ovarian Neoplasms; Platinum; Temperature; Tumor Cells, Cultured

1995
Effect of antitumor platinum compounds with trans geometry on the induction of cytotoxicity and cell cycle modifications.
    European journal of histochemistry : EJH, 1997, Volume: 41 Suppl 2

    Topics: Antineoplastic Agents; Cell Cycle; Cisplatin; Female; Flow Cytometry; Humans; Lethal Dose 50; Organometallic Compounds; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1997
Stability and cellular studies of [rac-1,2-bis(4-fluorophenyl)-ethylenediamine][cyclobutane-1,1- dicarboxylato]platinum(II), a novel, highly active carboplatin derivative.
    Journal of cancer research and clinical oncology, 1998, Volume: 124, Issue:11

    Topics: Breast Neoplasms; Carboplatin; Cell Size; Chromatography, High Pressure Liquid; Drug Screening Assays, Antitumor; Drug Stability; Female; Humans; Magnetic Resonance Spectroscopy; Ovarian Neoplasms; Platinum; Serum Albumin; Solubility; Tumor Cells, Cultured

1998
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    British journal of cancer, 1999, Volume: 80, Issue:7

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Deoxycytidine; DNA; DNA Adducts; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorometry; Gemcitabine; Humans; Intracellular Fluid; Lung Neoplasms; Mice; Ovarian Neoplasms; Platinum; RNA; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay

1999
Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer.
    Clinical biochemistry, 1999, Volume: 32, Issue:5

    Topics: Adolescent; Adult; Aged; Blotting, Western; Drug Resistance, Neoplasm; Drug Therapy, Combination; Epithelium; Female; Flow Cytometry; Genes, bcl-2; Humans; Immunoenzyme Techniques; Immunohistochemistry; Middle Aged; Mutation; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; ROC Curve; S Phase; Survival Rate; Tumor Suppressor Protein p53

1999
In vitro antitumour activity and cellular pharmacological properties of the platinum-iminoether complex trans-[PtCl2[E-HN=C(OMe)Me]2].
    International journal of oncology, 1999, Volume: 15, Issue:5

    Topics: Antineoplastic Agents; Biological Transport; Cell Cycle; Cell Division; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Organometallic Compounds; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1999
Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
    Chemico-biological interactions, 1999, Nov-15, Volume: 123, Issue:1

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Division; Cisplatin; DNA Adducts; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Growth Inhibitors; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Stereoisomerism; Tumor Cells, Cultured; Tumor Suppressor Protein p53

1999
Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
    Cancer letters, 2000, Apr-14, Volume: 151, Issue:2

    Topics: Blotting, Southern; Cisplatin; DNA Damage; DNA Helicases; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gene Dosage; Humans; Loss of Heterozygosity; Ovarian Neoplasms; Platinum; Proteins; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured; Xeroderma Pigmentosum Group D Protein

2000
[Pharmacologic markers predictive of neutropenia chemically induced by cisplatin (CDDP)].
    Journal de la Societe de biologie, 1999, Volume: 193, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Choriocarcinoma; Cisplatin; DNA Adducts; Drug Monitoring; Female; Fluorouracil; Humans; Lymphocytes; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Platinum; Predictive Value of Tests; Saliva

1999
Intraperitoneal chemotherapy and intraperitoneal washing cytology in management of ovarian cancer.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27 Suppl 2

    Topics: Antineoplastic Agents; Carboplatin; Female; Humans; Infusions, Parenteral; Neoplasm, Residual; Ovarian Neoplasms; Peritoneal Lavage; Platinum; Reoperation; Survival Analysis

2000
Chemotherapy for malignant mixed Müllerian tumors of the ovary.
    Gynecologic oncology, 2000, Volume: 79, Issue:2

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Female; Humans; Ifosfamide; Middle Aged; Mixed Tumor, Mullerian; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome

2000
Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human
    Biochemical pharmacology, 2000, Dec-01, Volume: 60, Issue:11

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; DNA Helicases; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Metallothionein; Ovarian Neoplasms; Platinum; Poly-ADP-Ribose Binding Proteins; RNA, Messenger; Transcription, Genetic

2000
The platelet-sparing effect of paclitaxel is not related to changes in the pharmacokinetics of carboplatin.
    Cancer chemotherapy and pharmacology, 2001, Volume: 47, Issue:1

    Topics: Age Factors; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Body Surface Area; Carboplatin; Cyclophosphamide; Female; Humans; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platelet Count; Platinum; Prospective Studies; Thrombocytopenia

2001
Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATA-binding proteins.
    The Journal of biological chemistry, 2001, Oct-19, Volume: 276, Issue:42

    Topics: Cisplatin; Cross-Linking Reagents; DNA; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; High Mobility Group Proteins; Humans; Ligands; Models, Chemical; Oligonucleotide Probes; Ovarian Neoplasms; Platinum; Protein Binding; Protein Structure, Tertiary; TATA-Box Binding Protein; Transcription Factors; Tumor Cells, Cultured

2001
Tumour markers in ovarian cancer.
    Hospital medicine (London, England : 1998), 2001, Volume: 62, Issue:8

    Topics: Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Female; Humans; Ovarian Neoplasms; Paclitaxel; Platinum; Predictive Value of Tests; Treatment Outcome

2001
Mitochondria in platinum resistant cells.
    Human cell, 2001, Volume: 14, Issue:3

    Topics: Adenocarcinoma, Clear Cell; Apoptosis; Cystadenocarcinoma, Serous; Cytochrome c Group; Drug Resistance, Neoplasm; Female; Humans; Membrane Potentials; Mitochondria; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured

2001
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Feb-01, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Intraoperative Care; Middle Aged; Multivariate Analysis; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Retrospective Studies

2002
Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-01, Volume: 20, Issue:5

    Topics: Female; Humans; Ovarian Neoplasms; Palliative Care; Platinum

2002
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-01, Volume: 20, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Female; Follow-Up Studies; Humans; Middle Aged; Models, Theoretical; Ovarian Neoplasms; Paclitaxel; Platinum; Retrospective Studies; Survival Rate; Treatment Outcome

2002
Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Journal of medicinal chemistry, 2002, Apr-25, Volume: 45, Issue:9

    Topics: Animals; Antineoplastic Agents; Cell Line; Cisplatin; Cross-Linking Reagents; Crystallography, X-Ray; DNA; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Mice; Molecular Structure; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Structure-Activity Relationship; Tumor Cells, Cultured

2002
[Platinum in tumor therapy].
    MMW, Munchener medizinische Wochenschrift, 1979, Jan-26, Volume: 121, Issue:4

    Topics: Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Kidney; Male; Ovarian Neoplasms; Platinum; Testicular Neoplasms

1979
New developments in chemotherapy of genitourinary cancers.
    Journal of the Medical Association of Georgia, 1978, Volume: 68, Issue:6

    Topics: Female; Humans; Male; Ovarian Neoplasms; Platinum; Testicular Neoplasms; Urogenital Neoplasms

1978
Kinetics of cis-dichlorodiammineplatinum.
    Clinical pharmacology and therapeutics, 1979, Volume: 25, Issue:3

    Topics: Animals; Blood Proteins; Breast Neoplasms; Cell Survival; Cisplatin; Female; Humans; In Vitro Techniques; Kinetics; Leukemia L1210; Mice; Ovarian Neoplasms; Platinum; Protein Binding

1979
Cytoreduction in ovarian cancer.
    Lancet (London, England), 1992, Oct-03, Volume: 340, Issue:8823

    Topics: Combined Modality Therapy; Female; Humans; Ovarian Neoplasms; Platinum; Survival Rate

1992
Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Confidence Intervals; Cyclophosphamide; Doxorubicin; Female; Humans; Meta-Analysis as Topic; Ovarian Neoplasms; Platinum; Randomized Controlled Trials as Topic; Survival Rate

1992
The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:8-9

    Topics: Adolescent; Adult; Aged; Carboplatin; Carcinoma; Cisplatin; Erythrocytes; Female; Humans; Liver; Male; Middle Aged; Osteosarcoma; Ovarian Neoplasms; Platinum; Teratoma; Testicular Neoplasms; Time Factors

1992
5-Fluorouracil (5-FU) and leucovorin in platinum-refractory advanced stage ovarian carcinoma.
    Gynecologic oncology, 1992, Volume: 46, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Resistance; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum; Remission Induction

1992
Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:4

    Topics: Carboplatin; Cisplatin; Drug Resistance; Female; Humans; Ovarian Neoplasms; Platinum; Salvage Therapy

1992
Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
    Cancer research, 1992, Feb-15, Volume: 52, Issue:4

    Topics: Antineoplastic Agents; Cell Line; Cell Survival; Cisplatin; Dicarboxylic Acids; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Molecular Structure; Ovarian Neoplasms; Platinum; Structure-Activity Relationship

1992
Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Cancer research, 1991, Sep-01, Volume: 51, Issue:17

    Topics: Buthionine Sulfoximine; Cisplatin; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance; Female; Glutathione; Glutathione Transferase; Humans; Methionine Sulfoximine; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1991
[Assessment of tissue platinum concentration, X-ray computed tomogram, and microangiography after CDDP intraperitoneal administration in VX2 ovarian tumor].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:11

    Topics: Angiography; Animals; Cisplatin; Colposcopy; Female; Infusions, Parenteral; Neoplasm Transplantation; Ovarian Neoplasms; Ovary; Platinum; Rabbits; Regional Blood Flow; Tomography, X-Ray Computed

1991
Comparative intraperitoneal pharmacokinetics of three platinum analogues.
    Cancer chemotherapy and pharmacology, 1991, Volume: 28, Issue:4

    Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Radioisotopes; Time Factors

1991
Lack of significant modulation of the formation and removal of platinum-DNA adducts by aphidicolin glycinate in two logarithmically-growing ovarian tumour cell lines in vitro.
    Carcinogenesis, 1991, Volume: 12, Issue:3

    Topics: Antibiotics, Antineoplastic; Aphidicolin; Cisplatin; Diterpenes; DNA; DNA Damage; DNA Polymerase II; DNA Repair; Female; Guanine; Humans; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1991
Synergistic cytotoxic actions of cisplatin and liposomal valinomycin on human ovarian carcinoma cells.
    Cancer chemotherapy and pharmacology, 1991, Volume: 28, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line; Cell Survival; Cisplatin; Drug Carriers; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Liposomes; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured; Valinomycin

1991
Tissue platinum concentrations and cisplatin schedules.
    Lancet (London, England), 1990, Oct-20, Volume: 336, Issue:8721

    Topics: Animals; Carcinoma; Cisplatin; Drug Administration Schedule; Female; Ganglia, Spinal; Injections, Intraperitoneal; Ovarian Neoplasms; Peripheral Nerves; Platinum; Rats

1990
In vitro evaluation of platinum, titanium and ruthenium metal complexes in cisplatin-sensitive and -resistant rat ovarian tumors.
    Cancer chemotherapy and pharmacology, 1991, Volume: 27, Issue:4

    Topics: Animals; Antineoplastic Agents; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Female; Ovarian Neoplasms; Platinum; Rats; Ruthenium; Titanium; Tumor Cells, Cultured

1991
Long term results of cyclophosphamide, adriamycin and platinum chemotherapy in advanced epithelial ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Remission Induction; Survival Analysis

1991
Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
    Cancer research, 1990, Apr-15, Volume: 50, Issue:8

    Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Cohort Studies; DNA; Female; Humans; Leukocytes; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Prognosis

1990
Neoadjuvant chemotherapy in stage X ovarian carcinoma.
    Gynecologic oncology, 1990, Volume: 37, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Platinum; Survival Analysis

1990
Rapid emergence of acquired cis-diamminedichloroplatinum(II) resistance in an in vivo model of human ovarian carcinoma.
    Cancer communications, 1990, Volume: 2, Issue:2

    Topics: Animals; Cell Line; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance; Female; Glutathione; Humans; Isoenzymes; L-Lactate Dehydrogenase; Metallothionein; Mice; Models, Biological; Neoplasm Transplantation; Ovarian Neoplasms; Phenotype; Platinum; Transplantation, Heterologous

1990
Excretion of platinum into breast milk.
    Lancet (London, England), 1989, Mar-04, Volume: 1, Issue:8636

    Topics: Adult; Cisplatin; Female; Humans; Lactation; Milk, Human; Ovarian Neoplasms; Platinum; Pregnancy

1989
[CDDP-ACR treatment in patients with recurrent ovarian cancer with prior chemotherapy containing CDDP--a preliminary study of a 14-day continuous infusion of CDDP with ACR].
    Nihon Sanka Fujinka Gakkai zasshi, 1989, Volume: 41, Issue:10

    Topics: Abdominal Neoplasms; Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukopenia; Lymphatic Metastasis; Middle Aged; Ovarian Neoplasms; Platinum; Recurrence; Remission Induction; Thrombocytopenia

1989
The disposition of carboplatin in ovarian cancer patients.
    Cancer chemotherapy and pharmacology, 1988, Volume: 22, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Chromatography, High Pressure Liquid; Female; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Protein Binding

1988
Pharmacokinetics of carboplatin after i.v. administration.
    Cancer treatment reports, 1987, Volume: 71, Issue:12

    Topics: Carboplatin; Carcinoma; Female; Humans; Injections, Intravenous; Organoplatinum Compounds; Ovarian Neoplasms; Platinum

1987
cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Cancer research, 1988, Jan-01, Volume: 48, Issue:1

    Topics: Carcinoma; Cell Membrane; Cisplatin; Dinitrophenols; Drug Resistance; Female; Humans; Ouabain; Ovarian Neoplasms; Platinum; Tumor Cells, Cultured

1988
Evaluation of the role of second-look surgery in ovarian cancer.
    Obstetrics and gynecology, 1988, Volume: 72, Issue:3 Pt 1

    Topics: Adolescent; Adult; Aged; Carcinoma; Combined Modality Therapy; Evaluation Studies as Topic; False Negative Reactions; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Regression Analysis; Reoperation; Retrospective Studies; Surgical Procedures, Operative; Time Factors

1988
Pharmacokinetics of cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV (iproplatinum, CHIP) in patients with normal and impaired renal function and following intraperitoneal administration.
    Medical oncology and tumor pharmacotherapy, 1988, Volume: 5, Issue:3

    Topics: Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Kidney Diseases; Metabolic Clearance Rate; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Cavity; Platinum

1988
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.
    Cancer chemotherapy and pharmacology, 1987, Volume: 19, Issue:2

    Topics: Cadmium; Carcinoma; Cell Compartmentation; Cells, Cultured; Cisplatin; Drug Resistance; Female; Glutathione; Humans; Metallothionein; Ovarian Neoplasms; Platinum; Zinc

1987
A modified pharmacokinetic model for platinum disposition in ovarian cancer patients receiving cisplatin.
    European journal of clinical pharmacology, 1987, Volume: 33, Issue:1

    Topics: Cisplatin; Female; Humans; Kidney; Metabolic Clearance Rate; Middle Aged; Models, Biological; Ovarian Neoplasms; Platinum; Protein Binding

1987
[Combined chemotherapy including platinum derivatives in the combined treatment of patients with stage-III to -IV ovarian cancer].
    Vestnik Akademii meditsinskikh nauk SSSR, 1986, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Platinum; Time Factors

1986
Disposition of total and free cisplatin on two consecutive treatment cycles in patients with ovarian cancer.
    Cancer chemotherapy and pharmacology, 1987, Volume: 19, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Fluid Compartments; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Half-Life; Humans; Kinetics; Middle Aged; Models, Biological; Ovarian Neoplasms; Platinum; Spectrophotometry, Atomic

1987
Clinical pharmacology of intraperitoneal cisplatin.
    Gynecologic oncology, 1985, Volume: 20, Issue:1

    Topics: Aged; Ascitic Fluid; Cisplatin; Drug Evaluation; Female; Humans; Injections, Intraperitoneal; Kinetics; Mesothelioma; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Spectrophotometry, Atomic

1985
Cystic fluid-platinum kinetics in ovarian cancer patients: relevance to cis-dichlorodiammine platinum (II) sensitivity testing in vitro.
    British journal of cancer, 1985, Volume: 52, Issue:2

    Topics: Cisplatin; Cystadenocarcinoma; Female; Humans; Kinetics; Ovarian Neoplasms; Platinum; Time Factors

1985
Doxorubicin and cisplatin excretion into human milk.
    Cancer treatment reports, 1985, Volume: 69, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Half-Life; Humans; Milk, Human; Ovarian Neoplasms; Platinum; Spectrophotometry, Atomic

1985
Secondary screening of platinum compounds in human ovarian cancer xenografts in nude mice.
    European journal of cancer & clinical oncology, 1985, Volume: 21, Issue:10

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Brain; Cell Line; Cisplatin; Female; Kidney; Liver; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Ovarian Neoplasms; Platinum

1985